STOCK TITAN

Health In Tech posts $7.07M Q3 2026 loss

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

Health In Tech, Inc. (HIT) reported third-quarter 2026 revenue of $6,587,052, versus $8,490,093 a year earlier, and a net loss attributable to common stockholders of $7,066,413, compared with net income of $452,176. For the first nine months, revenue was $23,415,318 versus $25,818,926, and the common-stockholder net loss was $11,165,718 versus net income of $1,581,399.

Third-quarter provision for credit losses was $5,337,768, including $2,408,425 related to Deferred Administrative Surplus from the 2025 Purchase. HIT also recorded a full allowance of $863,992 against principal and accrued interest on its loan to Kang Youle Limited. Operating activities used $7,277,043 in cash in the first nine months; cash was $10,127,237 at September 30, 2026. Financing activities provided $11,535,813, including $6,381,000 net PIPE proceeds and $6,650,000 net proceeds from convertible notes.

Effective January 1, 2026, SMR pivoted to pre-designed self-funded plans; more than 100 plans were available as of September 30, 2026. On March 27, HIT issued 5,600,000 Class A shares at $1.25 each in the PIPE.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 4 points

How the balance works

Positive

  • None.

Negative

  • Major pointCommon stockholders recorded a $7,066,413 quarterly loss, versus $452,176 income.
  • Moderate pointThird-quarter revenue was $6,587,052, versus $8,490,093 a year earlier.
  • Moderate pointOperating activities used $7,277,043 over nine months, versus $2,682,602 provided.
  • Minor pointThird-quarter credit-loss provision totaled $5,337,768.

Filing Explained

At September 30, 2026, HIT recorded $6,639,108 in convertible notes payable, with 4,448,681 potential note shares excluded from diluted EPS.

This Form 10-Q covers the quarter ended September 30, 2026 and reports that Health In Tech consolidated HITChain beginning April 10, 2026; HITChain’s assets can settle only its own obligations, and its creditors have no recourse to HIT’s general credit.

At September 30, the company reported $6,639,108 of convertible notes payable at fair value; 4,448,681 potential note shares were excluded from diluted earnings per share because their effect was antidilutive.

In the HITChain capitalization described in the filing, HIT held 85.72% of its economic interest but 28.58% of its voting interest.

Third-quarter revenue $6,587,052 Three months ended September 30, 2026; $8,490,093 in 2025
Third-quarter net loss attributable to common stockholders $7,066,413 loss Three months ended September 30, 2026; $452,176 net income in 2025
Nine-month revenue $23,415,318 Nine months ended September 30, 2026; $25,818,926 in 2025
Nine-month net loss attributable to common stockholders $11,165,718 loss Nine months ended September 30, 2026; $1,581,399 net income in 2025
Third-quarter provision for credit losses $5,337,768 Three months ended September 30, 2026
Operating cash flow $7,277,043 used Nine months ended September 30, 2026; $2,682,602 provided in 2025
Cash and cash equivalents $10,127,237 As of September 30, 2026
PIPE net proceeds $6,381,000 Completed March 27, 2026; 5,600,000 Class A shares issued at $1.25 per share
Deferred Administrative Surplus financial
"Credit loss expense related to Deferred Administrative Surplus"
provision for credit losses financial
"recorded a provision for credit losses of $863,992"
Provision for credit losses is an amount set aside by a financial institution to cover potential future losses from borrowers who may not repay their loans. It acts like a safety net, helping the institution manage risks and stay financially healthy. For investors, it signals how cautious a lender is about potential loan defaults and can impact the company's profitability and financial stability.
variable consideration financial
"constitutes variable consideration in its entirety"
Amount of promised consideration in a contract whose final value depends on future events or uncertainties — for example discounts, rebates, performance bonuses, refunds, rights of return, or milestone payments. Under modern revenue-recognition rules (IFRS 15 / ASC 606) an entity estimates variable consideration using either the expected value or the most likely amount, then includes it in the transaction price only to the extent it is probable the estimate will not result in a significant reversal of cumulative revenue when the uncertainty is resolved. The estimate is updated as facts and circumstances change and the effect of any change is recognized in revenue.
fair value option financial
"elected the fair value option for its eligible convertible note payable"
An accounting election that lets a company measure eligible financial assets and liabilities at their current market price, recording gains and losses in the income statement as those prices move. For investors it matters because choosing the fair value option makes reported profits and asset values respond immediately to market swings—like revaluing a house to today’s sale price—so it can increase earnings volatility while giving a more up‑to‑date view of value.
primary beneficiary technical
"determined that it is the primary beneficiary of HITChain"
nonaccrual approach financial
"Under the Company’s nonaccrual approach"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much revenue did HIT report in the third quarter of 2026?

Health In Tech reported revenue of $6,587,052 for the three months ended September 30, 2026, compared with $8,490,093 in the same period of 2025. For the nine months ended September 30, revenue was $23,415,318, compared with $25,818,926.

What changed in HIT's self-funded plan offerings in 2026?

Effective January 1, 2026, SMR pivoted to offering pre-designed self-funded plans to employers. As of September 30, 2026, SMR included more than 100 pre-designed plans that could be configured and bundled with stop-loss coverage.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
1 1 http://fasb.org/srt/2026#ChiefExecutiveOfficerMember 0002019505 false Q3 --12-31 0002019505 hit:TimJohnsonMember 2026-09-15 2026-09-15 0002019505 hit:TimJohnsonMember 2026-09-15 0002019505 2026-07-01 2026-09-30 0002019505 us-gaap:SubsequentEventMember 2026-11-10 0002019505 us-gaap:SubsequentEventMember us-gaap:SeriesAPreferredStockMember 2026-11-10 0002019505 us-gaap:SubsequentEventMember us-gaap:CommonClassBMember 2026-11-10 0002019505 us-gaap:SubsequentEventMember us-gaap:CommonClassAMember 2026-11-10 0002019505 us-gaap:SubsequentEventMember srt:MaximumMember 2026-11-10 0002019505 us-gaap:SubsequentEventMember srt:MinimumMember 2026-11-10 0002019505 us-gaap:SubsequentEventMember hit:SecondConvertibleNotesMember 2026-11-03 2026-11-03 0002019505 us-gaap:SubsequentEventMember hit:SecondConvertibleNotesMember 2026-11-02 0002019505 us-gaap:SubsequentEventMember hit:SecondConvertibleNotesMember 2026-11-02 2026-11-02 0002019505 hit:TwoThousandTwentyFourPlanMember us-gaap:SubsequentEventMember srt:MaximumMember 2026-11-10 0002019505 hit:TwoThousandTwentyFourPlanMember us-gaap:SubsequentEventMember srt:MinimumMember 2026-11-10 0002019505 us-gaap:CommonClassBMember hit:Market-BasedMember srt:ChiefFinancialOfficerMember 2026-10-20 2026-10-20 0002019505 us-gaap:CommonClassAMember hit:Market-BasedMember srt:ChiefFinancialOfficerMember 2026-10-20 2026-10-20 0002019505 us-gaap:PerformanceSharesMember srt:ChiefFinancialOfficerMember 2026-10-20 2026-10-20 0002019505 hit:Service-BasedMember srt:ChiefFinancialOfficerMember 2026-10-20 2026-10-20 0002019505 us-gaap:SubsequentEventMember us-gaap:CommonClassAMember hit:Market-BasedMember srt:MaximumMember 2026-10-20 2026-10-20 0002019505 us-gaap:SubsequentEventMember us-gaap:CommonClassAMember srt:MaximumMember 2026-10-20 2026-10-20 0002019505 us-gaap:SubsequentEventMember us-gaap:CommonClassBMember hit:Market-BasedMember 2026-10-20 2026-10-20 0002019505 us-gaap:SubsequentEventMember us-gaap:CommonClassAMember hit:Market-BasedMember 2026-10-20 2026-10-20 0002019505 us-gaap:SubsequentEventMember us-gaap:CommonClassAMember us-gaap:PerformanceSharesMember 2026-10-20 2026-10-20 0002019505 us-gaap:SubsequentEventMember us-gaap:CommonClassAMember hit:Service-BasedMember 2026-10-20 2026-10-20 0002019505 us-gaap:SubsequentEventMember us-gaap:CommonClassBMember 2026-10-20 2026-10-20 0002019505 us-gaap:SubsequentEventMember us-gaap:CommonClassAMember 2026-10-20 2026-10-20 0002019505 us-gaap:SubsequentEventMember us-gaap:CommonClassAMember 2026-10-15 2026-10-15 0002019505 us-gaap:SubsequentEventMember 2026-10-07 2026-10-07 0002019505 hit:TwoThousandTwentyFourPlanMember us-gaap:SubsequentEventMember 2026-10-07 2026-10-07 0002019505 2026-01-01 2026-09-30 0002019505 hit:SEPADerivativeLiabilityMember hit:MeasurementInputDown-RoundProbabilityMember 2026-09-30 0002019505 hit:SEPADerivativeLiabilityMember us-gaap:MeasurementInputDiscountRateMember 2026-09-30 0002019505 hit:SEPADerivativeLiabilityMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2026-09-30 0002019505 hit:SEPADerivativeLiabilityMember us-gaap:MeasurementInputOptionVolatilityMember 2026-09-30 0002019505 hit:SEPADerivativeLiabilityMember us-gaap:MeasurementInputSharePriceMember 2026-09-30 0002019505 hit:SEPADerivativeLiabilityMember us-gaap:MeasurementInputExpectedTermMember 2026-09-30 0002019505 hit:SEPADerivativeLiabilityMember 2026-01-01 2026-09-30 0002019505 hit:SEPADerivativeLiabilityMember 2026-07-01 2026-09-30 0002019505 hit:SEPADerivativeLiabilityMember 2026-09-30 0002019505 hit:ConvertibleNotesMember hit:MeasurementInputDown-RoundProbabilityMember 2026-09-30 0002019505 hit:ConvertibleNotesMember us-gaap:MeasurementInputDiscountRateMember 2026-09-30 0002019505 hit:ConvertibleNotesMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2026-09-30 0002019505 hit:ConvertibleNotesMember us-gaap:MeasurementInputOptionVolatilityMember 2026-09-30 0002019505 hit:ConvertibleNotesMember us-gaap:MeasurementInputSharePriceMember 2026-09-30 0002019505 hit:ConvertibleNotesMember us-gaap:MeasurementInputExpectedTermMember 2026-09-30 0002019505 hit:ConvertibleNotesMember 2026-01-01 2026-09-30 0002019505 hit:ConvertibleNotesMember 2026-07-01 2026-09-30 0002019505 hit:ConvertibleNotesMember 2026-09-30 0002019505 2026-09-30 0002019505 us-gaap:FairValueInputsLevel3Member 2026-09-30 0002019505 hit:TwoThousandTwentySixPlanMember us-gaap:CommonClassBMember 2026-01-01 2026-09-30 0002019505 hit:TwoThousandTwentySixPlanMember us-gaap:CommonClassBMember 2026-09-30 0002019505 us-gaap:RestrictedStockMember 2026-09-30 0002019505 us-gaap:RestrictedStockMember 2026-01-01 2026-09-30 0002019505 us-gaap:CommonClassBMember hit:TwoThousandTwentySixEquityIncentivePlanMember 2026-04-10 0002019505 us-gaap:CommonClassBMember 2026-04-10 2026-04-10 0002019505 us-gaap:CommonClassAMember 2026-04-10 2026-04-10 0002019505 2025-01-01 2025-09-30 0002019505 hit:TwoThousandTwentyTwoPlanMember 2026-09-30 0002019505 hit:TwoThousandTwentyTwoPlanMember 2026-01-01 2026-09-30 0002019505 hit:TwoThousandTwentyTwoPlanMember 2025-12-31 0002019505 us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-09-30 0002019505 us-gaap:RestrictedStockUnitsRSUMember 2026-09-30 0002019505 us-gaap:RestrictedStockUnitsRSUMember hit:TwoThousandTwentyFourEquityIncentivePlanMember 2026-09-30 0002019505 us-gaap:RestrictedStockUnitsRSUMember hit:TwoThousandTwentyFourEquityIncentivePlanMember 2026-01-01 2026-09-30 0002019505 hit:ServiceAndPerformanceBasedRSAsMember 2025-01-01 2025-09-30 0002019505 hit:ServiceAndPerformanceBasedRSAsMember 2026-01-01 2026-09-30 0002019505 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-09-30 0002019505 hit:PerformanceBasedRSAsMember 2026-09-30 0002019505 us-gaap:RestrictedStockMember hit:TwoThousandTwentyFourAndTwentyTwoEquityIncentivePlanMember 2026-09-30 0002019505 us-gaap:RestrictedStockMember hit:TwoThousandTwentyFourAndTwentyTwoEquityIncentivePlanMember 2026-01-01 2026-09-30 0002019505 us-gaap:RestrictedStockMember hit:TwoThousandTwentyFourAndTwentyTwoEquityIncentivePlanMember 2025-12-31 0002019505 us-gaap:RestrictedStockMember 2025-01-01 2025-09-30 0002019505 hit:PerformanceBasedRSAsMember 2025-01-01 2025-09-30 0002019505 hit:PerformanceBasedRSAsMember 2026-01-01 2026-09-30 0002019505 us-gaap:RestrictedStockMember 2026-08-14 2026-08-14 0002019505 us-gaap:RestrictedStockMember 2026-08-14 0002019505 2026-06-15 0002019505 2026-06-15 2026-06-15 0002019505 us-gaap:RestrictedStockMember hit:TwoThousandTwentyFourEquityIncentivePlanMember 2026-09-30 0002019505 us-gaap:RestrictedStockMember hit:TwoThousandTwentyFourEquityIncentivePlanMember 2026-01-01 2026-09-30 0002019505 us-gaap:RestrictedStockMember hit:TwoThousandTwentyFourEquityIncentivePlanMember 2025-12-31 0002019505 hit:TwoThousandTwentyFourEquityIncentivePlanMember 2026-01-01 2026-09-30 0002019505 srt:MaximumMember hit:TwoThousandTwentyFourEquityIncentivePlanMember 2026-01-01 2026-09-30 0002019505 srt:MinimumMember hit:TwoThousandTwentyFourEquityIncentivePlanMember 2026-01-01 2026-09-30 0002019505 us-gaap:RestrictedStockMember 2025-01-01 2025-12-31 0002019505 us-gaap:CommonClassBMember hit:TwoThousandTwentyFourEquityIncentivePlanMember 2025-10-03 2025-10-03 0002019505 srt:MaximumMember hit:TwoThousandTwentyFourEquityIncentivePlanMember 2025-10-03 2025-10-03 0002019505 srt:MinimumMember hit:TwoThousandTwentyFourEquityIncentivePlanMember 2025-10-03 2025-10-03 0002019505 hit:TwoThousandTwentyFourEquityIncentivePlanMember 2024-12-24 0002019505 hit:TwoThousandTwentyTwoEquityIncentivePlanMember 2022-12-21 2022-12-21 0002019505 hit:FirstConvertibleNoteMember 2026-09-30 0002019505 hit:FirstConvertibleNoteMember 2026-01-01 2026-09-30 0002019505 hit:FirstConvertibleNoteMember 2025-12-31 0002019505 hit:YorkvillesAgreementMember 2026-09-30 0002019505 2026-08-18 0002019505 hit:ConvertibleNotesAtFairValueMember 2026-09-30 0002019505 us-gaap:ConvertibleNotesPayableMember 2026-01-01 2026-09-30 0002019505 us-gaap:ConvertibleNotesPayableMember hit:ConvertibleNotesAtFairValueMember 2026-09-30 0002019505 hit:FinalInstallmentMember 2026-01-01 2026-09-30 0002019505 hit:SecondInstallmentMember 2026-01-01 2026-09-30 0002019505 hit:FirstInstallmentMember 2026-01-01 2026-09-30 0002019505 hit:ConvertibleNotesAtFairValueMember 2026-08-18 2026-08-18 0002019505 hit:ConvertibleNotesAtFairValueMember 2026-01-01 2026-09-30 0002019505 hit:YorkvillesAgreementMember 2026-01-01 2026-09-30 0002019505 2026-11-03 2026-11-03 0002019505 2026-11-02 0002019505 hit:ThirdTrancheMember 2026-09-30 0002019505 hit:SecondTrancheMember 2026-09-30 0002019505 hit:FirstTrancheMember 2026-09-30 0002019505 hit:StandbyEquityPurchaseAgreementSEPAMember 2026-01-01 2026-09-30 0002019505 hit:StandbyEquityPurchaseAgreementSEPAMember 2026-07-01 2026-09-30 0002019505 hit:StandbyEquityPurchaseAgreementSEPAMember 2026-09-30 0002019505 hit:StandbyEquityPurchaseAgreementSEPAMember 2026-08-12 2026-08-12 0002019505 2026-08-12 2026-08-12 0002019505 hit:StandbyEquityPurchaseAgreementSEPAMember hit:YAIIPNLTDYorkvilleMember 2026-08-12 2026-08-12 0002019505 hit:StandbyEquityPurchaseAgreementSEPAMember hit:YAIIPNLTDYorkvilleMember 2026-08-12 0002019505 hit:StandbyEquityPurchaseAgreementSEPAMember us-gaap:ConvertibleNotesPayableMember 2026-08-12 2026-08-12 0002019505 hit:StandbyEquityPurchaseAgreementSEPAMember us-gaap:ConvertibleNotesPayableMember 2026-08-12 0002019505 hit:StandbyEquityPurchaseAgreementSEPAMember us-gaap:CommonClassAMember 2026-08-12 2026-08-12 0002019505 us-gaap:StateAndLocalJurisdictionMember 2026-01-01 2026-09-30 0002019505 2025-12-31 0002019505 2025-01-01 2025-12-31 0002019505 2025-07-01 2025-09-30 0002019505 us-gaap:DomesticCountryMember 2025-01-01 2025-09-30 0002019505 us-gaap:DomesticCountryMember 2026-01-01 2026-09-30 0002019505 us-gaap:DomesticCountryMember 2025-07-01 2025-09-30 0002019505 us-gaap:DomesticCountryMember 2026-07-01 2026-09-30 0002019505 us-gaap:CommonClassBMember 2025-12-31 0002019505 us-gaap:CommonClassBMember 2026-09-30 0002019505 us-gaap:CommonClassAMember 2025-12-31 0002019505 us-gaap:CommonClassAMember 2026-09-30 0002019505 hit:PIPEMember 2026-03-27 2026-03-27 0002019505 2026-03-27 2026-03-27 0002019505 us-gaap:CommonClassAMember 2026-03-27 0002019505 us-gaap:CommonClassAMember 2026-03-27 2026-03-27 0002019505 us-gaap:SeriesAPreferredStockMember 2026-01-01 2026-09-30 0002019505 us-gaap:CommonClassAMember 2026-01-01 2026-09-30 0002019505 us-gaap:CommonClassBMember 2026-01-01 2026-09-30 0002019505 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2026-09-30 0002019505 2023-10-10 0002019505 hit:KangYouleLimitedMember 2023-10-10 2023-10-10 0002019505 hit:KangYouleLimitedMember 2023-10-10 0002019505 us-gaap:ConvertibleDebtSecuritiesMember 2026-01-01 2026-09-30 0002019505 us-gaap:ConvertibleDebtSecuritiesMember 2026-07-01 2026-09-30 0002019505 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-09-30 0002019505 us-gaap:EmployeeStockOptionMember 2026-07-01 2026-09-30 0002019505 us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-09-30 0002019505 us-gaap:RestrictedStockUnitsRSUMember 2026-07-01 2026-09-30 0002019505 us-gaap:RestrictedStockMember 2025-01-01 2025-09-30 0002019505 us-gaap:RestrictedStockMember 2026-01-01 2026-09-30 0002019505 us-gaap:RestrictedStockMember 2025-07-01 2025-09-30 0002019505 us-gaap:RestrictedStockMember 2026-07-01 2026-09-30 0002019505 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-09-30 0002019505 us-gaap:EmployeeStockOptionMember 2025-07-01 2025-09-30 0002019505 us-gaap:RestrictedStockMember 2025-07-01 2025-09-30 0002019505 hit:OtherReceivablesMember 2025-12-31 0002019505 hit:OtherReceivablesMember 2026-09-30 0002019505 2026-01-01 2026-03-31 0002019505 2024-01-01 2024-12-31 0002019505 hit:SelfFundedPlanAdministrationFeesMember 2026-01-01 2026-09-30 0002019505 hit:SelfFundedPlanAdministrationFeesMember 2026-07-01 2026-09-30 0002019505 hit:ProgramAndPlatformManagementFeesMember 2025-01-01 2025-09-30 0002019505 hit:ProgramAndPlatformManagementFeesMember 2026-01-01 2026-09-30 0002019505 hit:ProgramAndPlatformManagementFeesMember 2025-07-01 2025-09-30 0002019505 hit:ProgramAndPlatformManagementFeesMember 2026-07-01 2026-09-30 0002019505 hit:RevenuesFromFeesSMRMember 2025-01-01 2025-09-30 0002019505 hit:RevenuesFromFeesSMRMember 2026-01-01 2026-09-30 0002019505 hit:RevenuesFromFeesSMRMember 2025-07-01 2025-09-30 0002019505 hit:RevenuesFromFeesSMRMember 2026-07-01 2026-09-30 0002019505 hit:RevenuesFromUnderwritingModelingICEMember 2025-01-01 2025-09-30 0002019505 hit:RevenuesFromUnderwritingModelingICEMember 2026-01-01 2026-09-30 0002019505 hit:RevenuesFromUnderwritingModelingICEMember 2025-07-01 2025-09-30 0002019505 hit:RevenuesFromUnderwritingModelingICEMember 2026-07-01 2026-09-30 0002019505 hit:OtherReceivablesMember 2026-01-01 2026-09-30 0002019505 hit:TwoThousandTwentyFivePurchaseMember 2026-09-30 0002019505 hit:TwoThousandTwentyFivePurchaseMember 2026-07-01 2026-09-30 0002019505 hit:TwoThousandTwentyFivePurchaseMember 2026-06-30 0002019505 hit:TwoThousandTwentyFivePurchaseMember hit:AllowanceMember 2026-09-30 0002019505 hit:TwoThousandTwentyFivePurchaseMember hit:GrossReceivablesMember 2026-09-30 0002019505 hit:TwoThousandTwentyFivePurchaseMember hit:NetReceivablesMember 2026-07-01 2026-09-30 0002019505 hit:TwoThousandTwentyFivePurchaseMember hit:AllowanceMember 2026-07-01 2026-09-30 0002019505 hit:TwoThousandTwentyFivePurchaseMember hit:GrossReceivablesMember 2026-07-01 2026-09-30 0002019505 hit:TwoThousandTwentyFivePurchaseMember hit:NetReceivablesMember 2026-06-30 0002019505 hit:TwoThousandTwentyFivePurchaseMember hit:AllowanceMember 2026-06-30 0002019505 hit:TwoThousandTwentyFivePurchaseMember hit:GrossReceivablesMember 2026-06-30 0002019505 hit:TwoThousandTwentyFivePurchaseMember hit:AllowanceMember 2026-04-01 2026-06-30 0002019505 hit:TwoThousandTwentyFivePurchaseMember hit:GrossReceivablesMember 2026-04-01 2026-06-30 0002019505 hit:TwoThousandTwentyFivePurchaseMember hit:NetReceivablesMember 2026-04-01 2026-06-30 0002019505 hit:TwoThousandTwentyFivePurchaseMember hit:NetReceivablesMember 2026-03-31 0002019505 hit:TwoThousandTwentyFivePurchaseMember hit:GrossReceivablesMember 2026-03-31 0002019505 hit:TwoThousandTwentyFivePurchaseMember hit:NetReceivablesMember 2026-01-01 2026-03-31 0002019505 hit:TwoThousandTwentyFivePurchaseMember hit:GrossReceivablesMember 2026-01-01 2026-03-31 0002019505 hit:TwoThousandTwentyFivePurchaseMember hit:NetReceivablesMember 2025-12-31 0002019505 hit:TwoThousandTwentyFivePurchaseMember hit:GrossReceivablesMember 2025-12-31 0002019505 hit:TwoThousandTwentyFivePurchaseMember hit:NetReceivablesMember 2025-01-01 2025-12-31 0002019505 hit:TwoThousandTwentyFivePurchaseMember hit:GrossReceivablesMember 2025-01-01 2025-12-31 0002019505 hit:TwoThousandTwentyThreePurchaseMember 2026-09-30 0002019505 hit:TwoThousandTwentyThreePurchaseMember hit:AllowanceMember 2025-12-31 0002019505 hit:TwoThousandTwentyThreePurchaseMember hit:GrossReceivablesMember 2025-12-31 0002019505 hit:TwoThousandTwentyThreePurchaseMember hit:NetReceivablesMember 2025-01-01 2025-12-31 0002019505 hit:TwoThousandTwentyThreePurchaseMember hit:AllowanceMember 2025-01-01 2025-12-31 0002019505 hit:TwoThousandTwentyThreePurchaseMember hit:GrossReceivablesMember 2025-01-01 2025-12-31 0002019505 hit:TwoThousandTwentyFivePurchaseMember 2025-01-01 2025-09-30 0002019505 hit:TwoThousandTwentyFivePurchaseMember 2025-07-01 2025-09-30 0002019505 hit:TwoThousandTwentyFivePurchaseMember 2026-01-01 2026-09-30 0002019505 2025-03-18 2025-03-18 0002019505 hit:OtherReceivablesMember hit:TwoThousandTwentyFivePurchaseMember 2025-03-18 2025-03-18 0002019505 hit:OtherReceivablesMember 2025-03-18 2025-03-18 0002019505 hit:TwoThousandTwentyThreePurchaseMember 2023-12-28 2023-12-28 0002019505 hit:CarrierMember 2023-12-28 2023-12-28 0002019505 hit:DataServiceProvidersMember us-gaap:SupplierConcentrationRiskMember us-gaap:AccountsPayableMember 2025-01-01 2025-09-30 0002019505 hit:DataServiceProvidersMember us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember 2025-01-01 2025-09-30 0002019505 hit:DataServiceProvidersMember us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember 2025-07-01 2025-09-30 0002019505 hit:DataServiceProvidersMember us-gaap:SupplierConcentrationRiskMember us-gaap:AccountsPayableMember 2026-01-01 2026-09-30 0002019505 hit:DataServiceProvidersMember us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember 2026-01-01 2026-09-30 0002019505 hit:DataServiceProvidersMember us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember 2026-07-01 2026-09-30 0002019505 hit:ThreePrimaryServiceProviderMember us-gaap:SupplierConcentrationRiskMember us-gaap:AccountsPayableMember 2025-01-01 2025-09-30 0002019505 hit:TwoPrimaryServiceProviderMember us-gaap:SupplierConcentrationRiskMember us-gaap:AccountsPayableMember 2025-01-01 2025-09-30 0002019505 hit:OnePrimaryServiceProviderMember us-gaap:SupplierConcentrationRiskMember us-gaap:AccountsPayableMember 2025-01-01 2025-09-30 0002019505 hit:ThreePrimaryServiceProviderMember us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember 2025-01-01 2025-09-30 0002019505 hit:TwoPrimaryServiceProviderMember us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember 2025-01-01 2025-09-30 0002019505 hit:OnePrimaryServiceProviderMember us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember 2025-01-01 2025-09-30 0002019505 hit:ThreePrimaryServiceProviderMember us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember 2025-07-01 2025-09-30 0002019505 hit:TwoPrimaryServiceProviderMember us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember 2025-07-01 2025-09-30 0002019505 hit:OnePrimaryServiceProviderMember us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember 2025-07-01 2025-09-30 0002019505 hit:ThreePrimaryServiceProviderMember us-gaap:SupplierConcentrationRiskMember us-gaap:AccountsPayableMember 2026-01-01 2026-09-30 0002019505 hit:TwoPrimaryServiceProviderMember us-gaap:SupplierConcentrationRiskMember us-gaap:AccountsPayableMember 2026-01-01 2026-09-30 0002019505 hit:OnePrimaryServiceProviderMember us-gaap:SupplierConcentrationRiskMember us-gaap:AccountsPayableMember 2026-01-01 2026-09-30 0002019505 hit:ThreePrimaryServiceProviderMember us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember 2026-01-01 2026-09-30 0002019505 hit:TwoPrimaryServiceProviderMember us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember 2026-01-01 2026-09-30 0002019505 hit:OnePrimaryServiceProviderMember us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember 2026-01-01 2026-09-30 0002019505 hit:ThreePrimaryServiceProviderMember us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember 2026-07-01 2026-09-30 0002019505 hit:TwoPrimaryServiceProviderMember us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember 2026-07-01 2026-09-30 0002019505 hit:OnePrimaryServiceProviderMember us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember 2026-07-01 2026-09-30 0002019505 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember hit:NoBusinessEmployerMember 2025-01-01 2025-09-30 0002019505 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember hit:NoBusinessEmployerMember 2026-01-01 2026-09-30 0002019505 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember hit:NoBusinessEmployerMember 2025-01-01 2025-09-30 0002019505 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember hit:NoBusinessEmployerMember 2025-07-01 2025-09-30 0002019505 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember hit:NoBusinessEmployerMember 2026-01-01 2026-09-30 0002019505 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember hit:NoBusinessEmployerMember 2026-07-01 2026-09-30 0002019505 us-gaap:CustomerConcentrationRiskMember hit:CarrierAMember us-gaap:AccountsReceivableMember 2025-01-01 2025-09-30 0002019505 us-gaap:CustomerConcentrationRiskMember hit:CarrierAMember us-gaap:SalesRevenueNetMember 2025-01-01 2025-09-30 0002019505 us-gaap:CustomerConcentrationRiskMember hit:CarrierAMember us-gaap:SalesRevenueNetMember 2025-07-01 2025-09-30 0002019505 us-gaap:CustomerConcentrationRiskMember hit:CarrierAMember us-gaap:AccountsReceivableMember 2026-01-01 2026-09-30 0002019505 us-gaap:CustomerConcentrationRiskMember hit:CarrierAMember us-gaap:SalesRevenueNetMember 2026-01-01 2026-09-30 0002019505 us-gaap:CustomerConcentrationRiskMember hit:CarrierAMember us-gaap:SalesRevenueNetMember 2026-07-01 2026-09-30 0002019505 hit:HITChainMember 2026-04-10 2026-04-10 0002019505 hit:HITChainMember 2026-09-30 0002019505 2026-05-31 2026-05-31 0002019505 us-gaap:CommonClassBMember hit:HITChainMember 2026-09-30 0002019505 us-gaap:CommonClassAMember hit:HITChainMember 2026-09-30 0002019505 us-gaap:CommonClassBMember hit:HITChainIncMember 2026-09-30 0002019505 us-gaap:CommonClassAMember hit:HITChainIncMember 2026-09-30 0002019505 2025-09-30 0002019505 2024-12-31 0002019505 us-gaap:RetainedEarningsMember 2025-09-30 0002019505 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0002019505 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2025-09-30 0002019505 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2025-09-30 0002019505 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0002019505 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0002019505 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2025-07-01 2025-09-30 0002019505 2025-06-30 0002019505 us-gaap:RetainedEarningsMember 2025-06-30 0002019505 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0002019505 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2025-06-30 0002019505 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2025-06-30 0002019505 2025-04-01 2025-06-30 0002019505 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0002019505 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0002019505 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2025-04-01 2025-06-30 0002019505 2025-03-31 0002019505 us-gaap:RetainedEarningsMember 2025-03-31 0002019505 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0002019505 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2025-03-31 0002019505 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2025-03-31 0002019505 2025-01-01 2025-03-31 0002019505 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0002019505 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0002019505 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2025-01-01 2025-03-31 0002019505 us-gaap:RetainedEarningsMember 2024-12-31 0002019505 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0002019505 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2024-12-31 0002019505 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-12-31 0002019505 us-gaap:NoncontrollingInterestMember 2026-09-30 0002019505 us-gaap:RetainedEarningsMember 2026-09-30 0002019505 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0002019505 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2026-09-30 0002019505 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2026-09-30 0002019505 us-gaap:NoncontrollingInterestMember 2026-07-01 2026-09-30 0002019505 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0002019505 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0002019505 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2026-07-01 2026-09-30 0002019505 2026-06-30 0002019505 us-gaap:NoncontrollingInterestMember 2026-06-30 0002019505 us-gaap:RetainedEarningsMember 2026-06-30 0002019505 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0002019505 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2026-06-30 0002019505 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2026-06-30 0002019505 2026-04-01 2026-06-30 0002019505 us-gaap:NoncontrollingInterestMember 2026-04-01 2026-06-30 0002019505 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0002019505 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0002019505 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2026-04-01 2026-06-30 0002019505 2026-03-31 0002019505 us-gaap:RetainedEarningsMember 2026-03-31 0002019505 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0002019505 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2026-03-31 0002019505 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2026-03-31 0002019505 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0002019505 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0002019505 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2026-01-01 2026-03-31 0002019505 us-gaap:RetainedEarningsMember 2025-12-31 0002019505 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0002019505 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2025-12-31 0002019505 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2025-12-31 0002019505 us-gaap:CommonClassBMember 2026-11-11 0002019505 us-gaap:CommonClassAMember 2026-11-11 0002019505 hit:SelfFundedPlanAdministrationFeesMember 2025-07-01 2025-09-30 0002019505 hit:SelfFundedPlanAdministrationFeesMember 2025-01-01 2025-09-30 0002019505 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2026-07-01 2026-09-30 0002019505 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2025-07-01 2025-09-30 0002019505 hit:TwoThousandTwentyThreePurchaseMember hit:NetReceivablesMember 2025-12-31 0002019505 hit:TwoThousandTwentyFivePurchaseMember hit:AllowanceMember 2025-01-01 2025-12-31 0002019505 hit:TwoThousandTwentyFivePurchaseMember hit:AllowanceMember 2025-12-31 0002019505 hit:TwoThousandTwentyFivePurchaseMember hit:AllowanceMember 2026-01-01 2026-03-31 0002019505 hit:TwoThousandTwentyFivePurchaseMember hit:AllowanceMember 2026-03-31 0002019505 hit:TwoThousandTwentyFivePurchaseMember hit:NetReceivablesMember 2026-09-30 0002019505 us-gaap:RestrictedStockUnitsRSUMember 2025-07-01 2025-09-30 0002019505 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-09-30 0002019505 us-gaap:ConvertibleDebtSecuritiesMember 2025-07-01 2025-09-30 0002019505 us-gaap:ConvertibleDebtSecuritiesMember 2025-01-01 2025-09-30 0002019505 us-gaap:ForeignCountryMember 2026-07-01 2026-09-30 0002019505 us-gaap:ForeignCountryMember 2025-07-01 2025-09-30 0002019505 us-gaap:ForeignCountryMember 2026-01-01 2026-09-30 0002019505 us-gaap:ForeignCountryMember 2025-01-01 2025-09-30 0002019505 hit:TwoThousandTwentyTwoEquityIncentivePlanMember 2026-09-30 0002019505 hit:TwoThousandTwentyTwoEquityIncentivePlanMember 2025-12-31 0002019505 us-gaap:RestrictedStockUnitsRSUMember hit:TwoThousandTwentyFourEquityIncentivePlanMember 2025-12-31 0002019505 us-gaap:FairValueInputsLevel1Member 2026-09-30 0002019505 us-gaap:FairValueInputsLevel2Member 2026-09-30 0002019505 hit:ConvertibleNotesMember 2025-12-31 0002019505 hit:SEPADerivativeLiabilityMember 2025-12-31 0002019505 hit:TwoThousandTwentySixPlanMember us-gaap:CommonClassBMember 2025-12-31 0002019505 us-gaap:NoncontrollingInterestMember 2025-12-31 0002019505 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2026-01-01 2026-03-31 0002019505 us-gaap:NoncontrollingInterestMember 2026-01-01 2026-03-31 0002019505 us-gaap:NoncontrollingInterestMember 2026-03-31 0002019505 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2026-04-01 2026-06-30 0002019505 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2025-01-01 2025-03-31 0002019505 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2025-04-01 2025-06-30 0002019505 us-gaap:EmployeeStockOptionMember 2025-07-01 2025-09-30 0002019505 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-09-30 0002019505 us-gaap:SeriesAPreferredStockMember 2026-09-30 0002019505 us-gaap:SeriesAPreferredStockMember 2025-12-31 xbrli:shares iso4217:USD xbrli:shares iso4217:USD xbrli:pure hit:Segment

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

For the quarterly period ended September 30, 2026

 

OR

 

☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

For the transition period from _________to___________

 

Commission File Number: 001-42449

 

Health In Tech, Inc.
(Exact name of registrant as specified in its charter)

 

Nevada   87-3545722
(State or other jurisdiction of
incorporation or organization)
  (I.R.S. Employer
Identification No.)
 
701 S. Colorado Ave, Suite 1
Stuart, FL
  34994
(Address of principal executive offices)   (Zip Code)

 

888-373-0333
(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Class A common stock, par value $0.001 per share   HIT   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ Smaller reporting company ☒
    Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). ☐ Yes ☒ No

 

As of November 11, 2026, there were 67,086,059 shares of Class A common stock and 12,600,000 shares of Class B common stock, each with a par value of $0.001 per share, outstanding.

 

 

 

 

 

TABLE OF CONTENTS

 

    Page 
  PART I. FINANCIAL INFORMATION 1
Item 1 Financial Statements (unaudited) 1
  Consolidated Balance Sheets as of September 30, 2026 and December 31, 2025 1
  Consolidated Statements of Operations for the three and nine months ended September 30, 2026 and 2025 2
  Consolidated Statements of Changes in Stockholders’ Equity for the three and nine months ended September 30, 2026 and 2025 3
  Consolidated Statements of Cash Flows for the nine months ended September 30, 2026 and 2025 4
  Notes to Consolidated Financial Statements 5
Item 2 Management’s Discussion and Analysis of Financial Condition and Results of Operations 40
Item 3 Quantitative and Qualitative Disclosures About Market Risk 63
Item 4 Controls and Procedures 63
     
  PART II. OTHER INFORMATION 64
Item 1 Legal Proceedings 64
Item 1A Risk Factors 64
Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 66
Item 3 Defaults Upon Senior Securities 66
Item 4 Mine Safety Disclosures 67
Item 5 Other Information 67
Item 6 Exhibits 69
     
Signatures 70

 

i

 

 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This quarterly report, including, without limitation, statements under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes,” “estimates,” “anticipates,” “expects,” “intends,” “plans,” “may,” “will,” “potential,” “projects,” “objective,” “predicts,” “continue,” “aims” or “should,” or, in each case, their negative or other variations or comparable terminology.

 

We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions, including risks described in the section titled “Risk Factors” set forth in Part II, Item 1A of this Quarterly Report on Form 10-Q and in our other filings with the Securities and Exchange Commission (the “SEC”). It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events and trends discussed in this Quarterly Report on Form 10-Q may not occur, and actual results may differ materially and adversely from those anticipated or implied in the forward-looking statements. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements about:

 

● our financial performance;

 

  ● our ability to obtain funding for our operations, including funding necessary to enhance our current systems as well as the development of additional functionalities of our systems and to expand our service offerings;
     
  ● our ability to identify, negotiate, finance, complete and integrate acquisitions or other strategic transactions and investments on favorable terms, or at all;

 

  ● the success, cost and timing of our system offering development activities;
     
  ● our ability to regain and maintain compliance with The Nasdaq Stock Market LLC continued listing requirements;

 

  ● our ability to successfully integrate new management and attract and retain key personnel;

 

  ● our ability to hire and retain necessary qualified employees to expand our operations;

 

  ● our ability to attract new customers to utilize our platforms;

 

  ● our ability to develop new and enhance products and services to attract and retain customers, and to successfully monetize them;

 

ii

 

 

  ● the impact of competition in our industry and innovation by our competitors;

 

  ● risks related to cybersecurity incidents or other network disruptions;

 

  ● risks related to the use of third-party artificial intelligence;

 

  ● our ability to stay abreast of and comply with new or modified laws and regulations that currently apply or become applicable to our business, including with respect to the insurance services industry and data privacy requirements;

 

  ● our ability to protect our intellectual property rights and maintain and build our brand;

 

  ● the scope of protection we are able to establish and maintain for intellectual property rights covering our platform and technology;

 

  ● the future trading prices of our Class A common stock, par value $0.001 per share (“Class A Common Stock”); and

 

  ● potential claims relating to our intellectual property.

 

We caution you that the foregoing list may not contain all of the forward-looking statements made in this Quarterly Report on Form 10-Q. You should not rely upon forward-looking statements as predictions of future events. The events and circumstances reflected in the forward-looking statements may not be achieved or occur. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Except as required by law, we do not intend to update any of these forward-looking statements after the date of this Quarterly Report on Form 10-Q or to conform these statements to actual results or revised expectations.

 

Because some of these risks and uncertainties cannot be predicted or quantified and may be beyond our control, you should read this Quarterly Report on Form 10-Q with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.

 

This Quarterly Report on Form 10-Q contains estimates, projections and other information concerning our industry, our business and the markets for our products and services. We obtained the industry, market and similar data set forth in this report from our own internal estimates and research and from academic and industry research, publications, surveys and studies conducted by third parties, including governmental agencies. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. While we believe that the data we use from third parties are reliable, we have not separately verified these data. Further, while we believe our internal research is reliable, such research has not been verified by any third party. You are cautioned not to give undue weight to any such information, projections and estimates.

 

iii

 

 

PART I. FINANCIAL INFORMATION

 

Item 1. Financial Statements.

 

Health In Tech, Inc.

 

Consolidated Balance Sheets

(Unaudited)

 

    September 30,
2026
    December 31,
2025
 
Assets            
Current assets            
Cash and cash equivalents   $ 10,127,237     $ 7,669,754  
Accounts receivable, net of allowance for credit losses of $1,882,457 and $0 as of September 30, 2026 and December 31, 2025, respectively     3,177,652       756,288  
Loans receivable, net of allowance for credit losses of $863,992 and $0 as of September 30, 2026 and December 31, 2025, respectively     —       815,995  
Other receivables, net of allowance for credit losses of $3,502,581 and $377,587 as of September 30, 2026 and December 31, 2025, respectively     1,669,747       3,467,814  
Deferred offering costs     180,987       170,977  
Prepaid expenses and other current assets     1,933,469       3,280,148  
Total current assets     17,089,092       16,160,976  
Non-current assets                
Software     8,148,785       6,530,894  
Operating lease – right of use assets     85,776       139,940  
Long-term prepaid expenses     17,956       258,151  
Deferred tax assets, net     2,691,345       —  
Total non-current assets     10,943,862       6,928,985  
Total assets   $ 28,032,954     $ 23,089,961  
                 
Liabilities and stockholders’ equity                
                 
Current liabilities                
Accounts payable and accrued expenses   $ 8,348,263     $ 4,188,811  
SEPA derivative liability     82,629       —  
Convertible notes payable, at fair value     6,639,108       —  
Operating lease liabilities – current     83,831       76,195  
Other current liabilities     —       891,598  
Total current liabilities     15,153,831       5,156,604  
Non-current liabilities                
Deferred tax liabilities     —       757,675  
Operating lease liabilities – non-current     —       63,617  
Total non-current liabilities     —       821,292  
Total liabilities     15,153,831       5,977,896  
                 
Commitments and contingencies (Note 5)                
                 
Stockholders’ equity                
                 
Common stock, $0.001 par value; Class A Common stock 150,000,000 shares authorized, 53,600,790 and 46,006,000 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively     53,601       46,006  
Common stock, $0.001 par value; Class B Common stock 50,000,000 shares authorized, 11,700,000 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively     11,700       11,700  
Additional paid-in capital     18,727,294       11,834,121  
(Accumulated deficit) retained earnings     (5,945,480 )     5,220,238  
Noncontrolling interests     32,008       —  
Total stockholders’ equity     12,879,123       17,112,065  
Total liabilities and stockholders’ equity   $ 28,032,954     $ 23,089,961  

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

1

 

 

Health In Tech, Inc.

 

Consolidated Statements of Operations

(Unaudited)

 

    Three Months Ended
September 30,
    Nine Months Ended  
September 30,
 
    2026     2025     2026     2025  
Revenues                        
Revenues from underwriting modeling (ICE)   $ 632,613     $ 1,389,604     $ 3,374,074     $ 5,832,164  
Revenues from fees (SMR)     5,954,439       7,100,489       20,041,244       19,986,762  
Total revenues     6,587,052       8,490,093       23,415,318       25,818,926  
                                 
Cost of revenues     3,524,692       3,346,277       11,921,066       9,009,841  
                                 
Gross profit   $ 3,062,360     $ 5,143,816     $ 11,494,252     $ 16,809,085  
                                 
Operating expenses                                
Sales and marketing expenses     2,061,695       962,567       6,569,185       3,279,560  
General and administrative expenses     3,116,656       3,455,996       10,104,489       10,472,224  
Provision for credit losses     5,337,768       (4,089 )     6,074,587       1,901  
Research and development expenses     938,564       235,819       2,734,770       1,356,149  
Total operating expenses     11,454,683       4,650,293       25,483,031       15,109,834  
                                 
Other (expense) income:                                
Interest income     64,627       111,699       201,666       305,263  
Interest expenses     (20,000 )     —       (20,000 )     —  
Financing transaction costs     (799,630 )     —       (799,630 )     —  
Change in fair value of SEPA derivative liability     (2,235 )     —       (2,235 )     —  
Change in fair value of convertible notes – FVO     (69,502 )     —       (69,502 )     —  
Other income     310       —       122,644       118,399  
Other expense     (35,375 )     (5,000 )     (87,716 )     (5,000 )
Total other (expense) income, net     (861,805 )     106,699       (654,773 )     418,662  
                                 
(Loss) income before income tax expense   $ (9,254,128 )   $ 600,222     $ (14,643,552 )   $ 2,117,913  
                                 
Income tax benefit (expense)     2,147,653       (148,046 )     3,437,610       (536,514 )
                                 
Net (loss) income   $ (7,106,475 )   $ 452,176     $ (11,205,942 )   $ 1,581,399  
                                 
Net loss attributable to noncontrolling interests   $ (40,062 )   $ —     $ (40,224 )   $ —  
                                 
Net (loss) income attributable to common stockholders   $ (7,066,413 )   $ 452,176     $ (11,165,718 )   $ 1,581,399  
                                 
Net (loss) income per share:                                
Basic   $ (0.11 )   $ 0.01     $ (0.18 )   $ 0.03  
Diluted   $ (0.11 )   $ 0.01     $ (0.18 )   $ 0.03  
                                 
Weighted average common shares outstanding:                                
Basic     63,078,291       56,432,407       61,107,984       55,484,860  
Diluted     63,078,291       58,774,334       61,107,984       57,477,873  

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

2

 

 

Health In Tech, Inc.

 

Consolidated Statements of Changes in Stockholders’ Equity

For the Three and Nine Months Ended September 30, 2026 and 2025

(Unaudited)

 

    Common Stock                          
    Class A     Class B     Additional
Paid-in
    Retained
Earnings
(Accumulated
    Noncontrolling     Total
Stockholders’
 
    Shares     Amount     Shares     Amount     Capital     Deficit)     Interests     Equity  
Balance as of December 31, 2025     46,006,000     $ 46,006       11,700,000     $ 11,700     $ 11,834,121     $ 5,220,238     $ —     $ 17,112,065  
Issuance of common stock in connection with private investment in public equity financing, net of offering costs and placement agent fees     5,600,000       5,600       —       —       5,922,520       —       —       5,928,120  
Stock-based compensation     2,252,276       2,252       —       —       148,992       —       —       151,244  
Net loss     —       —       —       —       —       (1,588,281 )     —       (1,588,281 )
Balance as of March 31, 2026     53,858,276     $ 53,858       11,700,000     $ 11,700     $ 17,905,633     $ 3,631,957     $ —     $ 21,603,148  
Shares surrendered for settlement of minimum statutory tax withholdings     (206,785 )     (207 )     —       —       (256,091 )     —       —       (256,298 )
Offering costs related to resale registration statement reclassified to additional paid-in capital     —       —       —       —       (75,030 )     —       —       (75,030 )
Stock-based compensation     206,592       207       —       —       790,961       —       1,142       792,310  
Contributions from noncontrolling interests     —       —       —       —       —       —       71,428       71,428  
Net loss     —       —       —       —       —       (2,511,024 )     (162 )     (2,511,186 )
Balance as of June 30, 2026     53,858,083     $ 53,858       11,700,000     $ 11,700     $ 18,365,473     $ 1,120,933     $ 72,408     $ 19,624,372  
Shares surrendered for settlement of minimum statutory tax withholdings     (260,402 )     (260 )     —       —       (256,422 )     —       —       (256,682 )
Stock-based compensation     3,109       3       —       —       618,243       —       (338 )     617,908  
Net loss     —       —       —       —       —       (7,066,413 )     (40,062 )     (7,106,475 )
Balance as of September 30, 2026     53,600,790     $ 53,601       11,700,000     $ 11,700     $ 18,727,294     $ (5,945,480 )   $ 32,008     $ 12,879,123  

 

    Common Stock     Additional           Total  
    Class A     Class B     Paid-in     Retained     Stockholders’  
    Shares     Amount     Shares     Amount     Capital     Earnings     Equity  
Balance as of December 31, 2024     42,914,870     $ 42,915       11,700,000     $ 11,700     $ 9,173,017     $ 3,941,396     $ 13,169,028  
Stock-based compensation     58,334       58       —       —       493,113       —       493,171  
Net income     —       —       —       —       —       498,592       498,592  
Balance as of March 31, 2025     42,973,204     $ 42,973       11,700,000     $ 11,700     $ 9,666,130     $ 4,439,988     $ 14,160,791  
Stock-based compensation     1,706,460       1,706       —       —       1,630,475       —       1,632,181  
Net income     —       —       —       —       —       630,631       630,631  
Balance as of June 30, 2025     44,679,664     $ 44,679       11,700,000     $ 11,700     $ 11,296,605     $ 5,070,619     $ 16,423,603  
Stock-based compensation     106,107       106       —       —       283,078       —       283,184  
Net income     —       —       —       —       —       452,176       452,176  
Balance as of September 30, 2025     44,785,771     $ 44,785       11,700,000     $ 11,700     $ 11,579,683     $ 5,522,795     $ 17,158,963  

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

3

 

 

Health In Tech, Inc.

 

Consolidated Statements of Cash Flows

(Unaudited)

 

    Nine Months Ended
September 30,
 
    2026     2025  
CASH FLOWS FROM OPERATING ACTIVITIES:            
Net (loss) income   $ (11,205,942 )   $ 1,581,399  
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:                
Bad debt expense     1,888,293       1,901  
Amortization expense     1,002,534       489,947  
Provision for refund liability     492,256       2,369,088  
Provision for credit losses on other receivables     3,322,302       —  
Provision for credit losses on loans receivable     863,992       —  
Deferred tax benefit     (3,449,020 )     (53,867 )
Interest income, net     (27,997 )     (48,001 )
Financing transaction costs     799,630       —  
Change in fair value of SEPA derivative liability     2,235       —  
Change in fair value of convertible notes – FVO     69,502       —  
Stock-based compensation expense     2,054,453       1,493,686  
Changes in operating assets and liabilities:                
Accounts receivable     (4,309,657 )     776,574  
Other receivables     (1,188,320 )     (3,370,854 )
Prepaid expenses and other assets     1,086,441       (897,331 )
Operating lease right-of-use assets and liabilities, net     (1,817 )     55  
Accounts payable and accrued expenses     2,727,926       2,045,258  
Income taxes payable     —       (205,253 )
Other current liabilities     (1,403,854 )     (1,500,000 )
Net cash (used in) provided by operating activities     (7,277,043 )     2,682,602  
                 
CASH FLOWS FROM INVESTING ACTIVITIES:                
Development of software     (1,801,287 )     (2,358,213 )
Net cash used in investing activities     (1,801,287 )     (2,358,213 )
                 
CASH FLOWS FROM FINANCING ACTIVITIES:                
Proceeds from issuance of common stock in connection with private investment in public equity financing, net of placement agent fees and escrow agent fees     6,381,000       —  
Proceeds from the issuance of convertible notes payable, net of $350,000 discount     6,650,000       —  
Payments of deferred offering costs     (473,635 )     (150,024 )
Payments of financing costs related to SEPA and convertible notes     (580,000 )     —  
Contributions from noncontrolling interests     71,428       —  
Taxes paid related to net share settlement of equity awards     (512,980 )     —  
Net cash provided by (used in) financing activities     11,535,813       (150,024 )
                 
Increase in cash and cash equivalents     2,457,483       174,365  
Cash and cash equivalents, beginning of period     7,669,754       7,849,248  
Cash and cash equivalents, end of period   $ 10,127,237     $ 8,023,613  
                 
Supplemental disclosures of cash flow information:                
Cash paid for interest   $ 20,000     $ —  
Cash paid for income taxes   $ 10,035     $ 823,323  
                 
Summary of noncash investing and financing activities:                
Accrued deferred offering costs included in accounts payable and accrued expenses   $ 64,285     $ 55,827  
Accrued development of software included in accounts payable and accrued expenses   $ 800,058     $ 401,964  
Accrued financing costs in accounts payable and accrued expenses   $ 219,630     $ —  
Reclassification of deferred offering costs to additional paid-in capital upon private investment in public equity financing   $ 527,910     $ —  
Stock-based compensation capitalized for software development   $ 37,432     $ —  

 

The accompanying notes are an integral part of these unaudited consolidated financial statements

 

4

 

 

Health In Tech, Inc.

 

Notes to Consolidated Financial Statements

(Unaudited)

 

1. Organization

 

Description of Business

 

Health in Tech, Inc. (“HIT”), together with its consolidated subsidiaries (collectively, the “Company”), simplifies sales, service processes and reduces sales cycle time for third-party administrators and brokers. HIT was incorporated in November 2021 in the State of Nevada, and is based in Stuart, Florida. The Company was created with the intention of consolidating each of three standalone entities into a single organization: Stone Mountain Risk, LLC (“SMR”), Health Intelligence Card, LLC (“Hi Card”), and International Captive Exchange, LLC (“ICE”). Beginning April 10, 2026, the Company also consolidated HITChain Inc.

 

HITChain Inc. (“HITChain”), was incorporated as a Delaware corporation on January 2, 2026, to develop a blockchain-enabled healthcare insurance claims processing platform. This platform aims to establish an immutable, transparent and efficient claims ecosystem to reduce administrative costs and improve trust across all stakeholders. HITChain completed its initial capitalization on April 10, 2026. The Company contributed $428,571 in exchange for Class A common stock, representing an 85.72% economic interest and 28.58% voting interest. The Company’s Chief Executive Officer and Chief Financial Officer each contributed $35,714 in exchange for Class B common stock, representing a 7.14% economic interest and 35.71% voting interest each. Each share of Class A common stock is entitled to one vote, while each share of Class B common stock is entitled to 15 votes. Except for the differences in voting rights, the Class A and Class B common stock have identical economic rights and other terms, including rights with respect to dividends and distributions and rights upon liquidation.

 

On September 28, 2026 and September 30, 2026, the Company formed Anchor 36, LLC (“Anchor 36”) and HITRix, LLC (“HITRix”), respectively, to support its planned program offerings. Neither entity had commenced operations as of September 30, 2026.

 

The Company’s unaudited consolidated financial statements include the accounts of HIT, its wholly owned subsidiaries, and HITChain beginning April 10, 2026, for which the Company has been deemed to be the primary beneficiary under ASC 810 (see Note 2).

  

2. Summary of Significant Accounting Policies

 

Basis of Presentation

 

The Company’s unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial information. Certain information and note disclosures normally included in the consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in the Annual Report on Form 10-K for the year ended December 31, 2025.

 

The consolidated balance sheet as of December 31, 2025 included herein was derived from the audited financial statements as of that date, but does not include all disclosures including notes required by GAAP.

 

The accompanying consolidated financial statements reflect all normal recurring adjustments that are necessary to present fairly the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year ending December 31, 2026.

 

5

 

 

Health In Tech, Inc.

 

Notes to Consolidated Financial Statements

 

2. Summary of Significant Accounting Policies (cont.)

 

Segments

 

The Company’s chief operating decision maker (“CODM”), the Chief Executive Officer and executive committee, manages the Company’s business activities as a single operating and reportable segment at the consolidated level. Accordingly, the CODM uses consolidated net income to measure segment profit or loss, allocate resources and assess performance. Further, the CODM reviews and utilizes functional expenses (cost of revenues, sales and marketing, research and development, and general and administrative expenses) at the consolidated level to manage the Company’s operations. As of September 30, 2026 and December 31, 2025, the Company did not have a material balance of long-lived assets located outside of the United States.

 

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. Significant items subject to such estimates and assumptions include, but are not limited to, accounts receivable allowance for revenue billing changes driven by headcount changes during the billable period, allowance for credit losses, useful lives of software, variable consideration of revenues from underwriting modeling, the fair value of convertible notes and the derivative liability associated with the Standby Equity Purchase Agreement and stock-based compensation expense. It is at least reasonably possible that the estimates of the effect of conditions, situations or sets of circumstances that existed at the date of the financial statements, which management considered in formulating its estimates, could change in the near term due to one or more future confirming events. Actual results could differ from those estimates. 

 

Variable Interest Entity (“VIE”)

 

The Financial Accounting Standards Board (“FASB”) provides guidance in ASC 810, Consolidation (“ASC 810”) for determining whether an entity is a VIE. VIE’s are defined as entities in which equity investors of the entity do not have the characteristics of a controlling financial interest or do not have sufficient equity at risk for the entity to finance its activities without additional subordinated financial support. A VIE is required to be consolidated by its primary beneficiary, which is the party that (i) has the power to control the activities that most significantly impact the VIE’s economic performance and (ii) has the obligation to absorb losses, or the right to receive benefits, of the VIE that could potentially be significant to the VIE.

 

The Company determined that HITChain is VIE because its equity investment at risk is not sufficient to finance its expected activities without additional subordinated financial support.

 

The Company also determined that it is the primary beneficiary of HITChain. This conclusion was based on the following:

 

  ● The Company holds 85.72% of HITChain’s economic interest but 28.58% of its voting interest through Class A common stock. The Company’s Chief Executive Officer and Chief Financial Officer each hold 7.14% of HITChain’s economic interest and, together, 71.42% of its voting interest through Class B common stock. The Company, together with its related-party group, has the power to direct the activities that most significantly affect HITChain’s economic performance, such as software development strategy, commercialization decisions and financing activities.

 

  ● The Company has the obligation to absorb losses or the right to receive benefits that could potentially be significant to HITChain.

 

  ● Among the members of the related-party group, the Company is the party most closely associated with HITChain, as it holds the substantial majority of HITChain’s economic interest.

 

6

 

 

Health In Tech, Inc.

 

Notes to Consolidated Financial Statements

 

2. Summary of Significant Accounting Policies (cont.)

 

HITChain did not meet the definition of a business as of April 10, 2026. Upon initial consolidation of HITChain, the Company recognized a loss of $37,341, primarily attributable to formation-related liabilities incurred by HITChain prior to its initial capitalization.

 

By the end of May 2026, following an internal business review, the Company transferred certain in-development software assets with a carrying amount of $699,164 to HITChain. The transfer was recorded at carrying value, with no gain or loss recognized. HITChain recorded a corresponding intercompany payable to the Company, which was eliminated in consolidation. Subsequent to the transfer and through September 30, 2026, the Company continued to fund HITChain’s development activities. HITChain recorded the related amounts as an intercompany payable, which was eliminated in consolidation.

 

The following table summarizes the carrying amounts of the assets and liabilities of HITChain included in the Company’s unaudited consolidated financial statements as of September 30, 2026:

 

    September 30,
2026
 
Assets      
Cash and cash equivalents   $ 319,080  
Prepaid expenses and other current assets     1,836  
Software     1,088,358  
Deferred tax assets, net     73,165  
Total assets   $ 1,482,439  
Liabilities        
Accounts payable and accrued expenses   $ 122,372  
Total liabilities   $ 122,372  

 

The assets of HITChain can only be used to settle the obligations of HITChain and are not available to satisfy the obligations of the Company. The creditors of HITChain have no recourse to the general credit of the Company. 

 

The Company consolidated HITChain beginning April 10, 2026. The remaining 14.28% economic interest in HITChain is presented as noncontrolling interests in the accompanying unaudited consolidated financial statements.

 

Cash and Cash Equivalents

 

Cash and cash equivalents consist of demand deposit with original maturities less than three months, which are unrestricted as to withdrawal or use.

 

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, accounts receivable and loans receivable for financial periods ended September 30, 2026 and December 31, 2025. The Company further manages its credit risk on liquid funds through diversification of investment type and credit exposures. For cash, the Company places cash deposits with large financial institutions. For accounts receivable, the credit risk is managed through the use of mitigating controls, including the use of credit checks and credit limits on customers. For loans receivable, the Company monitors the exposures and counterparty credit risk on a regular basis.

 

Concentration of customers

 

Revenues from Stop-Loss Insurance Carriers

 

For the three and nine months ended September 30, 2026 and 2025, one stop-loss insurance carrier (“Carrier A”) individually represented greater than 10% of Company’s total gross revenues. Revenue from Carrier A accounted for 10.1% and 14.8% of the Company’s total gross revenues for the three and nine months ended September 30, 2026, respectively. The amount due from Carrier A was approximately 48.4% of gross accounts receivable, after allowance for revenue billing adjustments but before the allowance for credit losses, as of September 30, 2026. For the three and nine months ended September 30, 2025, revenue from Carrier A accounted for 28.1% and 27.1% of the Company’s total gross revenues for the three and nine months ended September 30, 2025, respectively. The amount due from Carrier A was approximately 39.6% of accounts receivable, after allowance for revenue billing adjustments but before the allowance for credit losses, as of September 30, 2025. While the Company is working to cooperate with more stop-loss insurance carriers, it may experience temporary service disruptions in the event the Company deems it necessary to cease use of a stop-loss insurance carrier.

 

7

 

 

Health In Tech, Inc.

 

Notes to Consolidated Financial Statements

 

2. Summary of Significant Accounting Policies (cont.)

 

Revenues from Business Employer Customers

 

The Company does not have significant concentration of revenues from any of its business employer customers. The Company has a diversified customer base and did not have any business employer that accounted for more than 2.0% or 1.5% of the Company’s total gross revenues for the three and nine months ended September 30, 2026 and 2025, respectively. No individual business employer accounted for more than 2.5% or 5.0% of accounts receivable, after allowance for revenue billing adjustments but before the allowance for credit losses, as of September 30, 2026 and 2025, respectively.

 

Concentration of Cost of Revenues Service Providers

 

For the three months ended September 30, 2026, the Company’s three primary service providers represented 18.8%, 23.2% and 18.7% of the Company’s cost of revenues, respectively. For the nine months ended September 30, 2026, these three primary service providers accounted for 28.3%, 18.3% and 14.9% of the Company’s cost of revenues, respectively. As of September 30, 2026, they accounted for 45.4%, 11.4% and 2.5% of accounts payable balance, respectively. For the three months ended September 30, 2025, the Company’s three primary service providers (including one data service provider, disclosed in “Concentration of Data Service Providers from Third Party Artificial Intelligence Providers”) accounted for 79.2%, 5.4% and 4.5% of the Company’s cost of revenues, respectively. For the nine months ended September 30, 2025, these three primary service providers accounted for 78.9%, 6.0% and 4.9% of the Company’s cost of revenues, respectively. As of September 30, 2025, they accounted for 74.4%, 0.0% and 0.0% of accounts payable balance, respectively. The Company, if necessary, could utilize others as part of its service offerings with a limited impact on the Company’s operations.

 

Concentration of Data Service Providers from Third Party Artificial Intelligence Providers

 

The Company currently utilizes one third-party Artificial Intelligence (“AI”) data service provider. For the three and nine months ended September 30, 2026, this provider accounted for 5.1% and 4.5% of the Company’s cost of revenues. As of September 30, 2026, this provider accounted for 1.1% of accounts payable balance. For the three and nine months ended September 30, 2025, this provider accounted for 5.4% and 6.0% of the Company’s cost of revenues, respectively. As of September 30, 2025, this provider accounted for 0.0% of accounts payable balance. The Company, if necessary, could utilize others as part of its service offerings with a limited impact on the Company’s operations.

 

Leases

 

The Company accounts for its leases under the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) ASC 842, Leases (“ASC 842”).

 

The Company assesses its contracts at inception to determine whether the contract contains a lease, including evaluation of whether the contract conveys the right to control an explicitly or implicitly identified asset for a period of time. The Company recognizes right-of-use assets and lease liabilities that represent the net present value of future lease payments utilizing a discount rate corresponding to the Company’s incremental borrowing rate and amortizing over the remaining terms of the leases, which was determined to be 10% during the three and nine months ended September 30, 2026 and 2025. The Company accounts for the leases of less than twelve months as short-term leases and does not recognize right-of-use assets and corresponding lease liabilities. During the year ended December 31, 2025, the Company entered into a 12-month short-term lease agreement with a monthly fixed rent payable, commencing in December of 2025. The Company had one lease classified as short-term leases as of December 31, 2025. During the three months ended March 31, 2026, the Company terminated the short-term lease agreement. The Company had no leases classified as short-term leases as of September 30, 2026.

 

8

 

 

Health In Tech, Inc.

 

Notes to Consolidated Financial Statements

 

2. Summary of Significant Accounting Policies (cont.)

 

Accounts Receivable and Allowance for Credit Losses and for Revenue Billing Adjustments

 

Accounts receivable are carried at original invoice amount, less any estimate made for doubtful accounts or credit losses. In accordance with ASC 326, Financial Instruments — Credit Losses, the allowance for credit losses is the Company’s best estimate of the amount of expected credit losses in the Company’s existing receivables over the contractual term. The Company evaluates its exposure to credit loss on both a collective and individual basis. The Company evaluates such receivables on an individual customer basis and takes into account any relevant available information, which begins with historical credit loss experience and consideration of current and expected conditions and market trends (such as general economic conditions, other microeconomic and macroeconomic considerations, etc.) and reasonable and supportable forecasts that could impact the collectability of such receivables over the contractual term individually or in the aggregate. Changes in circumstances relating to these factors may result in the need to increase or decrease the allowance for credit losses in the future. The allowance for credit losses was $1,882,457 and $0 as of September 30, 2026 and December 31, 2025, respectively. The transition to a new carrier required the Company, the applicable third-party administrators (“TPAs”) and the carriers to perform additional policy-level reconciliations involving enrollment, premiums, claims and other adjustments. These procedures delayed the settlement and collection of certain Accounts Receivable.

 

During the three months ended September 30, 2026, the TPAs began making payments and collection activity improved. The Company evaluated the remaining receivables under ASC 326, considering their aging, reconciliation status, historical collection experience, counterparty creditworthiness and current collection trends. Although collections improved, certain balances remained outstanding for an extended period and certain reconciliations remained unresolved. Accordingly, the Company recorded an allowance for credit losses of $1,882,457 as of September 30, 2026. The Company continues to pursue collection of the outstanding amounts and will reassess the allowance at each reporting date based on collection activity and other relevant facts and circumstances.

 

The following table summarizes the changes in the allowance for credit losses during the nine months ended September 30, 2026 and 2025:

 

    September 30,
2026
    September 30,
2025
 
Beginning balance     —       —  
Current period provision     1,888,293       1,901  
Write-offs and other     (5,836 )     (1,901 )
Ending balance     1,882,457       —  

 

The Company also makes the allowance for revenue billing adjustments, under the consideration of the revenues associated with enrolled customers would have changed during the 12-month contractual term. The final reconciliation with the customers is on the 14th month. During the year ended December 31, 2025, the Company’s monthly revenue provision was 1.3% of total revenues. The provision for customers ending their 12-month plan as of December 31, 2025 without completion of reconciliation was $143,251. The total provision amounted to $634,982 or 1.7% of total revenues for the year ended December 31, 2025. The balance of accounts receivable allowance for revenue billing adjustments related to current year enrollment adjustment was $287,651 as of December 31, 2025. In the first nine months of 2026, the Company completed the reconciliation for customer policies that ended as of December 31, 2025. The balance of accounts receivable allowance for revenue billing adjustments related to prior year enrollment adjustment was $5,341 as of September 30, 2026. Starting from January 2026, the Company’s monthly revenue provision was 1.7% of total revenues, which was based on the full review of 2025 revenue adjustments. The balance of accounts receivable allowance for revenue billing adjustments related to current year enrollment adjustment was $308,197 as of September 30, 2026. This incorporates three separate categories:

 

  ● There is a revenue adjustment that is driven by enrollment changes. It is based upon the actual individuals enrolled in a plan throughout the term compared to the initial employees enrolled in the first month.

 

  ● There is a revenue adjustment that is determined at the cancellation of a policy due to delayed payment. Specifically, a Carrier may cancel a plan when the customer does not remit payment in accordance with the respective agreement for a certain period of time (approximately three months). This may be adjusted if there is a slight delay in the completion and execution of required legal documents.

 

  ● There is a revenue adjustment and change triggered by re-underwrite of stop loss insurance policy, as defined by the Carrier’s underwriting guideline.

 

9

 

 

Health In Tech, Inc.

 

Notes to Consolidated Financial Statements

 

2. Summary of Significant Accounting Policies (cont.)

 

Other Receivables

 

Certain business customers elect to receive a discount on premiums payable to carriers. In return, carriers can collect and retain these customers’ positive claim fund balance amounts. The positive claim fund is maintained in a designated account specifically earmarked for claims, held by the employer, known as “Deferred Administrative Surplus.” As the platform company, the Company tracks and processes claims for carriers. With necessary information for collection available on our platform, the Company signed an agreement on December 28, 2023 with the third-party Roscommon Captive Management and Roscommon Insurance Company (collectively the “Carrier”), to purchase the rights, title, interest, and collection rights to fees totaling $3,100,000 in Deferred Administrative Surplus for $1,650,000, which is 53% of the total collection rights (the “2023 Purchase”). Additionally, the Company entered into a separate agreement with the Carrier on March 18, 2025, to purchase the final batch of Deferred Administrative Surplus totaling $17,408,421 for $3,481,684, which is 20% of the total collection rights (the “2025 Purchase”). Subsequent to the purchase, following the final review and net of inactive insurance policies, the face value of the 2025 Purchase was approximately $13.8 million. This final batch includes stop-loss insurance policies unexpired as of the date of the 2025 Purchase (“active policies”), which were not present in the 2023 Purchase.

 

When entering into a stop-loss insurance policy, a business employer can elect to purchase discounted stop-loss insurance policies premiums from the Carrier by agreeing to return any positive balance in claim fund. These claim funds are held in the name of the business employer, and the Carrier has no claim to these funds until the policy and the policy run-out period ends, which is 18 months following commencement of the policy term (the “Policy End Date”). The “run-out period” refers to six-month period after the policy or plan has expired during which claims can still be submitted and processed. After the Policy End Date, any funds remaining in the claim fund belong to the Carrier. The Carrier will provide the business employers with a reconciliation of what amounts are specifically owed. This is based on the amount of funds in the business employers’ claim fund account, and the value of claims incurred during the policy and run-out period (the “Deferred Administrative Surplus”). The Deferred Administrative Surplus is owned by the Carrier and not subject any contingencies other than the ability to collect from the business employer.

 

As part of the Company’s services to the Carrier, ICE contracted with the Carrier to collect premium and process claims expense. Therefore, in its internal system, the Company can calculate the approximate amount of positive balance in the claims fund. The exact amount will be determined after full reconciliation of the claims fund after completion of the run-out period.

 

In the case of the 2023 Purchase, the Company purchased the policies with related run-out periods that had lapsed and had positive claim fund balances according to the Company’s internal system. As such, the Company knows the value of the Deferred Administrative Surplus purchased. The 2025 Purchase includes all the remaining policies with deferred administrative surplus as a product feature from the Carrier. Collectively, the Carrier and HIT platform stopped offering this feature in August 2024. Thus, 2025 purchased policies are in different periods and stages, including in the policy coverage period, in the run-out period and the out of run-out periods. For policies in the coverage period and in the run-out periods, the final Deferred Administrative Surplus cannot be determined until the policy completes the run-out period and finalizes the reconciliation. The run-out period for the latest expiring policies included in the 2025 Purchase ended on December 31, 2025. Accordingly, no additional claims relating to those policies may be submitted following expiration of the applicable run-out period. Following the purchase, following completion of the run-out period, the Company obtains and reviews final claims and related information from the TPAs and completes a policy-level reconciliation to determine the amount of Deferred Administrative Surplus ultimately collectible. Once the reconciliation for a policy is sufficiently complete, the Company issues the applicable collection request and proceeds with its collection efforts. The Company requests payment within 30 days of the collection request.

 

The key risks associated with the collection of the Deferred Administrative Surplus relate to the Company’s limited collections experience related to the Deferred Administrative Surplus at the time of purchase from the Carrier. To reduce the Company’s collection risk, the Company negotiated with the Carrier to purchase the Deferred Administrative Surplus at 53% the estimated face value of the 2023 Purchase and 20% of estimated face value of 2025 Purchase. This was due to the Carrier does not have the sufficient resources and procedures to collect the Deferred Administrative Surplus. Moreover, the 2025 Purchase was the final batch of policies with the Deferred Administrative Surplus. The Company would have to collect less than 53% of the Deferred Administrative Surplus balance for the 2023 Purchase to incur a loss, and less than 20% for the 2025 Purchase to incur a loss. As of September 30, 2026, the Company collected $1,272,413 for the 2023 Purchase and $333,486 for the 2025 Purchase. The lower collection amount related to the 2025 Purchase reflects the ongoing reconciliation and collection process. As of September 30, 2026, the underlying policies were at varying stages of the reconciliation and collection process. Although the contractual run-out period has ended, completion of the reconciliation and collection process requires the Company to obtain and validate information from the applicable TPAs and resolve any remaining policy-level items.

 

10

 

 

Health In Tech, Inc.

 

Notes to Consolidated Financial Statements

 

2. Summary of Significant Accounting Policies (cont.)

 

The purchase of the Deferred Administrative Surplus does not represent a purchase of a financial asset with credit deterioration as defined in accordance with ASC 326, Financial Instruments — Credit Losses. Furthermore, the Company only has approximately three months of historical collection success rates at the time of entering into the 2023 Purchase contract. These collection success rates are based upon limited experience given the Company has only collected on these types of assets for a short period of time. Moreover, the historical collection success rates for the 2023 Purchase were not applicable for the 2025 Purchase at contract inception, due to the differing components of the two purchases, such as active policies in the 2025 Purchase. As such, the Company has accounted for these assets under a nonaccrual approach. The Company will continue to assess this policy as additional collection information is received and collection trends are identified. The Company recorded the consideration as other receivables both as of September 30, 2026 and as of December 31, 2025. The Company collected $43,203 and $55,427 under the Deferred Administrative Surplus during the three and nine months ended September 30, 2026, respectively. The Company collected $39,431 and $205,233 under the Deferred Administrative Surplus during the three and nine months ended September 30, 2025. Payments made for purchases and collections from the Deferred Administrative Surplus are included in the “other receivables” line of operating activities in the Company’s consolidated statements of cash flows. 

 

The following tables summarize the changes in the gross carrying amounts, allowances for credit losses, and net carrying amounts of receivables associated with the 2023 Purchase and the 2025 Purchase.

 

2023 Purchase

 

    Gross
Receivables
    Allowance     Net
Receivables
 
Purchases   $ 1,650,000     $ —     $ 1,650,000  
Accumulated Collections     (1,272,413 )     —       (1,272,413 )
Provision for credit losses     —       (377,587 )     (377,587 )
Balance as of December 31, 2025   $ 377,587     $ (377,587 )   $ —  

 

There were no changes in the gross receivables related to the 2023 Purchase or the related allowance for credit losses during the nine months ended September 30, 2026. Accordingly, the net carrying amount of these receivables remained $0 as of September 30, 2026.

 

2025 Purchase 

 

    Gross
Receivables
    Allowance     Net
Receivables
 
Purchases   $ 3,481,684     $ —     $ 3,481,684  
Accumulated Collections     (278,059 )     —       (278,059 )
Balance as of December 31, 2025   $ 3,203,625     $ —     $ 3,203,625  
Collections     (12,224 )     —       (12,224 )
Balance as of March 31, 2026   $ 3,191,401     $ —     $ 3,191,401  
Provision for credit losses     —       (739,773 )     (739,773 )
Write-offs     (23,203 )     23,203       —  
Balance as of June 30, 2026   $ 3,168,198     $ (716,570 )   $ 2,451,628  
Collections     (43,203 )     —       (43,203 )
Provision for credit losses     —       (2,408,425 )     (2,408,425 )
Balance as of September 30, 2026   $ 3,124,995     $ (3,124,995 )   $ —  

  

The run-out period for the latest expiring policies included in the 2025 Purchase ended on December 31, 2025. Following completion of the applicable run-out periods, the Company obtains and reviews final claims and related information from the applicable TPAs, performs policy-level reconciliations and pursues collection of amounts determined to be due to the Company.

 

11

 

 

Health In Tech, Inc.

 

Notes to Consolidated Financial Statements

 

2. Summary of Significant Accounting Policies (cont.)

 

The Company evaluates the receivables associated with the Deferred Administrative Surplus for expected credit losses at each reporting date. In estimating the allowance for credit losses, the Company considers, among other factors, the aging and collection history of the receivables, the length of time amounts have remained outstanding, the status and progress of the reconciliation and collection process, information obtained through collection efforts, counterparty-specific information and other relevant facts and circumstances affecting expected collectability.

 

As of June 30, 2026, the Company had recorded an allowance for credit losses of $716,570 related to the 2025 Purchase, resulting in a net carrying amount of $2,451,628. During the three months ended September 30, 2026, the Company collected approximately $43,203 of the outstanding Deferred Administrative Surplus. Based on the limited amount collected during the quarter and the lack of sufficient progress in completing the remaining reconciliation and collection process, the Company revised its estimate of expected credit losses as of September 30, 2026. Accordingly, during the three months ended September 30, 2026, the Company recorded an additional provision for credit losses of $2,408,425. As a result, as of September 30, 2026, the Company had recorded an allowance for credit losses equal to the entire remaining gross carrying amount of $3,124,995 associated with the 2025 Purchase, resulting in a net carrying amount of $0.

 

The recognition of a full allowance for credit losses does not constitute a write-off of the underlying receivables or indicate that the Company has ceased its reconciliation or collection efforts. The Company will continue to pursue reconciliation and collection of the outstanding amounts and will reassess the allowance for credit losses at each reporting date based on collection activity, the status of individual reconciliations, aging of the receivables, responsiveness of the applicable TPAs and counterparties and other relevant facts and circumstances. The Company distinguishes the recognition of an allowance for credit losses from the ultimate write-off of a receivable. A receivable may be fully reserved before it is formally written off. The Company will write off individual receivable balances when it concludes that collection is no longer reasonably expected, including after the applicable reconciliation has been completed and reasonable collection efforts have been exhausted. Accordingly, the Company is not currently able to reasonably estimate the exact date on which the remaining amounts associated with the 2025 Purchase will be formally written off. The timing of any ultimate write-off may extend beyond December 31, 2026.

 

Credit loss expense related to Deferred Administrative Surplus, which is presented within Provision for credit losses in the Company’s consolidated statements of operations, was $2,408,425 and $3,148,198 for the three and nine months ended September 30, 2026, respectively, compared with $0 for the three and nine months ended September 30, 2025. The credit loss expense recognized during the three and nine months ended September 30, 2026 related entirely to the 2025 Purchase. No additional credit loss expense related to the 2023 Purchase was recognized during the three or nine months ended September 30, 2026.

 

No income was recognized on the Deferred Administrative Surplus during any of the periods presented because collections received did not exceed the carrying value of the applicable receivables at the time of collection. Under the Company’s nonaccrual approach, income is recognized only upon actual cash receipt and only to the extent amounts received exceed the carrying value of the applicable receivable at the time of collection.

 

In addition to the Deferred Administrative Surplus discussed above, other receivables increased by $1,213,184 related to amounts due from a TPA and $192,375 in miscellaneous receivables as of September 30, 2026, compared to December 31, 2025. The TPA receivable arose from fees payable to the Company that the TPA erroneously remitted to an unrelated third party.

 

Loans Receivable, Net

 

On October 10, 2023, the Company entered into a Promissory Note Agreement with Kang Youle Limited, which constitutes an unsecured lending arrangement. Under this Promissory Note Agreement, the Company agreed to lend $800,000 in principal amount, which bears 8% interest per annum. The note’s maturity date is October 10, 2026. During the three months ended September 30, 2026, the Company recorded a provision for credit losses of $863,992, representing the entire outstanding principal and accrued interest, due to the borrower’s financial difficulties and management’s assessment of its ability to repay the outstanding amounts. The allowance for credit losses was $863,992 and $0 as of September 30, 2026 and December 31, 2025, respectively. The Company recorded this loan receivable at amortized cost, net of the allowance for credit losses, on the consolidated balance sheets. See Note 3.

 

12

 

 

Health In Tech, Inc.

 

Notes to Consolidated Financial Statements

 

2. Summary of Significant Accounting Policies (cont.)

 

Software Capitalization

 

The Company incurs certain costs associated with the development of its Hi-Card, eDIYBS systems and other systems. In accordance with ASC 350-40, Intangibles — Goodwill and Other: Internal-Use Software, the Company capitalizes certain costs associated with the development of its internal-use software after the preliminary project stage is complete and until the design, coding, installation, and testing of the software have been completed. Upgrades and enhancements are capitalized if they will result in added functionality. Capitalized costs are amortized over an expected three-year period. In May of 2023, the Company determined that its eDIYBS system was ready for its intended use. In September 2025, an expansion of the eDIYBS system was also completed and placed into service. As such, the Company has entered the eDIYBS system in the post-implementation phase. The Company has amortized $278,747 and $1,002,534 of the capitalized costs associated with eDIYBS and other systems for the three and nine months ended September 30, 2026, respectively, and $217,981 and $489,947 for the three and nine months ended September 30, 2025, respectively, which is included in the cost of revenues line item of the Company’s consolidated statements of operations. During the three and nine months ended September 30, 2026, the Company capitalized $1,229,814 and $2,620,425, respectively, of software development costs, and $881,562 and $2,710,177 during the three and nine months ended September 30, 2025, respectively.

 

Impairment of Long Lived Assets

 

In accordance with ASC 360, Property, Plant, and Equipment, the Company evaluates the recoverability of amortizable long-lived assets whenever events or changes in circumstances indicate the carrying value of such asset may not be recoverable. Should there be an indication of impairment, the Company tests recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss. There were no impairment losses recognized on long-lived assets during the three and nine months ended September 30, 2026 and 2025.

 

Fair Value Option of Accounting

 

When financial instruments contain various embedded features that may otherwise require bifurcation and separate accounting, Accounting Standards Codification (“ASC”) 825, Financial Instruments, allows issuers to elect the fair value option (“FVO”) for the entire eligible instrument. The FVO may be elected on an instrument-by-instrument basis and is irrevocable unless a new election date occurs. The FVO allows the issuer to account for the entire financial instrument at fair value with subsequent remeasurements of that fair value recorded through the statements of operations at each reporting date, except for changes attributable to instrument-specific credit risk, which are recognized in other comprehensive income. A financial instrument is generally eligible for the FVO if, amongst other factors, no part of the convertible, or contingently convertible, instrument is classified in stockholders’ equity.

 

Based on its assessment of the applicable eligibility requirements, the Company elected the FVO for its eligible convertible note payable at initial recognition. Convertible notes for which the Company elects the FVO are referred to as the “FVO Notes.” The Company makes such elections on an instrument-by-instrument basis because of operational efficiencies in valuing and reporting these debt instruments in their entirety at each reporting date.

 

13

 

 

Health In Tech, Inc.

 

Notes to Consolidated Financial Statements

 

2. Summary of Significant Accounting Policies (cont.)

 

The FVO Notes contain embedded features that would otherwise be evaluated for bifurcation under ASC 815, Derivatives and Hedging. Under the FVO, the Company accounts for each FVO Note, including its embedded features, as a single instrument. The FVO Notes are initially recorded at fair value as liabilities on the consolidated balance sheets and are subsequently re-measured at fair value at the end of each reporting period presented within the consolidated financial statements. Accrued and unpaid contractual interest is included in the fair value measurement of the FVO Notes. The changes in the fair value of the FVO Notes, other than changes attributable to instrument-specific credit risk are recorded in change in fair value of convertible notes – FVO in the consolidated statements of operations. The component related to accrued and unpaid contractual interest is also included within change in fair value of convertible notes – FVO on the consolidated statements of operations rather than presented separately as interest expense. See additional information on valuation methodologies and significant assumptions used in Note 10.

 

Fair Value of Financial Instruments

 

The Company applies the provisions of ASC 820, Fair Value Measurements and Disclosures, which provides a single authoritative definition of fair value, sets out a framework for measuring fair value and expands on required disclosures about fair value measurement. Fair value represents the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses the following hierarchy in measuring the fair value of the Company’s assets and liabilities, focusing on the most observable inputs when available:

 

Level 1 - Valuations based on quoted prices for identical assets and liabilities in active markets.

 

Level 2 - Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.

 

Level 3 - Valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.

 

To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

 

The Company’s financial instruments include cash and cash equivalents, accounts receivable, other receivables, loans receivable, accounts payable and accrued expenses, convertible notes payable and SEPA (as defined in Note 7 – Standby Equity Purchase Agreement) derivative liability. The carrying amounts of cash and cash equivalents and accounts payable and accrued expenses approximate their fair value due to their short-term nature. The carrying amounts of accounts receivable, other receivables and loans receivable are net of an allowance that reflects management’s best estimate of expected credit losses. The Company’s convertible notes payable and SEPA derivative liability are measured at fair value on a recurring basis. See Note 10 for fair value measurements.

 

14

 

 

Health In Tech, Inc.

 

Notes to Consolidated Financial Statements

 

2. Summary of Significant Accounting Policies (cont.)

 

Revenue Recognition

 

The objective of ASC 606, Revenue from Contracts with customers (“ASC 606”) is to establish the principles that an entity shall apply to report useful information to users of the financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from a contract with a customer. An entity shall recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services, as defined in ASC 606-10-10-1 and ASC 606-10-10-2.

 

This evaluation under ASC 606 follows a five-step model, including:

 

  Step 1: Identify the contract(s) with a customer
     
  Step 2: Identify the performance obligations in the contract
     
  Step 3: Determine the transaction price
     
  Step 4: Allocate the transaction price to the performance obligations in the contract
     
  Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation

 

In general, ASC 606’s core principle is to recognize revenue in a manner that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Required disclosures under ASC 606 include qualitative and quantitative information about contracts with customers and significant judgments and estimates as to the application of the 5-step revenue recognition analysis, among others. 

 

The Company accounts for its revenue under the accounting guidance of ASC 606. The Company’s contracts that are within the scope of ASC 606 specifically relate to the services that are associated with customers who purchase self-funded benefits plans. These plans are facilitated through a network of brokers, TPAs, MGUs, carriers, and other third-party agents.

 

Identification of the Performance Obligations

 

The Company analyzes each of the deliverables pursuant to its contracts with customers. For each of the deliverables, the Company performs a detailed analysis to determine whether the deliverables are separately identifiable. The Company notes that although the deliverables can vary from day to day, all specifically relate to one kind of service, representing one performance obligation that is provided by each of its subsidiaries (SMR and ICE), as further described below.

 

SMR Specific Considerations

 

Program and Platform Management Services (Legacy)

 

Under SMR’s Program and platform management services, the Company’s insurance marketplace allows brokers to customize an employer’s self-funded benefits plan and stop loss insurance policies. When licensed brokers log in to the Company’s platform, they upload an employee census representing the employee base of the business employer, select which network they wish to use, what plan designs they want to offer to the business employer and then quickly obtain a bindable self-funded medically underwritten stop loss quote they can provide to their business customers. The chosen vendors provide benefit services as outlined on the platform. The fees that the Company and others charge for the service offerings within the quote are outlined and expressly agreed to by the employer. The employer customizes their health insurance plan and executes an annual agreement. This agreement includes a sold case breakdown (SCB) that outlines the individual stop loss insurance and benefits service offerings selected by the employer and the cost of each, including any optional services offered by the Company or other vendors. Through this, the Company is aware of the services that the broker is offering to the employer for the health insurance plan period, which is normally twelve (12) months. This includes each of the performance obligations provided by its subsidiaries as further outlined below. Subsequent to the execution of the initial bindable SCB with its customers, the Company may modify the health insurance plan during the plan period when a non qualified event occurs based on the definition provided by the carriers. For example, if there is a significant fluctuation or changes of enrolled employees (EEs) from the first month. 

 

15

 

 

Health In Tech, Inc.

 

Notes to Consolidated Financial Statements

 

2. Summary of Significant Accounting Policies (cont.)

 

The Company has business relationships with licensed brokers, as licensed brokers register on the Company’s platform to select and sell benefits plans and stop loss policies to employers as discussed above. However, there is no contractual relationship between the Company or any of its subsidiaries and the brokers. The Company’s platform provides credentialing for licensed brokers, allowing them to access its marketplace to select and sell self-funded benefits plans for the business employer at no cost. Brokers are paid by the businesses, with no contractual relationship between the Company and the brokers, only a credentialing process, and free access is provided.

 

TPAs are contracted and authorized by the business employers to enter into service contracts with SMR on behalf of the business employers. ASC 606 defines a customer as a party that has contracted with an entity to obtain goods or services that are an output of the ordinary activities of the company in exchange for consideration. SMR is not providing services to the TPAs, but instead, has contracts to collaborate with the TPAs to facilitate the administration of health benefit plans and stop-loss insurance policies to its customers, which are the business employers. The TPA will administer the purchased health benefits plan and manage the multiple service providers associated with the health benefits plan and stop-loss insurance policy. Such service providers are listed on the bindable quotes via the bindable sold case breakdown, which outlines the individual stop loss insurance and benefits service offerings selected by the business and the cost of each. Only the business employer can start or terminate the relationship with SMR. The TPA cannot start or terminate the relationship with SMR. As such, the Company has concluded that the TPAs are not customers and that the business employers are the customers of SMR pursuant to ASC 606.

 

Effective January 1, 2026, the Company has pivoted its services to offer pre-designed self-funded plans to employers, leveraging years of experience in selecting and managing the vendors that are essential to the plan.

 

Self-funded Plan Administration Services (Effective January 1, 2026)

 

SMR develops pre-configured, self-funded health benefit plans that integrate full administrative services and then are bundled with stop-loss insurance for employer clients. SMR delivers a comprehensive, end-to-end self-funded health plan solution spanning plan design and ongoing administration.

 

SMR curates and onboards a network of specialized administrative vendors, contracting directly and tailoring service configurations based on deep operational experience and sector expertise. This enables consistent execution while maintaining flexibility to meet the specific needs of employers and distribution partners.

 

As of September 30, 2026, SMR includes more than 100 pre-designed plans that can be efficiently configured and bundled with stop-loss coverage, significantly streamlining implementation.

 

This model simplifies the complexity of self-funded plan administration, materially improves operational efficiency, and provides a differentiated, flexible solution for both employers and sales agents.

 

ICE Specific Considerations

 

ICE has contractual relationships with carriers. ICE underwrites a stop-loss insurance policy and processes claims per the respective carrier’s underwriting guideline and claims processing guideline. In these instances, the carrier is the Company’s customer.

 

The Company’s performance obligations related to its revenue can be summarized as follows:

 

Underwriting modeling and risk services: As a part of the Company’s overall insurance marketplace, ICE provides underwriting modelling, machine learning-driven underwriting services, and risk services to its customers. Through its web-based SaaS quoting platform, eDIYBS (Enhance Do It Yourself Benefit System), brokers log in to eDIYBS, upload census, select plans and generate bindable quotes. eDIYBS medically underwrites each employer. ICE continues to assess risks and may re-underwrite based on underwriting risk guidelines provided by carriers. Any enrollment changes in a business can have large fluctuations during a policy period that may trigger a re-underwrite. ICE not only monitors and manages these activities but also facilitates insurance reporting. Revenue related to these services are included in the “Revenues from underwriting modeling” within the Consolidated Statements of Operations. These services are provided by ICE for carriers. Unlike the Company’s other performance obligations, the Company’s agreements for its underwriting modeling and risk performance obligations are with stop loss carriers. Under these agreements, the Company develops and maintains all underwriting models, defines risk criteria based on risk guidelines provided by carriers, manages underwriting of risk, manages claims activity, ensures reinsurance reporting, and handles monthly reinsurance filings. The purpose of these services is to ensure that the stop loss carrier is assuming an appropriate amount of risk when taking on a new insurance policy, and further that the premiums being charged are appropriate based upon the population of the new insurance policy (age, demographic, etc.).

 

16

 

 

Health In Tech, Inc.

 

Notes to Consolidated Financial Statements

 

2. Summary of Significant Accounting Policies (cont.)

 

Program and platform management services: As a part of the Company’s overall insurance marketplace, SMR is a program manager specializing in customized self-funded benefits programs for businesses. SMR’s expertise in health benefits enables the Company to analyze, review and select vendors that have sufficient experience, which is an essential component of a health plan that is constantly evolving with its business employers based on factors such as employee headcount and a specific employee’s geographic location. SMR will then design health plans, select networks, and sets up the benefits plan for the business employers. Licensed brokers log in to the marketplace to select and sell self-funded benefits plans to businesses. The Company throughout the contract period is actively working with the TPA to assist administration of the plan specifically due to headcount changes. The Company’s service offerings encompass reference-based pricing, group insurance captives, community health plans, and association health programs. This service is performed for employers to ensure that they have access to a customized health benefits program. For these Program and Platform Management Services, the Company acts as a facilitator and does not control the underlying services prior to transfer to customers. The Company accounts for these services under ASC 606-10-25-14(b) as a series of distinct services that are substantially the same per enrolled employee and have the same pattern of transfer as the delivery of the specified services is satisfied over time, and each service is substantially the same and has the same measure of progress. Revenue related to these services are included in the “Revenues from fees” within the Consolidated Statements of Operations.

 

Self-funded plan administration services: SMR delivers a comprehensive, end-to-end self-funded health plan solution to business employers, spanning plan design and ongoing administration. SMR establishes independent pricing for services, and acts as the primary party responsible for service fulfillment. The Company acts as the principal under ASC 606 for these Plan administration services, as it controls the services prior to transfer to employers and is primarily responsible for fulfillment. These services are accounted for under ASC 606-10-25-14(b) as a series of distinct services that are substantially the same per enrolled employee and have the same pattern of transfer. Revenue related to these services are included in the “Revenues from fees” within the Consolidated Statements of Operations.

 

Each of the services above allows for the customers to simultaneously receive and consume the benefits of the Company’s performance as it performs. Services provided by SMR (either program and platform management or self-funded plan administration) and underwriting modeling and risk services provided by ICE (including eDIYBS) are interdependent, as they cannot function effectively without being combined.

 

As such, the Company has determined that it is appropriate to recognize revenue over a period of the defined contractual term. The Company has determined that the pattern of transfer of control to the customers is commensurate with its right to invoice given the fact that at the end of each reporting period, all performance obligations of the Company have been satisfied and provided to the Company’s customers, and as such, the Company records its revenue based on the sold policy enrollment.

 

Payments required throughout the duration of the policy start once a policy has become effective, and are subsequently due on policy effective date of the month through the duration of the policy. Given the Company’s policy terms, there are no performance obligations that remain unperformed at the end of each reporting period.

 

Disaggregation of Revenue

 

A summary of the Company’s disaggregated revenues is as follows:

 

    Three Months Ended
September 30,
    Nine Months Ended  
September 30,
 
    2026     2025     2026     2025  
Revenues:                        
Revenues from underwriting modeling (ICE)   $ 1,016,467       2,802,949     $ 3,866,330       8,201,252  
Revenues from fees (SMR)     6,065,306       7,122,602       20,135,567       20,239,596  
Program and platform management fees     1,030,950       7,122,602       5,551,286       20,239,596  
Self-funded plan administration fees     5,034,356       —       14,584,281       —  
Subtotal     7,081,773       9,925,551       24,001,897       28,440,848  
Contra revenue for billing adjustments     (110,867 )     (22,113 )     (94,323 )     (252,834 )
Contra revenue for refund liability     (383,854 )     (1,413,345 )     (492,256 )     (2,369,088 )
Total revenues   $ 6,587,052       8,490,093     $ 23,415,318       25,818,926  

 

17

 

 

Health In Tech, Inc.

 

Notes to Consolidated Financial Statements

 

2. Summary of Significant Accounting Policies (cont.)

 

Variable Consideration

 

With the exception of its business relationship with one stop-loss insurance carrier, the Company does not have variable consideration that would require constraint from the transaction price of its contracts with customers as the Company receives monthly payments either based on a fixed percentage of the monthly premiums paid by the carrier, or a fixed dollar amount based on the end users serviced during a given month paid by employers. The Company has reviewed all contracts with its customers and determined that, other than the contract described below, none include terms that could result in the Company refunding amounts to a carrier or receiving variable cash flows.

 

For this stop-loss insurance carrier, with which the Company’s new policy underwriting otherwise ended in 2024, ICE entered into a Program Manager Agreement (the “Agreement”), effective August 1, 2023. Under the Agreement, ICE provides underwriting modeling and risk program services in connection with self-funded stop-loss policies issued by the carrier and charges the carrier a Manager Fee of up to 12% of gross written premiums. Pursuant to Addendum 3 to the Agreement, the Manager Fee is subject to a Manager Fee Adjustment (the “Adjustment”) that may reduce the fee retained by ICE, ranging from $nil to the full Manager Fee of 12% of gross written premiums. The possible consideration amounts were contractually bounded and determined pursuant to a defined fee-adjustment formula. The Manager Fee constitutes variable consideration in its entirety, as the amount ICE is ultimately entitled to retain depends on the Adjustment. The carrier pays ICE the Manager Fee monthly based on gross written premiums collected in the preceding month, with any Adjustment determined and settled separately.

 

The Agreement covers 11 consecutive policy batches from August 2023 through June 2024 (each group of policies sharing the same effective date month, a “policy batch”). Each policy batch passes through three stages: (i) a 12-month in-effect stage; (ii) a six-month run-out stage, during which claims are submitted — upon completion, claims data for that batch is substantially complete; and (iii) a six-month reconciliation stage, during which the carrier finalizes the Aggregate Accommodation calculation relating to amounts previously advanced to fund certain employer claims. Under the Aggregate Accommodation arrangement, the carrier advanced funds during the policy term to pay certain employer claims. Some amounts initially advanced by the carrier could ultimately be determined to be the employer’s responsibility and due back to the carrier. After expiration of the six-month run-out period, additional stop-loss claims could not be submitted and accepted.

 

At agreement inception and through December 31, 2024, none of the policy batches had completed their run-out period. Based on the Company’s industry experience and ongoing monitoring of each policy batch’s performance, the performance of the underlying policies was favorable at each reporting date. At inception, the Company had favorable historical experience with the prior carrier under substantially similar Program Manager Agreement and stop-loss processes. As the current carrier’s policies became effective, the Company evaluated actual premiums paid, actual stop-loss claims submitted and accepted as the carrier’s responsibility, denied claims, projected Aggregate Accommodation recoveries and the monthly performance reports reviewed by the carrier. The Company acknowledged that the amount of stop-loss claims ultimately submitted was susceptible to factors outside of the Company’s influence, including the occurrence and severity of medical claims and the actions of third-party TPAs. However, the Company did not view the 18 months as a period during which the entire claims uncertainty remained unresolved. Instead, claims information became available and the related uncertainty was progressively resolved throughout the 12-month policy term and the subsequent six-month run-out period. The Company considered both the likelihood and magnitude of a potential significant revenue reversal based on the totality of the information available at each reporting date. Accordingly, the Company concluded that it was probable that a significant reversal of cumulative revenue recognized would not occur when the remaining uncertainty was resolved, and the estimated transaction price for each policy batch equaled the full Manager Fee of 12% of gross written premiums. No revenue reduction was recorded in 2023 or 2024.

 

The Company began recording a revenue reversal adjustment in the first quarter of 2025, when the first policy batch completed its six-month run-out period. At that point, the Company had both (i) substantially more mature claims information for the earliest policy batches and (ii) sufficiently sustained unfavorable performance information from the developing portfolio to conclude that its prior estimate of the variable consideration should be revised. The Company’s decision to record the revenue reversal was therefore based on the additional actual information that became available as the policies matured, rather than merely on the passage of 18 months or on a change in the claims-administration process. The Company continued to reassess the variable consideration as subsequent policy batches completed their respective run-out periods through November 2025.

 

18

 

 

Health In Tech, Inc.

 

Notes to Consolidated Financial Statements

 

2. Summary of Significant Accounting Policies (cont.)

 

For the three and nine months ended September 30, 2026, the Company recognized contra revenue of $383,854 and $492,256, respectively, and $1,413,345 and $2,369,088 for the three and nine months ended September 30, 2025, respectively, related to the Adjustment. These amounts reduced revenue from underwriting modeling services provided to the carrier. The cumulative reduction in revenue recorded through September 30, 2026 was approximately $4.4 million, comprising approximately $3.9 million in 2025 and approximately $0.5 million in the first three quarters of 2026. As of September 30, 2026 and December 31, 2025, refund liabilities of $0 and $891,598 related to the Adjustment were recorded in other current liabilities, respectively. During the three months ended September 30, 2026, the amount of the Adjustment was finalized, and the Company made a final payment of $403,854, consisting of $383,854 related to the Adjustment and $20,000 recognized as interest expense. As of September 30, 2026, the Company had made aggregate payments of $4,383,854 related to the Adjustment, excluding interest expense.

 

Contract Assets and Contract Liabilities

 

Contract assets represent the Company’s right to consideration in exchange for goods or services that the entity has transferred to a customer when that right is conditioned on something other than the passage of time. Contract liabilities represent the Company’s obligation to transfer goods or services to a customer for which the entity has received consideration. As of September 30, 2026 and December 31, 2025, the Company did not have contract assets or liabilities.

 

Costs to Obtain a Contract

 

Under ASC 340-40, Other Assets and Deferred Costs — Contracts with Customers (“ASC 340”) incremental costs of obtaining a contract, such as sales commissions and bonus programs afforded to brokers, are capitalized if they are expected to be recovered. The Company elected the practical expedient under ASC 340 to expense the costs to obtain a contract as incurred when the expected amortization period is one year or less. As of September 30, 2026 and December 31, 2025, there were no such capitalized costs. All eligible contract acquisition costs expensed by the Company have been included in sales and marketing expenses on the Company’s consolidated statements of operations for the three and nine months ended September 30, 2026 and 2025.

 

Significant Financing Components

 

The Company elected the practical expedient that allows the Company to not assess a contract for a significant financing component if the period between the customer’s payment and the transfer of the goods or services is one year or less. There were no significant financing components during the three and nine months ended September 30, 2026 and 2025, respectively.

 

Cost of Revenues

 

The Company’s cost of revenues primarily consists of direct costs attributable to operating its platform and delivering platform-enabled services, many of which vary with the volume of services delivered, (i) infrastructure costs to operate its platform, such as hosting fees, fees paid to various third-party partners for access to their technology and services, and amortization expenses of the Company’s capitalized internal-use software related to its platform, (ii) costs of plan administrative services provided by the TPA designated in each pre-designed plan and other vendors assigned to each TPA, and (iii) costs related to the captive management activities. The captive management activities include introducing new carriers, conducting due diligence on carriers, conducting feasibility studies to determine the viability to be a stop-loss carrier on the platform, negotiating terms and contracts, coordinating audit requests, managing relationship with unrelated carriers and their regulators and auditor firms to ensure that the risk associated with the Company’s service offerings is minimized. Personnel costs associated with underwriting oversight, claims management, enrollment support and other operational functions are classified as general and administrative expenses. These employees support the Company’s overall operating platform and service infrastructure across its portfolio of carrier and employer relationships, rather than performing activities that are directly identifiable to a specific revenue contract or separately priced service deliverable.

 

19

 

 

Health In Tech, Inc.

 

Notes to Consolidated Financial Statements

 

2. Summary of Significant Accounting Policies (cont.)

 

Stock-Based Compensation Expense

 

In accordance with ASC 718, Compensation — Stock Compensation, the Company’s share-based compensation program provides for the grant of stock options, restricted stock awards (“RSAs”), restricted stock units (“RSUs”) and unrestricted stock awards to officers, employees, directors and non-employees. The fair value of stock options granted in July 2023 and August 2024 was determined using the binomial option-pricing model. The fair value of RSAs granted before the Company’s initial public offering (the “initial public offering” or the “IPO”) was based on the fair value of the Company’s common stock on the date of the grant, using the discounted cash flow method and back-solve method, respectively. The fair value of unrestricted and restricted stock and restricted stock units granted after the IPO is based on the closing market price on the date of the grant.

 

Effective April 10, 2026, following the consolidation of HITChain, the Company’s stock-based compensation expense also includes equity awards granted under HITChain’s equity incentive plan. HITChain’s share-based compensation program grant awards include stock options and RSAs to officers, directors and non-employees. The fair value of stock options granted was determined using the binomial option-pricing model. The fair value of RSAs granted was based on the fair value of HITChain’s common stock on the date of the grant. See Note 9 for further details.

 

The Company grants stock options, RSAs and RSUs that are subject to either service or service and performance-based vesting conditions. Compensation expense for awards to officers, employees and directors with service-based vesting conditions is recognized using the straight-line method over the requisite service period, which is generally the vesting period of the respective award. Forfeitures are estimated at the time of grant and revised in subsequent periods if actual forfeitures differ from those estimates. The Company uses historical data to estimate awards’ forfeitures and records stock-based compensation expense only for those awards that are expected to vest. Compensation expense for awards to non-employees with service-based vesting conditions is recognized in the same manner as if the Company had paid cash in exchange for services, which is generally over the vesting period of the award. Should the Company terminate any of its consulting agreements, the unvested options, RSAs and RSUs underlying the agreements would be cancelled. Compensation expense for awards to officers, employees, directors and non-employees with service and performance-based vesting conditions is recognized based on the grant-date fair value over the requisite service period on a straight-line basis to the extent achievement of the performance condition is probable. The Company reassesses the probability of achieving the performance condition at each reporting date and begins recognizing expense only when it is probable that the condition will be met.

 

The Company’s expected stock price volatility assumption is based on the volatility of comparable public companies. The expected term of a stock option granted to employees and directors (including non-employee directors) is based on the average of the contractual term (generally 5 years) and the vesting period. For non-employee options, the expected term is the contractual term. The risk-free interest rate is based on the yield of U.S. Treasury securities consistent with the life of the option. The expected dividend yield was set to zero as the Company does not pay dividends on its common stock and there was no expectation of doing so as of the respective grant dates.

 

Net Income (Loss) Per Share

 

Net income (loss) per share is provided in accordance with ASC 260, Earnings per Share. The Company computes basic net income (loss) per share by dividing net income (loss) attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. The Company’s Class A Common Stock and Class B common stock, $0.001 par value per share (“Class B Common Stock” and together with the Class A Common Stock, “common stock” or “Common Stock”), have identical dividend and liquidation rights and are therefore considered a single class for purposes of calculating earnings per share.

 

20

 

 

Health In Tech, Inc.

 

Notes to Consolidated Financial Statements

 

2. Summary of Significant Accounting Policies (cont.)

 

Diluted net income (loss) per share includes the potential dilutive effect of common stock equivalents as if such securities were converted or exercised during the period, when the effect is dilutive, including unvested RSAs and RSUs, outstanding stock options and convertible notes. For the purpose of computing diluted net income (loss) per share, RSAs, RSUs and options with a performance-based vesting condition are considered contingently issuable, and such contingent shares are included in the denominator for computing diluted net income (loss) per share based on the number of shares that would be issuable assuming the end of the reporting period were the end of the contingency period, and only to the extent such RSAs, RSUs and options are dilutive. The potential dilutive effect of convertible notes is evaluated using the if-converted method. For the three and nine months ended September 30, 2026, no diluted shares attributable to RSAs, RSUs, options or convertible notes were included in the calculation of net loss per share. For the three months ended September 30, 2025, diluted shares attributable to 833,899 RSAs and 1,508,028 options were included in the calculation of net income per share. For the nine months ended September 30, 2025, diluted shares attributable to 463,591 RSAs and 1,529,422 options were included in the calculation of net income per share.

 

The following table sets forth the computation of basic and diluted net income (loss) per share of common stock for the three and nine months ended September 30, 2026 and 2025:

 

    Three Months Ended
September 30,
    Nine Months Ended  
September 30,
 
    2026     2025     2026     2025  
Net (loss) income attributable to common stockholders   $ (7,066,413 )   $ 452,176     $ (11,165,718 )   $ 1,581,399  
Weighted average shares outstanding                                
Basic     63,078,291       56,432,407       61,107,984       55,484,860  
Total dilutive effect of outstanding equity awards     —       2,341,927       —       1,993,013  
Diluted     63,078,291       58,774,334       61,107,984       57,477,873  
Net (loss) income per share attributable to common stockholders                                
Basic   $ (0.11 )   $ 0.01     $ (0.18 )   $ 0.03  
Diluted   $ (0.11 )   $ 0.01     $ (0.18 )   $ 0.03  

 

The following outstanding stock awards and convertible notes were not considered in the computation of diluted net income (loss) per share attributable to holders of common stock as they had antidilutive effects for the three and nine months ended September 30, 2026 and 2025:

 

    Three Months Ended
September 30,
    Nine Months Ended  
September 30,
 
    2026     2025     2026     2025  
Restricted stock awards     2,256,830       82,000       2,256,830       82,000  
Restricted stock units     20,000       —       20,000       —  
Option awards     1,900,825       —       1,900,825       —  
Convertible notes     4,448,681       —       4,448,681       —  
Total     8,626,336       82,000       8,626,336       82,000  

 

21

 

 

Health In Tech, Inc.

 

Notes to Consolidated Financial Statements

 

2. Summary of Significant Accounting Policies (cont.)

 

Recently Issued Accounting Standards Not Yet Adopted

 

In November 2024, the FASB issued ASU 2024-03 Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. This standard calls for enhanced disclosures about components of expense captions on the face of the income statement. This standard will be effective for fiscal years beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with the option to apply it retrospectively. Early adoption is allowed. Currently, the Company is assessing the potential impact of this guidance on its consolidated financial statement disclosures.

 

In September 2025, the FASB issued ASU 2025-06 Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software, which amends certain aspects of the accounting for and disclosure of software costs under ASC 350-40. The new standard is effective for annual periods beginning after December 15, 2027, and interim reporting periods within those annual reporting periods. Early adoption is allowed. The new standard may be applied prospectively, retrospectively, or via a modified prospective transition method. Currently, the Company is assessing the potential impact of this guidance on its consolidated financial statement disclosures.

 

In December 2025, the FASB issued ASU 2025-12 Codification Improvements (“ASU 2025-12”). This update addresses suggestions received from stakeholders regarding the Accounting Standards Codification (“Codification”) and makes other incremental improvements to GAAP. The update represents changes to the Codification that clarify, correct errors in or make other improvements to a variety of topics that are intended to make it easier to understand and apply. ASU 2025-12 is effective for fiscal years beginning after December 15, 2026 and interim periods within those fiscal years. Entities are required to apply the amendments to ASC 260, Earnings Per Share, retrospectively. All other amendments may be applied prospectively or retrospectively. Early adoption is permitted. Currently, the Company is assessing the potential impact of this guidance on its consolidated financial statement disclosures.

 

3. Loans Receivable, Net

 

On October 10, 2023, the Company entered into a Promissory Note Agreement with Kang Youle Limited, which constitutes an unsecured lending arrangement. Under this Promissory Note Agreement, the Company agreed to lend $800,000 in principal amount, which bears 8% interest per annum. The note’s maturity date is October 10, 2026. As of September 30, 2026 and December 31, 2025, the outstanding principal amount was $800,000. The Company accrued interest that is due and receivable in the amount of $63,992 and $15,995 as of September 30, 2026 and December 31, 2025, respectively. The outstanding principal and accrued interest, net of the related allowance for credit losses, are included within “Loans receivable, net” on the consolidated balance sheets.

 

Although not part of HIT’s core business, the Company will strategically invest its assets in a manner to maximize risk-adjusted return and promote shareholder wealth. The Company provided the promissory note to Kang Youle Limited, an independent third party with access to a network of insurance sectors internationally.

 

During the three months ended September 30, 2026, due to financial difficulties experienced by Kang Youle Limited, the Company reassessed the collectability of the outstanding loan and accrued interest. Based on this assessment, the Company recorded an allowance for credit losses of $863,992, representing the full outstanding principal and accrued interest. No allowance for credit losses was recorded as of December 31, 2025. Accordingly, the net carrying amount of the loan receivable was $0 and $815,995 as of September 30, 2026 and December 31, 2025, respectively.

 

22

 

 

Health In Tech, Inc.

 

Notes to Consolidated Financial Statements

 

4. Stockholders’ Equity

 

The Company has three classes of stock: (1) Class A Common Stock; (2) Class B Common Stock, and (3) Series A Preferred Stock.

 

The total number of shares of stock that the Company has authority to issue is 220,000,000, consisting of 150,000,000 shares of Class A Common Stock, 50,000,000 shares of Class B Common Stock and 20,000,000 shares of Series A Preferred Stock, $0.001 par value per share (“Series A Preferred Stock”).

 

Holders of Class B Common Stock are entitled to ten votes per share while holders of Class A Common Stock are entitled to one vote per share. Both classes of common stock vote collectively with the holders of Series A Preferred Stock. Each share of Series A Preferred Stock is entitled to one vote. In addition, the affirmative vote of a majority of the outstanding Series A Preferred Stock is required to approve certain fundamental corporate actions, including mergers, liquidations, the issuance of senior or parity equity securities, and any amendments to the Company’s governing documents that would adversely affect the rights of holders of Series A Preferred Stock.

 

Holders of Class A Common Stock and Class B Common Stock are entitled to dividends when, and if, declared at the discretion of the Company. However, holders of Series A Preferred Stock are entitled to receive non-cumulative dividends prior and in priority to any dividends declared on the common stock. Accordingly, no dividends may be paid on common stock unless all declared dividends on the Series A Preferred Stock have been paid or set aside for payment.

 

On March 27, 2026, the Company completed a public equity financing (the “PIPE”) through which it issued and sold 5,600,000 shares of Class A Common Stock, at a price of $1.25 per share. The Company received net proceeds of $6,381,000 in the PIPE after deducting placement agent fees and escrow agent fees of $619,000.

 

On June 15, 2026, the Company issued 95,238 RSAs outside of its equity incentive plans to a consulting firm in reliance upon the exemption from the securities registration requirements of the Securities Act of 1933, as amended, afforded by the provisions of Section 4(a)(2) thereof and the rules and regulations promulgated thereunder, in exchange for consulting services. On August 14, 2026, the Company terminated the consulting engagement, resulting in the automatic forfeiture of 63,492 unvested RSAs without consideration. The remaining 31,746 RSAs had vested prior to the termination. For further details regarding the related stock-based compensation, please refer to Note 9.

 

As of September 30, 2026 and December 31, 2025, 53,600,790 and 46,006,000 shares of Class A Common Stock were issued and outstanding, respectively. As of both September 30, 2026 and December 31, 2025, 11,700,000 shares of Class B Common Stock were issued and outstanding. As of both September 30, 2026 and December 31, 2025, no shares of Series A Preferred Stock were issued and outstanding.

 

From time to time, the Company issues shares of common stock in connection with the granting of RSAs and the exercise of stock options, and grants RSUs under its equity incentive plans. For a detailed summary of these issuances and related stock-based compensation, please refer to Note 9.

 

23

 

 

Health In Tech, Inc.

 

Notes to Consolidated Financial Statements

 

5. Commitments and Contingencies

 

Legal Proceedings

 

From time to time, the Company is party to various litigation matters incidental to the conduct of its business. The Company is not presently party to any legal proceedings the resolution of which it believes would have a material adverse effect on its business, prospects, financial condition, liquidity, results of operation, cash flows or capital levels.

 

Leases

 

The Company entered into a five-year lease for its corporate headquarters in Stuart, Florida, commencing in November of 2022. The Company’s real estate lease also includes executory costs such as common area maintenance (non-lease component) and real estate taxes (not considered a component of the Company’s lease). As a practical expedient permitted under ASC 842, the Company has elected to account for the lease and non-lease components as a single lease component. For the three and nine months ended September 30, 2026 and 2025, the rent-related expenses for this lease were $20,812 and $62,436, respectively. The Company had no short-term leases as of September 30, 2026, and one short-term lease as of December 31, 2025.

 

The Company’s office lease is classified as an operating lease. At the inception date of the office lease, the Company recorded a right-of-use asset of $330,554 in operating lease right-of-use asset, as well as an operating lease liability of $324,021. This lease liability represented the net present value of future lease payments for the lease utilizing a discount rate of 10%, which corresponded to the Company’s incremental borrowing rate.

 

During the three and nine months ended September 30, 2026, the Company made cash payments of $21,417 and $64,251 for amounts included in the measurement of lease liabilities, respectively.

 

The following table reconciles the undiscounted lease liabilities to the total lease liabilities recognized on the Consolidated Balance Sheet as of September 30, 2026:

 

2026     22,060  
2027     66,180  
Total undiscounted lease liabilities   $ 88,240  
Less effects of discounting     (4,409 )
Total lease liabilities   $ 83,831  

 

The remaining lease term was 1.1 years and 1.8 years as of September 30, 2026 and December 31, 2025, respectively.

 

The discount rate used to determine the operating lease liability was 10% both as of September 30, 2026 and December 31, 2025.

 

24

 

 

Health In Tech, Inc.

 

Notes to Consolidated Financial Statements

 

6. Income Taxes

 

(Loss) income before income taxes consists of the following: 

 

    Three Months Ended
September 30,
    Nine Months Ended  
September 30,
 
    2026     2025     2026     2025  
                         
Federal   $ (9,254,128 )     600,222     $ (14,643,552 )     2,117,913  
Foreign     —       —       —       —  
(Loss) income before income taxes   $ (9,254,128 )     600,222     $ (14,643,552 )     2,117,913  

 

During the three and nine months ended September 30, 2026, the Company recognized an income tax benefit of $2,147,653 and $3,437,610, respectively. During the three and nine months ended September 30, 2025, the Company recognized an income tax expense of $148,046 and $536,514, respectively.

 

The Company’s income tax provision consists of the following for the three and nine months ended September 30, 2026 and 2025:

 

    Three Months Ended
September 30,
    Nine Months Ended
September 30,
 
    2026     2025     2026     2025  
Current income tax expense                        
Federal   $ —     $ 109,948     $ —     $ 480,607  
State     3,256       25,418       11,410       109,774  
Total current income tax expense   $ 3,256     $ 135,366     $ 11,410     $ 590,381  
                                 
Deferred income tax benefit                                
Federal     (1,913,050 )     11,051       (3,052,455 )     (53,586 )
State     (237,859 )     1,629       (396,565 )     (281 )
Total deferred income tax benefit   $ (2,150,909 )   $ 12,680     $ (3,449,020 )   $ (53,867 )
                                 
Total income tax provision   $ (2,147,653 )   $ 148,046     $ (3,437,610 )   $ 536,514  

 

Beginning in its 2025 annual financial reporting, the Company adopted ASU 2023-09 on a prospective basis. The following table presents the reconciliation of income taxes computed at the U.S. federal statutory tax rate to income tax provision for the three and nine months ended September 30, 2026 after the adoption of ASU 2023-09:

 

    Three Months Ended
September 30, 2026
    Nine Months Ended
September 30, 2026
 
    Amount     Rate     Amount     Rate  
Statutory federal income tax rate     (1,932,769 )     21.0 %     (3,064,514 )     21.0 %
State taxes (net of federal benefit)     (269,933 )     2.9       (437,596 )     3.0  
Permanent difference     20,401       (0.2 )     14,453       (0.1 )
Other     34,648       (0.3 )     50,047       (0.3 )
Effective tax rate     (2,147,653 )     23.4 %     (3,437,610 )     23.6 %

 

25

 

 

Health In Tech, Inc.

 

Notes to Consolidated Financial Statements

 

6. Income Taxes (cont.)

 

The following table presents the reconciliation of income taxes computed at the U.S. federal statutory tax rate to income tax provision for the three and nine months ended September 30, 2025 prior to the adoption of ASU 2023-09:

 

    Three Months
Ended
September 30,
2025
    Nine Months
Ended
September 30,
2025
 
Statutory federal income tax rate     21.0 %     21.0 %
State taxes (net of federal benefit)     3.6       4.1  
Permanent difference     0.1       0.2  
Effective tax rate     24.7 %     25.3 %

 

 

The Company’s net deferred tax assets and liabilities consisted of the following as of September 30, 2026 and December 31, 2025:

 

    September 30,     December 31,  
    2026     2025  
Deferred tax assets:            
Net Operating Loss     2,823,544       388,182  
Stock-based compensation     70,651       53,586  
Bad debt allowance     1,504,451       91,828  
Accrued liability     8,059       8,140  
Financial instruments     17,271       —  
Gross deferred tax assets   $ 4,423,976     $ 541,736  
                 
Deferred tax liabilities:                
Research & Development credits     (1,732,600 )     (1,299,380 )
Right of use assets/Lease Liability     (31 )     (31 )
Total Deferred Tax Liabilities   $ (1,732,631 )   $ (1,299,411 )
                 
Net deferred tax assets (liabilities):   $ 2,691,345     $ (757,675 )

 

As of September 30, 2026, the Company had federal net operating loss carryforwards of approximately $11.9 million, which may be carried forward indefinitely to offset future taxable income, but are subject to the 80% taxable income limitation upon utilization. Additionally, the Company had state net operating loss carryforwards of approximately $10.5 million as of September 30, 2026. Certain state net operating loss carryforwards may be carried forward indefinitely, while the remaining carryforwards begin to expire in 2033 through 2055, depending on the applicable state jurisdiction. State net operating loss carryforwards are also subject to various state-specific utilization limitations.

 

In general, under Section 382 of the U.S. Internal Revenue Code of 1986, as amended, a corporation that undergoes an “ownership change” is subject to limitations on its ability to utilize its pre-change net operating loss carryforwards (“NOLs”) to offset future taxable income. As of September 30, 2026, the Company has not performed such an analysis evaluation the potential limitation of the Company’s net operating loss carryforwards due to the “Change in ownership” as defined under Section 382 of the Internal Revenue Code. 

 

26

 

 

Health In Tech, Inc.

 

Notes to Consolidated Financial Statements

 

6. Income Taxes (cont.)

 

The Company evaluates the realizability of its deferred tax assets and the need for a valuation allowance at the end of each fiscal quarter. Based on all available positive and negative evidence, including forecasts of future taxable income and statutory carryforward periods, management concluded that it is more likely than not that its deferred tax assets will be realized. Accordingly, no valuation allowance was required as of September 30, 2026. 

 

On July 4, 2025, the One Big Beautiful Bill Act (“OBBBA”) was signed into law, introducing significant changes to the U.S. federal tax system. Among other provisions, the OBBBA restored the immediate deduction of qualifying domestic research and experimental (“R&E”) expenditures for tax years beginning after December 31, 2024, provided transition relief for certain previously capitalized domestic R&E expenditures, and reinstated EBITDA-based limitations on business interest expense deductions.

 

On its 2025 federal income tax return, the Company deducted its qualifying 2025 domestic R&E expenditures and elected to deduct the remaining unamortized balance of qualifying domestic R&E expenditures from prior years ratably over 2025 and 2026. Accordingly, the Company deducted 50% of that balance in 2025 and included the remaining 50% in its estimated 2026 federal income tax deduction. The Company did not apply retroactive treatment to prior tax years.

 

For financial reporting purposes, the Company capitalizes qualifying R&D costs and amortizes them over three years. The difference between the book and tax bases of these costs resulted in a deferred tax liability of approximately $1.7 million as of September 30, 2026, compared with $1.3 million as of December 31, 2025.

 

The R&E deductions did not result in a material change to current federal income taxes for the nine months ended September 30, 2026, as the Company was in a federal tax loss position.

 

The amounts of cash income taxes paid by the Company were as follows:

 

    Nine Months
Ended
September 30,
2026
 
Federal     —  
State     10,035  
Foreign     —  
Total   $ 10,035  

 

27

 

 

Health In Tech, Inc.

 

Notes to Consolidated Financial Statements

 

7. Standby Equity Purchase Agreement

 

On August 12, 2026, the Company entered into a Standby Equity Purchase Agreement (“SEPA”) with YA II PN, LTD (“Yorkville”) . Under the SEPA, the Company has the right to sell to Yorkville up to $20.0 million of its Class A common stock (the “common stock”), subject to certain limitations and conditions set forth in the SEPA, from time to time, over a 36-month period. Sales of the common stock to Yorkville under the SEPA, and the timing of any such sales, are at the Company’s option, and the Company is under no obligation to sell any shares of common stock to Yorkville under the SEPA.

 

The SEPA also provides for pre-paid advances of up to $15.0 million, to be evidenced by convertible promissory notes (collectively, the “Convertible Notes”), which are discussed separately in Note 8. Issuances under the SEPA and upon conversion of the Convertible Notes are subject to an aggregate exchange cap of 13,100,378 shares (the “Exchange Cap”), unless the requisite stockholder approval is obtained. Issuances under the SEPA are also subject to a 4.99% beneficial ownership limitation. On November 10, 2026, at the 2026 Annual Meeting, the Company’s stockholders approved, for purposes of complying with Nasdaq Listing Rules 5635(b) and 5635(d), the issuance of more than 20% of the Company’s issued and outstanding Class A common stock pursuant to the SEPA, including upon conversion of the Convertible Notes issued or issuable thereunder.

 

Upon the satisfaction of the conditions precedent in the SEPA, which include having a resale registration statement for shares of common stock issued to Yorkville declared effective, the Company has the right to direct Yorkville to purchase a specified number of shares of common stock through advances (each, an “Advance”) by delivering written notice (each an “Advance Notice”). An Advance Notice may not direct Yorkville to purchase a number of shares exceeding 100% of the average daily trading volume of the common stock on Nasdaq during the five consecutive trading days immediately preceding the Advance Notice, unless otherwise agreed in writing by the parties.

 

Yorkville will generally purchase shares pursuant to an Advance at a price per share equal to 97% of the lowest daily VWAP of the Company’s Class A Common Stock on Nasdaq during the three consecutive trading days commencing on the date of the delivery of the Advance Notice (excluding trading days on which the volume-weighted average price (“VWAP”) is below any minimum acceptable price specified by the Company or no VWAP is available, subject to the applicable adjustments under the SEPA). While any Convertible Notes remain outstanding, proceeds from Advances under the SEPA are required to be used to repay amounts outstanding under the Convertible Notes, unless otherwise agreed by Yorkville.

 

The SEPA will automatically terminate on the earliest to occur of (i) the 36-month anniversary of the date of the SEPA, provided that all outstanding Convertible Notes have been repaid, or (ii) the date on which Yorkville shall have made full payment of the Advances pursuant to the SEPA. The Company has the right to terminate the SEPA at no cost or penalty upon five trading days’ prior written notice to Yorkville, provided that there are no outstanding Advance Notices for which shares of common stock need to be issued and no Convertible Notes remain outstanding and all amounts owed to Yorkville under the SEPA have been paid. The Company and Yorkville may also agree to terminate the SEPA by mutual written consent The SEPA also restricts certain variable-rate financing transactions, and repayments of related-party obligations. The SEPA further limits the Company’s and its subsidiaries’ ability to incur additional indebtedness or create liens, subject to certain exceptions and Yorkville’s prior written consent. The Company may enter into at-the-market offering arrangements, provided that an affiliate designated by Yorkville serves as the sole executing broker and is granted a participation right of at least 33% of such facility for a period ending 12 months after the First Pre-Paid Advance Closing and serves as the sole executing broker for so long as any Convertible Notes remain outstanding.

 

As consideration for Yorkville’s commitment to purchase the shares of common stock pursuant to the SEPA, the Company paid Yorkville a $25 thousand cash structuring fee. In addition, the Company agreed to pay a commitment fee equal to 1.0% of the $20.0 million commitment amount, or $200,000, which was earned as of the effective date of the SEPA. One-half of the commitment fee, or $100,000, was paid in cash, and the remaining $100,000 is payable by the six-month anniversary of the effective date of the SEPA. The Company recognized $225,000 of SEPA-related fees as financing transaction costs in the consolidated statements of operations for the three and nine months ended September 30, 2026.

 

28

 

 

Health In Tech, Inc.

 

Notes to Consolidated Financial Statements

 

7. Standby Equity Purchase Agreement (cont.)

 

In connection with the entry into the SEPA, on August 18, 2026, the Company entered into a registration rights agreement with Yorkville (the “Registration Rights Agreement”), pursuant to which the Company agreed to file with the SEC within 21 calendar days after the date of the Registration Rights Agreement, a registration statement for the resale by Yorkville of the shares of common stock issuable under the SEPA and upon conversion of the Convertible Notes. Under the Registration Rights Agreement, certain failures to file timely, obtain effectiveness of, or maintain the effectiveness of the resale registration statement constitute events of default under the Convertible Notes.

 

The Company agreed to register the resale of the applicable shares and maintain the effectiveness of the registration statement, subject to the terms of the Registration Rights Agreement and the SEPA. The Company did not have the ability to request any Advances under the SEPA until such resale registration statement was declared effective by the SEC, which occurred on October 15, 2026. As of September 30, 2026, no Advances had been requested or completed under the SEPA.

 

The Company accounts for the SEPA as a derivative liability under ASC 815, Derivatives and Hedging. The SEPA derivative liability is initially measured at fair value and subsequently remeasured at fair value at each reporting date, with changes in fair value recognized in earnings. The fair value of the SEPA derivative liability was $80,394 upon initial recognition and $82,629 as of September 30, 2026. During the three and nine months ended September 30, 2026, the Company recognized a loss of $2,235 from the change in fair value of the SEPA derivative liability, which was included in change in fair value of SEPA derivative liability in the consolidated statements of operations. See Note 10, Fair Value Measurements, for additional information regarding the fair value measurement of the SEPA derivative liability.

 

8. Debt

  

The following table summarizes the Company’s outstanding debt for the periods indicated:

 

    September 30,     December 31,  
    2026     2025  
Convertible notes at fair value            
First Convertible Note   $ 6,639,108       —  

 

Convertible Notes at Fair Value

 

Pursuant to the SEPA described in Note 7, Yorkville has agreed to provide the Company with pre-paid advances (each, a “Pre-Paid Advance”) in an aggregate principal amount of up to $15.0 million, to be evidenced by the Convertible Notes. The Pre-Paid Advances are structured in three tranches consisting of a first tranche of $7.0 million, a second tranche of $3.0 million and a third tranche of up to $5.0 million, subject to the satisfaction of specified conditions. On November 2, 2026, the Company issued the second Convertible Note in the principal amount of $3.0 million in connection with the second tranche of the Pre-Paid Advances. The Company received net proceeds of $2.85 million on November 3, 2026. See Note 11, Subsequent Events. The third tranche, if requested by the Company, is subject to Yorkville’s agreement in its sole and absolute discretion. Each Pre-Paid Advance is subject to a 5% purchase price discount to the principal amount of the applicable Convertible Note.

 

29

 

 

Health In Tech, Inc.

 

Notes to Consolidated Financial Statements

 

8. Debt (cont.)

 

The Convertible Notes bear interest at 8.75% per annum (increasing to 18% upon certain events of default as specified therein). The maturity date of each of the Convertible Notes issued in connection with each Pre-Paid Advance will be February 18, 2028, subject to extension at Yorkville’s option.

 

The Convertible Notes are unsecured. Pursuant to a Global Guaranty Agreement dated August 18, 2026, the Company’s payment and performance obligations under the SEPA, the Convertible Notes and related transaction documents are jointly and severally guaranteed by three subsidiaries, SMR, ICE and Hi Card. On October 9, 2026, Anchor 36 and HITRix became additional guarantors pursuant to a Joinder to the Global Guaranty Agreement.

 

Beginning on the 60th calendar day after August 18, 2026, and continuing on each subsequent monthly installment date, the Company shall repay a portion of the outstanding balance of the Pre-Paid Advance, consisting of principal, a 4% payment premium, and accrued and unpaid interest. Based on the outstanding principal amount of the First Convertible Note as of September 30, 2026, the scheduled principal installments are $250,000 in October 2026, $609,000 per month from November 2026 through September 2027, and a final installment of $51,000 in October 2027, subject to adjustments under the terms of the Convertible Note. Installment payments may be satisfied in cash or through the application of net proceeds from sales of common stock under the SEPA, in which case the 4% payment premium does not apply. The Company may also redeem amounts outstanding under the Convertible Notes before maturity, subject to certain conditions, including a redemption premium of 5% of the principal amount redeemed and a requirement that the VWAP of the Company’s common stock be below the Fixed Price on the date of the redemption notice, unless otherwise agreed by Yorkville.

 

Yorkville may convert all or any portion of the outstanding principal amount, accrued and unpaid interest and other amounts outstanding under the Convertible Notes into shares of the Company’s Class A common stock at any time during the term of the Convertible Notes, at an initial fixed conversion price of $1.5735 per share (the “Fixed Price”), subject to certain antidilution and price protection adjustments as provided in the Convertible Notes.

 

If the Company fails to timely pay any installment amount when due (a “Payment Failure”), Yorkville may elect to convert all or part of the unpaid installment amount at a variable conversion price (the “Variable Price”) equal to the lower of (i) the Fixed Price then in effect and (ii) 95% of the lowest daily VWAP during the five consecutive trading days immediately preceding the date of conversion, but not lower than the floor price of $0.204 per share, subject to adjustment.

 

Upon an Event of Default (as defined in the applicable Convertible Note), Yorkville may require repayment in cash of the outstanding principal, applicable Payment Premium, accrued and unpaid interest and other amounts due, subject to the terms of the applicable Convertible Note. If an Event of Default remains uncured or unwaived for 30 days, Yorkville may also convert all or any portion of the applicable Convertible Note at the Variable Price while such Event of Default continues.

 

Conversions under the Convertible Notes are subject to the aggregate Exchange Cap described in Note 7 and a 4.99% beneficial ownership limitation, which may be increased upon at least 65 days’ prior written notice in accordance with the terms of the Convertible Notes.

 

The Convertible Notes also restrict the Company and its subsidiaries, without the Yorkville’s consent, from repurchasing equity securities, amending organizational documents in a manner that adversely affects the Yorkville’s rights, or entering into arrangements that would impair the Company’s ability to perform its obligations under the Convertible Notes.

 

As of September 30, 2026, the Company was in compliance with the applicable covenants under the SEPA and the First Convertible Note.

 

30

 

 

Health In Tech, Inc.

 

Notes to Consolidated Financial Statements

 

8. Debt (cont.)

 

The first Pre-Paid Advance in the net amount of $6,650,000 was disbursed to the Company on August 18, 2026, in exchange for the Company’s issuance to Yorkville of a convertible promissory note in the principal amount of $7.0 million (the “First Convertible Note”), reflecting a 5% purchase price discount of $350,000.

 

In connection with the transactions contemplated by the SEPA, the Company entered into an engagement agreement with Independent Investment Bankers, Corp. (“IIB”), a registered broker-dealer and member of the Financial Industry Regulatory Authority, Inc., pursuant to which IIB will receive a success fee from the Company equal to 6.5% of the gross principal amount of each Pre-Paid Advance. The Company recognized $455,000 of such fees in financing transaction costs in the consolidated statements of operations for the three and nine months ended September 30, 2026.

 

The Company elected the FVO under ASC 825, Financial Instruments, for the First Convertible Note upon its initial recognition on August 18, 2026. See Note 2, Summary of Significant Accounting Policies, for the Company’s accounting policy related to the FVO.

 

The following table presents the changes in the fair value of the First Convertible Note from its issuance through September 30, 2026:

 

    First
Convertible
Note
 
First Convertible Note   $ 6,569,606  
Change in fair value     69,502  
Fair value as of September 30, 2026   $ 6,639,108  

 

The following table presents the difference between the fair value and the unpaid principal balance of the First Convertible Note as of September 30, 2026:

 

    Fair Value     Unpaid
Principal
Balance
    Difference  
First Convertible Note   $ 6,639,108     $ 7,000,000     $ (360,892 )

 

9. Stock-Based Compensation

 

HIT Equity Awards

 

2022 Equity Incentive Plan

 

On December 21, 2022, the Company adopted and approved the Health in Tech Equity Incentive Plan (the “2022 Plan”), which provides for the issuance of 4,501,683 shares of Class A Common Stock for purposes of attracting, retaining, and motivating key employees, directors, and consultants. The 2022 Plan provides for the grant of incentive stock options, nonqualified stock options, RSAs and restricted stock units. Upon the consummation of the Company’s initial public offering on December 24, 2024, the 2024 Equity Incentive Plan (the “2024 Plan”) went into effect. The terms of the 2022 Plan continue to govern the RSAs and options outstanding thereunder as of September 30, 2026 and December 31, 2025. There are no shares reserved for future issuance under the 2022 Plan.

 

31

 

 

Health In Tech, Inc.

 

Notes to Consolidated Financial Statements

 

9. Stock-Based Compensation (cont.)

 

2024 Equity Incentive Plan

 

On December 24, 2024, the Company adopted and approved the 2024 Plan. The 2024 Plan is a comprehensive incentive compensation plan under which the Company can grant 7,677,849 shares of equity-based and other incentive awards to officers, employees, directors, consultants and advisers. On October 3, 2025, the Company’s stockholders approved an amendment to the 2024 Plan to (i) increase the total number of shares of Class A common stock authorized for issuance pursuant to awards granted thereunder from 7,677,849 shares to 10,677,849 shares and (ii) include the issuance of up to 2,000,000 shares of Class B Common Stock and options convertible into Class B Common Stock to executive officers of the Company. The purpose of the 2024 Plan is to help the Company attract, motivate and retain such persons with awards under the 2024 Plan and thereby enhance shareholder value. The 2024 Plan provides for the grant of stock options, stock appreciation rights, performance share awards, performance unit awards, distribution equivalent right awards, RSAs, restricted stock unit awards and unrestricted stock awards. Under the 2024 Plan, 1,288,000 shares of unrestricted stock, 3,816,139 RSAs and 20,000 RSUs were granted as of September 30, 2026, and 1,288,000 shares of unrestricted stock and 1,363,744 RSAs were granted as of December 31, 2025.

 

Some RSAs granted under the 2024 Plan have service-based vesting conditions and vest over a period from one to two years. Some RSAs and RSUs granted under the 2024 Plan are subject to both service and performance-based vesting conditions. These awards vest upon the achievement of specified metrics. Depending on the award, these metrics are either measured over a concurrent service period, or act as a prerequisite that must be met to initiate a subsequent 12-month service-based vesting schedule, with the awards vesting in equal monthly installments. The assessment for this prerequisite may occur within a fixed period or be indefinite. Compensation expense for awards with service and performance-based vesting conditions is recognized based on the grant-date fair value over the requisite service period on a straight-line basis to the extent achievement of the performance condition is probable. As of each reporting date, the Company estimates the probability that specified performance criteria will be met and does not recognize compensation expense until it is probable that the performance-based vesting condition will be achieved.

 

Restricted Stock Awards

 

Service-based RSAs

 

The table below identifies service-based RSA activity under the 2024 Plan and certain awards granted outside of the Company’s equity incentive plans for the relevant periods presented:

 

    Numbers of
RSAs
    Weighted
Average
Fair Value
Per RSA
 
Unvested as of December 31, 2025     321,060     $ 0.92  
Granted (1)     217,633       1.13  
Vested     (327,310 )     1.10  
Canceled/Forfeited     (77,932 )     0.98  
Unvested as of September 30, 2026     133,451     $ 0.77  

 

(1) On June 15, 2026, the Company granted 95,238 RSAs to a consulting firm outside of its equity incentive plans at a grant-date fair value of $1.05 per share, subject to vesting monthly over a 6-month period commencing on June 15, 2026. On August 14, 2026, the Company terminated the consulting engagement, resulting in the automatic forfeiture of 63,492 unvested RSAs without consideration. The remaining 31,746 RSAs had vested prior to the termination.

 

32

 

 

Health In Tech, Inc.

 

Notes to Consolidated Financial Statements

 

9. Stock-Based Compensation (cont.)

 

As of September 30, 2026, there was $65,248 of unrecognized compensation cost, adjusted for estimated forfeitures based on historical data, related to non-vested service-based RSAs. The RSAs are expected to be recognized over a weighted-average remaining requisite service period of 0.5 years, using the straight-line method. The total fair value of the RSAs vested was $360,851 and $173,089 during the nine months ended September 30, 2026 and 2025, respectively. The weighted-average grant-date fair value per share of RSAs granted was $1.13 and $0.79 during the nine months ended September 30, 2026 and 2025, respectively.

 

Service and performance-based RSAs

 

The table below identifies service and performance-based RSA activity under the 2022 Plan and the 2024 Plan for the relevant periods presented:

 

    Numbers of
RSAs
    Weighted
Average
Fair Value
Per RSA
 
Unvested as of December 31, 2025     386,768     $ 2.58  
Granted     2,330,000           1.55  
Vested     (585,665 )     1.71  
Canceled/Forfeited     (7,724 )     0.71  
Unvested as of September 30, 2026     2,123,379     $ 1.69  

 

As of September 30, 2026, there was $936,215 of unrecognized compensation cost, adjusted for estimated forfeitures based on historical data, related to non-vested service and performance-based RSAs that were considered probable of achievement. The RSAs are expected to be recognized over a weighted-average remaining requisite service period of 0.3 years, using the straight-line method. The total fair value of the RSAs vested was $925,777 and $452,204 during the nine months ended September 30, 2026 and 2025, respectively. As of September 30, 2026, there was $2,074,900 of unrecognized compensation expense related to non-vested service and performance-based RSAs that were considered not probable of achievement. The weighted-average grant-date fair value per share of RSAs granted was $1.55 and $2.88 during the nine months ended September 30, 2026 and 2025, respectively.

 

During the nine months ended September 30, 2026 and 2025, the Company cancelled and retired 467,187 and 0 shares of common stock, respectively, surrendered by three executive officers to satisfy tax withholding obligations in connection with the net settlement of service and performance-based RSAs.

 

33

 

 

Health In Tech, Inc.

 

Notes to Consolidated Financial Statements

 

9. Stock-Based Compensation (cont.)

 

Restricted Stock Units

 

Service and performance-based RSUs

 

Starting in September 2026, the Company began granting RSUs under the 2024 Plan. Each of the RSUs represents the right to receive one share of the Company’s Class A Common Stock upon vesting.

 

The table below identifies service and performance-based RSU activity under the 2024 Plan for the relevant periods presented:

 

    Numbers of
RSUs
    Weighted
Average
Fair Value
Per RSUs
 
Unvested as of December 31, 2025     —     $ —  
Granted     20,000       0.82  
Vested     —       —  
Canceled/Forfeited     —       —  
Unvested as of September 30, 2026     20,000     $ 0.82  

 

As of September 30, 2026, there was $16,414 of unrecognized compensation expense related to non-vested service and performance-based RSUs that were considered not probable of achievement. The weighted-average grant-date fair value per share of RSUs granted was $0.82 during the nine months ended September 30, 2026. There were no RSUs granted during the nine months ended September 30, 2025.

 

Options

 

The table below identifies stock options activity under the 2022 Plan for the relevant periods presented:

 

    Outstanding
stock options
    Weighted
average
exercise
price
    Weighted
average
remaining
contractual
life (years)
    Aggregate
intrinsic
value
 
Balance as of December 31, 2025     2,151,947     $ 0.76       2.4     $ 1,805,713  
Granted     —       —                  
Exercised     —       —                  
Canceled/Forfeited     (251,122 )     1.14                  
Balance as of September 30, 2026     1,900,825     $ 0.71       1.8     $ 210,421  
Vested as of September 30, 2026     1,854,047     $ 0.71       1.8     $ 205,243  
Vested and expected to vest as of September 30, 2026     1,900,825     $ 0.71       1.8     $ 210,421  

 

The intrinsic value of a stock option is calculated as the difference between the per share exercise price of the underlying stock option award and the closing stock price on the last trading day in fiscal quarter. There were no stock options granted or exercised during the nine months ended September 30, 2026 and 2025. The total fair value of options vested during the nine months ended September 30, 2026 and 2025 was $44,692 and $500,091, respectively.

 

34

 

 

Health In Tech, Inc.

 

Notes to Consolidated Financial Statements

 

9. Stock-Based Compensation (cont.)

 

As of September 30, 2026, there was $13,751 of unrecognized compensation cost, adjusted for estimated forfeitures based on historical data, related to non-vested service and performance-based stock options, which is expected to be recognized over a weighted-average remaining requisite service period of 0.2 years, using the straight-line method.

 

HITChain Equity Awards

 

2026 Equity Incentive Plan

 

On April 10, 2026, HITChain adopted and approved the 2026 Equity Incentive Plan (the “2026 Plan”), which provides for the issuance of 5,000,000 shares of Class A Common Stock and 2,000,000 shares of Class B Common Stock of HITChain, each with par value $0.001 per share, for purposes of attracting, retaining, and motivating key employees, directors, and consultants. The 2026 Plan provides for the grant of stock options, unrestricted stock awards, RSAs, stock appreciation rights, restricted stock units and performance stock units. Under the 2026 Plan, 500,000 RSAs and 2,000,000 stock options were granted as of September 30, 2026.

 

Restricted Stock Awards

 

Service and performance-based RSAs

 

The table below identifies service and performance-based RSA activity for shares of Class A Common Stock under the 2026 Plan for the relevant periods presented:

 

    Numbers of
RSAs
    Weighted
Average
Fair Value
Per RSA
 
Unvested as of December 31, 2025     —     $ —  
Granted     500,000       0.01  
Vested     —       —  
Canceled/Forfeited     —       —  
Unvested as of September 30, 2026     500,000     $ 0.01  

 

As of September 30, 2026, there was no unrecognized compensation cost, adjusted for estimated forfeitures based on historical data, related to non-vested service and performance-based RSAs that were considered probable of achievement. As of September 30, 2026, there was $2,550 of unrecognized compensation expense related to non-vested service and performance-based RSAs that were considered not probable of achievement. The weighted-average grant-date fair value per share of RSAs granted was $0.01 during the nine months ended September 30, 2026.

 

35

 

 

Health In Tech, Inc.

 

Notes to Consolidated Financial Statements

 

9. Stock-Based Compensation (cont.)

 

Options

 

The table below identifies the stock options activity for shares of Class B Common Stock granted under the 2026 Plan to the individuals serving as the Company’s Chief Executive Officer and Chief Financial Officer as of September 30, 2026, for the relevant periods presented:

 

    Outstanding
stock options
    Weighted
average
exercise
price
    Weighted
average
remaining
contractual
life (years)
    Aggregate
intrinsic
value
 
Balance as of December 31, 2025     —     $ —       —     $ —  
Granted     2,000,000       0.01       10.0          
Exercised     —       —                  
Canceled/Forfeited     —       —                  
Balance as of September 30, 2026     2,000,000     $ 0.01       9.5     $ —  
Vested as of September 30, 2026     2,000,000     $ 0.01       9.5     $ —  
Vested and expected to vest as of September 30, 2026     2,000,000     $ 0.01       9.5     $ —  

 

The intrinsic value of a stock option is calculated as the difference between the per share exercise price of the underlying stock option award and the estimated per share fair value of the HITChain’s common stock at the measurement date. There were no stock options exercised during the nine months ended September 30, 2026. The weighted-average fair value of options granted during the nine months ended September 30, 2026 was $0.003 per share. The total fair value of options vested during the nine months ended September 30, 2026 was $5,633. As of September 30, 2026, there was no unrecognized compensation cost.

 

The estimated fair value of stock options was calculated using the binomial option-pricing model, based on the following range of assumptions:

 

    Nine Months Ended
September 30,
2026
 
Expected volatility     58.35 %
Risk-free interest rate     4.48 %
Exercise multiples     2.80  
Expected term     —  
Expected dividend yield     — %
Forfeited rates     — %
Fair market value per common share     0.01  

 

 

36

 

 

Health In Tech, Inc.

 

Notes to Consolidated Financial Statements

 

9. Stock-Based Compensation (cont.)

 

Expected volatilities are based on historical volatilities of the similar public companies’ common shares over the respective expected term of the share-based awards. Risk-free interest rate is based on the yield of U.S. Treasury Strips with maturity terms similar to the expected term on the share-based awards. The exercise multiples are the share price multiples upon which the employees are likely to exercise share options. Fair market value per common share is the market value of HITChain’s stocks on the grant date. The shares of common stock to be issued upon the exercise of stock options are made available from authorized and unissued common stock.

 

10. Fair Value Measurements

 

The following table presents the Company’s liabilities that are measured at fair value on a recurring basis as of September 30, 2026:

 

    September 30, 2026  
    Level 1     Level 2     Level 3     Total  
Liabilities:                        
Convertible Notes   $ —     $ —     $ 6,639,108     $ 6,639,108  
SEPA derivative liability     —       —       82,629       82,629  
Total liabilities, at fair value   $ —     $ —     $ 6,721,737     $ 6,721,737  

 

As of December 31, 2025, the Company had no assets or liabilities measured at fair value on a recurring basis.

 

Convertible Notes

 

The following table presents the changes in the Convertible Notes measured at fair value during the three and nine months ended September 30, 2026:

 

    Three
Months
Ended
September 30,
2026
    Nine
Months
Ended
September 30,
2026
 
Beginning balance   $ —     $ —  
Issuance     6,569,606       6,569,606  
Changes in fair value recognized in earnings     69,502       69,502  
Ending balance   $ 6,639,108     $ 6,639,108  

 

For the three and nine months ended September 30, 2026, the Company recognized an unrealized loss of $69,502 related to changes in the fair value of the Convertible Notes outstanding as of September 30, 2026, which was included in Change in fair value of convertible notes — FVO in the consolidated statements of operations.

 

The fair value of the Convertible Notes was estimated using a Monte Carlo simulation model incorporating probability-weighted outcomes for scheduled repayments, conversions, early redemptions and defaults. The projected cash flows were discounted using risk-adjusted discount rates.

 

37

 

 

Health In Tech, Inc.

 

Notes to Consolidated Financial Statements

 

10. Fair Value Measurements (cont.)

 

The following table summarizes the key inputs used in determining the fair value of the Convertible Notes as of September 30, 2026:

 

    September 30,
2026
 
Remaining contractual term (years)     1.39  
Stock price   $ 0.82  
Expected volatility     104.43 %
Risk-free interest rate     4.57 %
Risk-adjusted discount rate     11.22 %
Down-round probability     5 %

 

The down-round probability represents an unobservable input based on management’s assumptions. Changes in this assumption may affect the probability and timing of redemption and conversion outcomes and, consequently, the estimated fair value of the Convertible Notes.

 

SEPA Derivative Liability

 

The following table presents the changes in the SEPA derivative liability measured at fair value during the three and nine months ended September 30, 2026:

 

    Three
Months
Ended
September 30,
2026
    Nine
Months
Ended
September 30,
2026
 
Beginning balance   $ —     $ —  
Initial recognition     80,394       80,394  
Changes in fair value recognized in earnings     2,235       2,235  
Ending Balance   $ 82,629     $ 82,629  

 

For the three and nine months ended September 30, 2026, the Company recognized an unrealized loss of $2,235 related to changes in the fair value of the SEPA derivative liability outstanding as of September 30, 2026, which was included in Change in fair value of SEPA derivative liability in the consolidated statements of operations.

 

The estimated fair value of the SEPA derivative liability was determined using a Monte Carlo simulation model incorporating the expected utilization of the SEPA to fund repayments of the Convertible Notes and the value of the share purchase discount applicable to such repayments.

 

38

 

 

Health In Tech, Inc.

 

Notes to Consolidated Financial Statements

 

10. Fair Value Measurements (cont.)

 

The following table summarizes the key inputs used in determining the fair value of the SEPA derivative liability as of September 30, 2026:

 

    September 30,
2026
 
Expected term (years)     1.39  
Stock price   $ 0.82  
Expected volatility     104.43 %
Risk-free interest rate     4.57 %
Risk-adjusted discount rate     11.22 %
Down-round probability     5 %

 

The down-round probability represents an unobservable input based on management’s assumptions. Changes in this assumption may affect the expected utilization of the SEPA and the resulting fair value measurement.

 

11. Subsequent Events

 

Equity Awards and Share Cancellation

 

On October 7, 2026, the Company granted an aggregate of 52,602 RSAs to its two independent directors under the 2024 Plan, with 26,301 RSAs to each independent director. These awards were vested in full on the grant date, subject to the director’s requisite service in the third quarter of 2026.

 

On October 15, 2026, the Company cancelled and retired 174,000 shares of Class A common stock surrendered by three executive officers to satisfy tax withholding obligations in connection with the net settlement of equity awards. 

 

Leadership Transition and Related Equity Awards

 

On October 20, 2026, the Company’s Board of Directors appointed Sanjay Shrestha as Chief Executive Officer, succeeding Tim Johnson, who transitioned to Executive Chairman of the Board.

 

In connection with the leadership transition, the Company granted Mr. Shrestha RSAs under the 2024 Plan covering 5,000,000 shares of Class A Common Stock and 500,000 shares of Class B Common Stock, consisting of (i) 2,000,000 Class A shares subject to service-based vesting conditions, (ii) 1,500,000 Class A shares subject to performance-based vesting conditions and continued service requirements, and (iii) 1,500,000 Class A shares and 500,000 Class B shares subject to market-based conditions followed by service-based vesting. The number of shares under the performance-based award may increase by up to an additional 500,000 Class A shares, as determined by the Compensation Committee upon satisfaction of the applicable performance condition. The Board also approved additional awards covering 2,500,000 Class A shares subject to market-based conditions followed by service-based vesting, contingent upon stockholder approval of an amendment to the 2024 Plan, which approval was granted at the 2026 Annual Meeting. Mr. Shrestha’s employment agreement and restricted stock award agreement, each dated October 20, 2026, are filed herewith as Exhibit 10.14 and Exhibit 10.15, respectively.

 

In addition, the Board approved RSA arrangements for Mr. Johnson and Linlin Qian, the Company’s Chief Financial Officer, each covering (i) 650,000 Class A shares subject to service-based vesting conditions, (ii) 800,000 Class A shares subject to performance-based vesting conditions and continued service requirements, and (iii) 1,600,000 Class A shares and 200,000 Class B shares subject to market-based conditions followed by service-based vesting. All such awards were contingent upon stockholder approval of an amendment to increase the shares authorized under the 2024 Plan, which approval was granted at the 2026 Annual Meeting.

 

On November 10, 2026, the Company’s stockholders approved the amendment to the 2024 Plan, increasing the number of Class A shares authorized for issuance under the 2024 Plan from 10,677,849 to 30,677,849 shares and satisfying the stockholder approval conditions applicable to the above awards and arrangements.

 

Issuance of Second Convertible Notes

 

On November 2, 2026, pursuant to the SEPA with Yorkville, the Company issued the second Convertible Note in the principal amount of $3,000,000 in connection with the second tranche of the Pre-Paid Advances. The second Convertible Note was issued at a 5% purchase price discount, and the Company received net proceeds of $2,850,000 on November 3, 2026. The second Convertible Note is subject to substantially the same terms and conditions as the First Convertible Note issued on August 18, 2026, as described in Note 8, Debt, except that installment payments under the second Convertible Note commence in October 2027.

 

Amendment to Second Amended and Restated Articles of Incorporation

 

On November 10, 2026, the Company’s stockholders approved, to be effective as of the same date, an amendment to the Company’s Second Amended and Restated Articles of Incorporation to increase the total authorized shares of capital stock of the Company from 220,000,000 to 720,000,000, consisting of 650,000,000 shares of Class A Common Stock, 50,000,000 shares of Class B Common Stock and 20,000,000 shares of Series A Preferred Stock, $0.001 par value per share.

 

39

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

You should read the following discussion of our financial condition and results of operations in conjunction with our consolidated financial statements and the related notes included elsewhere in this Quarterly Report on Form 10-Q and with our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission. In addition to our historical consolidated financial information, the following discussion contains forward-looking statements that reflect our plans, estimates, and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this Quarterly Report on Form 10-Q, particularly in Part II, Item 1A, “Risk Factors.”

 

Overview

 

Health In Tech (“HIT”) is an insurance technology platform company, which offers a marketplace that aims to improve processes in the healthcare industry through vertical integration, process simplification, and automation. By removing friction and complexities, we streamline the underwriting, sales and service process for insurance companies, licensed brokers, Managing General Underwriters (MGUs) and Third-Party Administrators (TPAs).

 

Marketplace: We are a health insurance marketplace where insurance companies can list various stop-loss policy options for self-funded benefits plans. Licensed brokers registered on our platform can log in, upload certain required information, select policy plans, obtain a bindable quote and sell them to businesses. In most cases, our technology enables us to medically underwrite insurance policies and produce bindable quotes within about two minutes for small employers (10-100 employees) and about two weeks for larger employers (exceeding 100 employees), allowing us to deliver an integrated and seamless sales cycle.

 

Customizable Solutions: Beyond policy underwriting and sales, our marketplace offers customization of health benefits plans, vendors, claims, and network services. Brokers can select customized plans that suit their customers.

 

Accessibility and Savings: We make self-funded benefits plans and stop loss insurance accessible online for businesses. We aim to deliver meaningful cost savings for low-risk employers with comparatively healthy employees through a digital medical underwriting process. We seek to deliver time savings for employers, brokers, TPAs, and carriers, by leveraging both external and internally developed technology.

 

As of September 30, 2026, we had 357 business clients in 35 states, with our services and platforms actively utilized by 661 brokers, 11 TPAs, and 312 additional third-party agencies. For the nine months of 2026, total revenues were $23.4 million, a decrease of approximately 9% compared to $25.8 million for the same period in 2025. The decrease in revenue primarily reflected delays in the commencement of certain new policies associated with the transition to a new carrier. The new carrier’s different underwriting criteria and procedures required additional underwriting and approval before certain new policies could be bound and become effective. These requirements temporarily extended processing times for new business, resulting in fewer new clients being onboarded during the reporting period than in the comparative period. For these new policies, revenue recognition did not begin until the applicable contractual requirements were satisfied and the policies became effective, consistent with our revenue recognition policy. Accordingly, the principal revenue effect of the transition was a timing impact on the commencement of certain new policies.

 

The new carrier was onboarded during the second quarter of 2026, and transfers of existing in-force policies from the prior carrier to the new carrier were substantially completed as of September 30, 2026. The portfolio transfers did not interrupt employer coverage or change the policies’ existing contractual expiration dates. Upon each transfer, the new carrier assumed the applicable carrier responsibilities, while we continued to provide our contracted services and retained an enforceable right to consideration for those services over the remaining policy terms under the applicable contractual arrangements. Revenue from existing in-force policies continued to be recognized over the applicable policy terms, with no material reduction or delay attributable solely to the portfolio transfers.

 

40

 

 

The portfolio transfers required additional administrative coordination among us, the carriers and the applicable third-party administrators, including reconciliations of premiums, enrollment information, claims and other amounts. These procedures affected the timing of certain carrier settlements and receivable collections but did not cause us to suspend or defer revenue recognition, or reverse previously recognized revenue, for services provided under existing in-force policies.

 

We currently generate most of our revenue from service fees and underwriting fees, that are associated with customers who purchase self-funded benefits plans and stop loss insurance. These plans are facilitated through a network of brokers, TPAs, MGUs, carriers, and other third-party agents. These agencies either directly engage our services or provide valuable client referrals.

 

Recent Developments

 

Launch of HitRix. On September 30, 2026, we launched HitRix, an AI-powered, broker-first marketplace designed to modernize the large-group self-funded stop-loss insurance placement process. By automating data ingestion, streamlining submissions across multiple carriers and managing general underwriters (“MGUs”), and enabling more efficient proposal comparisons, HitRix aims to reduce manual workflows, enhance broker productivity, improve quoting efficiency, and drive higher policy placement conversion rates. HitRix launches across our existing distribution ecosystem of brokers, third-party administrators, and agencies. In connection with the launch, on September 30, 2026, we formed HITRix, LLC, a wholly-owned subsidiary, to support the platform’s operations. HITRix, LLC had not commenced operations as of September 30, 2026.

 

Three-Year Rate Stabilization Program. We continue to advance our Three-Year Rate Stabilization Program, designed to provide employers with greater predictability in stop-loss insurance costs over a multi-year period. We have secured our first client and are progressing toward an associated note issuance exceeding $50 million. With the initial launch targeted by year-end 2026, we are prioritizing disciplined execution and aim to establish a foundation for converting our pipeline, representing potential note issuances in potentially sizeable dollar amounts, into future commercial growth. On September 28, 2026, we formed Anchor 36, LLC, a wholly-owned subsidiary, to support the planned program offering. Anchor 36, LLC had not commenced operations as of September 30, 2026.

 

Strategic Leadership Transition. Appointed Sanjay Shrestha as Chief Executive Officer, effective October 20, 2026, to lead commercial execution, business expansion, and strategic growth. Mr. Shrestha brings extensive experience in public-company leadership, capital markets, and strategic acquisitions, as well as an established understanding of Health In Tech through both his prior service as a member of our Board and, later, as a strategic advisor to our Board. Founder Tim Johnson transitioned to Executive Chairman to focus on long-term strategy, technology innovation, and product development.

 

Strengthened Board Expertise. Elected Tim Cortes as an independent director at our November 10, 2026 Annual Meeting of Stockholders, bringing extensive technology and engineering leadership experience to our Board.

 

Updated 2026 Revenue Outlook. We revised our full-year 2026 revenue outlook to approximately $30 million, modestly below 2025 revenue. The revision primarily reflects the delayed commencement of certain new policies resulting from the transition to a new carrier, which temporarily extended underwriting and onboarding timelines. These delays shifted the anticipated revenue contribution from certain new business opportunities into 2027, rather than reflecting a loss of the underlying opportunities. With the carrier transition substantially completed, we are focused on accelerating policy onboarding, improving conversion rates, and translating our existing pipeline into revenue growth in 2027.

 

Key Factors Affecting our Performance

 

Our ability to retain and expand our network of brokers, TPAs, MGUs and other third-party agents.

 

While we generate our revenue primarily from employers and insurance carriers, we currently derive substantially all of our business through brokers, TPAs, and other third-party agents who provide referrals. As a result, the size of our network is critical to our success. We have experienced significant network growth since we commenced operations, and we believe we have the opportunity to continue to grow our network by providing superior innovation in automation, great client experience, competitive pricing, access to quality providers, and competitive insurance coverage relative to other insurers in the same geographic and insurance markets.

 

Our ability to enter into more collaborations with insurance carriers and offer new products and plans

 

Our business growth will depend on our ability to collaborate with a diverse range of insurance carriers to service the excess coverage needs of our clients. These collaborations are essential for expanding our portfolio of products and services. Our growth strategy is heavily reliant on our capability to introduce innovative insurance products and plans. By collaborating with multiple insurance carriers, we can leverage their expertise and resources to develop a broader range of offerings. This not only enables us to meet the specific requirements of our clients but also helps in staying competitive in a rapidly changing market.

 

41

 

 

Our ability to accurately perform underwriting procedures

 

Our growth is significantly dependent on our ability to accurately perform underwriting procedures and maintain strong relationships with brokers, TPAs, carriers, MGUs, and other third-party agents who utilize our platforms. A failure to conduct precise underwriting actuarial reviews and adjustments to our underwriting tools could result in increased costs and pricing for health plans.

 

While we are not bound by any agreements that would necessitate paying fees exceeding estimated insurance costs, nor do we have agreements that require indemnification of the carrier, such a failure could cause reputational harm to our eDIYBS platform. This could lead to increased premiums for plans accessed through our platform, potentially affecting our financial standing and market competitiveness.

 

Our ability to continue invest in technology and innovation

 

Our ongoing commitment to investing in technology is crucial for driving advancements in automation and enhancing operational efficiency across all aspects of our business. We are dedicated to regularly updating and developing new technology. This continuous investment in technology and innovation will position us at the forefront of the insurance technology.

 

Seasonality

 

Our business is generally affected by the seasonal patterns of our enrollment and medical expenses. Usage of our underwriting and quoting platform is seasonal, primarily due to the common renewal of health plan policies in December and January. While we believe we have visibility into the seasonality of our business, our rapid growth rate over the last couple years may have made seasonal fluctuations more difficult to detect. If our rate of growth slows over time, seasonal or cyclical variations in our operations may become more pronounced, and our business, results of operations and financial position may be adversely affected.

 

Key Financial and Operating Performance Metrics

 

We regularly monitor a number of financial and operating metrics in order to measure our current performance and project our future performance. These metrics help us develop and refine our growth strategies and make strategic decisions. We discuss revenues, cost of revenues, and the components of operating expenses. We utilize other key metrics as described below.

 

Contracted Revenue

 

Contracted Revenue is a period-based operating metric and is not a point-in-time backlog measure. Contracted Revenue includes contractual revenue associated with policies that are in force at any time during the applicable reporting period. For the nine months ended September 30, 2026, the reporting period covers January 1, 2026 through September 30, 2026.

 

For each such policy, Contracted Revenue includes:

 

● contractual revenue attributable to the portion of the policy term falling within the reporting period, including the amount recognized as GAAP revenue during the reporting period; and

 

● remaining contractual revenue expected to be recognized in future periods over the remaining contractual term of that policy.

 

42

 

 

Revenue attributable to periods before the beginning of the applicable reporting period is excluded. A policy that expired or lapsed before the beginning of the reporting period is also excluded. If a policy expires or lapses during the reporting period, Contracted Revenue includes revenue attributable to that policy only through its expiration or lapse date, and no revenue is included for periods thereafter.

 

Standard self-funded plan policies generally have a contractual term of 12 months, while our Three-Year Rate Stabilization Program is designed with a 36-month contractual term. Revenue is recognized under U.S. GAAP on a straight-line basis over the policy term, beginning on the policy’s effective date.

 

Contracted Revenue totaled $32.7 million for the nine months ended September 30, 2026, of which $24.4 million was recognized as GAAP revenue during the reporting period of first three quarters. The remaining $6.1 million and $2.2 million are expected to be recognized as GAAP revenue in the fourth quarter of 2026 and in 2027, respectively.

 

The following table presents the changes in Contracted Revenue from the six months ended June 30, 2026 to the nine months ended September 30, 2026:

 

in $ Million   Total
Contracted
Revenue (1)
    GAAP
revenue
recognized
during
reporting
period (2)
    Revenue
expected to be
recognized
during the
remainder of
2026 (3)
    Revenue
expected to be
recognized
in 2027 (4)
 
For the six months ended June 30, 2026     32.31       17.27       14.05       0.99  
Increase / (decrease): Revenue from existing in-force policy included in the prior reporting period     —       7.46       (7.46 )     —  
Increase: Revenue from new in-force policies effective in Q3 2026     2.40       0.37       0.60       1.43  
Decrease: Policies no longer in force and other adjustments     (2.01 )     (0.74 )     (1.05 )     (0.22 )
For the nine months ended September 30, 2026     32.70       24.36       6.14       2.20  

  

(1) Contracted Revenue includes contractual revenue associated with policies that are in force at any time during the applicable reporting period. If a policy expires or lapses during the reporting period, Contracted Revenue includes revenue attributable to that policy only through its expiration or lapse date, and no revenue is included for periods thereafter. For the nine months ended September 30, 2026, Total Contracted Revenue from in-force policy was $32.70 million, derived from $32.31 million for the six months ended June 30, 2026, plus $2.40 million of contractual revenue from new in-force policies effective during the third quarter of 2026, less $2.01 million related to policies that are no longer in force and other adjustments.
(2)

For the nine months ended September 30, 2026, we recognized $24.36 million in revenue in accordance with GAAP, including $17.27 million recognized during the six months ended June 30, 2026. Third-quarter revenue reflected the $7.46 million previously expected to be recognized from existing in-force policies, plus $0.37 million recognized from new policies that became effective during the third quarter, less $0.74 million reflecting reductions in expected revenue from policies no longer in force and other adjustments. Revenue was recognized as we provided services under the applicable policies.

 

43

 

 

(3)

As of September 30, 2026, we expected to recognize $6.14 million in revenue during the fourth quarter of 2026 from policies then in force. As of June 30, 2026, the Company had expected to recognize $14.05 million during the remainder of 2026, comprising $7.46 million in the third quarter and $6.59 million in the fourth quarter. The updated fourth-quarter estimate reflects the previous estimate of $6.59 million, increased by $0.60 million attributable to new in-force policies sold during the third quarter and reduced by $1.05 million previously expected from policies no longer in force and other adjustments.

(4)

As of September 30, 2026, the Company expected to recognize $2.20 million in revenue during 2027 from policies then in force. This amount reflects the $0.99 million previously expected to be recognized in 2027 as of June 30, 2026, plus $1.43 million attributable to new in-force policies that became effective during the third quarter, less $0.22 million related to policies no longer in force and other adjustments.

 

Contracted revenue is presented prior to the impact of monthly employers’ enrollment adjustments during contractual period, including changes in enrolled employees, plan mix, and other factors that may affect premium and fees. Accordingly, actual revenue recognized in future periods may differ from Contracted Revenue.

 

Pipeline Revenue

 

Pipeline Revenue represents revenue from self-funded plan policies that are being quoted, are in binding status, or have been contracted subsequent to the end of the reporting period. This metric reflects the entire contractual term of the underlying policies, some of which may not ultimately convert to revenue.

 

As of October 30, 2026, opportunities at various stages of our sales pipeline represented approximately $156.4 million in potential revenue, including $2.6 million attributable to contracted business. Management estimates a closing rate of 3% to 7% for the remaining sales opportunities.

 

Platform Placed Plan Value (PPPV)

  

Platform Placed Plan Value represents the aggregate contractual value of self-funded health plans with stop-loss insurance (self-funded stop-loss plans) placed through our platform during the fiscal year through the applicable fiscal quarter end, measured over each plan’s full contractual term of typically 12 or 36 months from the plan’s effective date. PPPV reflects the total economic value flowing through the platform, including premium, claim funding, and administrative fees, and is a measure of platform transaction volume rather than an indication of our own revenue or take rate.

 

As of September 30, 2026, the platform placed $91.8 million of self-funded stop-loss plans.

 

Adjusted EBITDA

 

Adjusted EBITDA represents our net income (loss) attributable to common stockholders before net interest income, taxes and amortization expense, adjusted to eliminate stock-based compensation expense, including employer payroll taxes related to stock-based awards, provision for credit losses on other receivables and loans receivable, financing transaction costs, change in fair value of SEPA derivative liability, change in fair value of convertible notes and other non-recurring items. Adjusted EBITDA is not a measure calculated in accordance with United States Generally Accepted Accounting Principles, or GAAP. Please refer to “Results of Operations” in this item for a discussion of the limitations of adjusted EBITDA and reconciliations of adjusted EBITDA to net income (loss) attributable to common stockholders, the most comparable GAAP measurements, respectively, for the three and nine months ended September 30, 2026 and 2025. We exclude certain non-recurring or non-cash items when calculating Adjusted EBITDA, and we believe this approach provides a more meaningful measure by offering a clearer view of our underlying operational performance.

 

44

 

 

Components of Operating Results

 

Revenues

 

While we generate our revenue primarily from employers and insurance carriers, we grow our business primarily from offering solutions that streamline sales processes, enhance service delivery, and reduce the sales cycle. We offer our services through our subsidiaries. Program and platform management services and self-funded plan administration services provided by SMR and MGU activities provided by ICE (including eDIYBS) are interdependent, as they cannot function effectively without being combined. Currently ICE does not offer underwriting services as a standalone service. In the future, we may consider offering standalone service based on different functionalities and technology deliveries.

 

  (i)

SMR is a program manager specializing in customized self-funded benefits programs and pre-designed bundled plan options for businesses. Under its legacy program and platform management services, it creates the program, selects networks and adds vendors, and sets up benefits plans on the marketplace after the vendors are selected by the brokers for the plan, including benefits structures, coverage options, and provider networks. Licensed brokers log in to the marketplace to select and sell self-funded benefits plans for businesses. SMR collaborates with TPAs and licensed brokers to design health plans that meet the specific needs of employers.

 

Starting January 1, 2026, SMR has expanded its service scope and launched the new self-funded plan administration services, enhancing its service model to deliver pre-configured, end-to-end self-funded health benefit solutions. Leveraging long-term vendor management experience, SMR develops a full suite of pre-designed customized plans bundled with stop-loss insurance coverage. The distribution partners, mainly brokers for now, are presented with over 100 configured plans. The Company curates and directly contracts with a dedicated network of specialized administrative vendors, tailoring service setups to fit employer and distribution partner needs with balanced standardization and flexibility. As of September 2026, over 100 configurable pre-designed plan options are available, which are rapidly implemented and combined with stop-loss coverage, greatly reducing plan administration complexity and driving overall operational efficiency. This enhanced service model provides employers and sales with more streamlined, differentiated and flexible self-funded plan arrangements.

 

The revenue from SMR is derived from a set fee charged per enrolled employee (EE) per month (PEPM). The fee varies depending on the type of plans selected by the broker or other distribution partner. These fees may vary based on plan design, covered population. SMR’s fees are part of self-funded stop loss plan payments, paid by employers.

 

  (ii) ICE develops and maintains all underwriting models. It defines risk criteria based on risk guidelines provided by carriers, manages underwriting of risk, manages claims activity, ensures reinsurance reporting, and handles monthly reinsurance filings. The revenue from ICE is derived as a specific percentage from the premium received, in our capacity as the Managing General Underwriter (MGU) of insurance companies (Carriers). ICE’s fees are paid by carriers.

 

The following table sets forth the components of our revenues by subsidiaries and percentages of our total revenues for the periods presented:

 

    Three Months Ended September 30,     Nine Months Ended September 30,  
    2026     % of
revenue
    2025     % of
revenue
    2026     % of
revenue
    2025     % of
revenue
 
Revenues                                                
Revenues from underwriting modeling (ICE)   $ 632,613       9.6 %   $ 1,389,604       16.4 %   $ 3,374,074       14.4 %   $ 5,832,164       22.6 %
Revenues from fees (SMR)     5,954,439       90.4 %     7,100,489       83.6 %     20,041,244       85.6 %     19,986,762       77.4 %
Total revenues     6,587,052       100.0 %     8,490,093       100.0 %     23,415,318       100.0 %     25,818,926       100.0 %

 

45

 

 

Cost of revenues

 

Cost of revenues primarily consists of direct costs attributable to operating its platform and delivering platform-enabled services, many of which vary with the volume of services delivered, (i) infrastructure costs to operate our platform, such as hosting fees, fees paid to various third-party partners for access to their technology and services, and amortization expenses of our capitalized internal-use software related to the platform, (ii) costs of plan administrative services provided by the TPA designated in each pre-designed plan and other vendors assigned to each TPA, and (iii) costs related to the captive management activities. We mainly outsource captive management services and data services from the third-party companies. Our internal proprietary system seeks to consistently improve underwriting and services results through machine learning and data feeds. The captive management activities include introducing new carriers, conducting due diligence on carriers, conducting feasibility studies to determine the viability to be a stop-loss carrier on the platform, negotiating terms and contracts, coordinating audit requests, managing relationship with unrelated carriers and their regulators and auditor firms to ensure that our risk associated with our service offerings is minimized. Personnel costs associated with underwriting oversight, claims management, enrollment support and other operational functions are classified as general and administrative expenses. These employees support the our overall operating platform and service infrastructure across our portfolio of carrier and employer relationships, rather than performing activities that are directly identifiable to a specific revenue contract or separately priced service deliverable. See Part II, “Item 1A. Risk Factors — Risks Related to our Business and Industry” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the SEC on March 25, 2026 for additional information on the risks associated with our service offerings.

 

Sales and marketing expenses

 

Sales and marketing expenses primarily consist of (i) costs associated with expanding our distribution channels through third-party agents, which are variable and based on policies sold and fees collected, and (ii) costs related to the internal sales team responsible for onboarding agencies and agents onto the platform. These expenses include commissions, incentive compensation, salaries and benefits, and other related selling costs. Sales and marketing expenses also include the costs for advertising, promotional and other marketing activities, as well as certain fees paid to various third-party for sales and customer acquisition.

 

General and administrative expenses

 

General and administrative expenses primarily consist of personnel-related costs and related expenses for our executives, finance, legal, human resources, technical support, and operations personnel, as well as the costs associated with professional fees for external legal, accounting, and other consulting services, and insurance premiums. Personnel in the operations division, including those providing underwriting oversight, claims management, enrollment support and other operational functions, are classified as general and administrative because they support our overall operating platform and service infrastructure across our portfolio of carrier and employer relationships, rather than performing activities directly attributable to specific revenue contracts or separately priced service deliverables.

 

Provision for credit losses

 

Provision for credit losses consists of expected credit losses recognized on our accounts receivable, other receivables and loans receivable in accordance with ASC 326, Financial Instruments — Credit Losses.

 

Research and development expenses

 

Research and development expenses primarily consist of personnel-related costs, including salaries, stock-based compensation expense and benefits for our research and development personnel. Additional expenses include costs related to research, design, and preliminary planning of new technology, as well as routine maintenance of its existing platform.

 

46

 

 

Financing Transaction Costs

 

Financing transaction costs primarily consist of commitment and structuring fees associated with the SEPA, success fees related to the promissory convertible note, and legal and other professional fees incurred in connection with these financing arrangements.

 

Change in Fair Value of SEPA Derivative Liability

 

In August 2026, we entered into a SEPA with Yorkville, under which we have the right, but not the obligation, to sell up to $20.0 million of our Class A common stock over a 36-month period, subject to certain conditions and limitations. The SEPA was recognized as a derivative liability measured at fair value at initial recognition and is subsequently remeasured at fair value at the end of each reporting period, with changes in fair value recognized in the consolidated statements of operations.

 

Change in Fair Value of Convertible Notes – FVO

 

We elected the fair value option to account for the Convertible Notes issued in connection with the SEPA. Under this election, the Convertible Notes, including accrued and unpaid interest, are measured at fair value at initial recognition and subsequently remeasured at fair value at each reporting date. Changes in fair value are recognized in the consolidated statements of operations, except for changes attributable to instrument-specific credit risk, which are recognized in other comprehensive income.

 

Income tax benefit (expense)

 

Income tax benefit (expense) consists primarily of changes to our current and deferred federal and state tax assets and liabilities. Deferred income taxes are recognized for the tax consequences of temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Our deferred tax assets and liabilities are calculated by applying the current tax rates and laws to taxable years in which such differences are expected to reverse.

 

We continually review the need for, and the adequacy of, valuation allowances, and recognize benefits from our deferred tax assets only when an analysis of both positive and negative factors indicates that it is more likely than not such benefits will be realized.

 

47

 

 

Results of Operations

 

The following table sets forth our consolidated statements of operations for the periods presented, both in absolute amount and as a percentage of our total revenues for the periods presented:

 

    Three Months Ended September 30,     Nine Months Ended September 30,  
    2026     %  of
revenue
    2025     %  of
revenue
    2026     %  of
revenue
    2025     %  of
revenue
 
Revenues                                                
Revenues from underwriting modeling (ICE)   $ 632,613       9.6 %   $ 1,389,604       16.4 %   $ 3,374,074       14.4 %   $ 5,832,164       22.6 %
Revenues from fees (SMR)     5,954,439       90.4 %     7,100,489       83.6 %     20,041,244       85.6 %     19,986,762       77.4 %
Total revenues     6,587,052       100.0 %     8,490,093       100.0 %     23,415,318       100.0 %     25,818,926       100.0 %
                                                                 
Cost of revenues     3,524,692       53.5 %     3,346,277       39.4 %     11,921,066       50.9 %     9,009,841       34.9 %
Gross profit   $ 3,062,360       46.5 %   $ 5,143,816       60.6 %   $ 11,494,252       49.1 %   $ 16,809,085       65.1 %
                                                                 
Operating expenses                                                                
Sales and marketing expenses     2,061,695       31.3 %     962,567       11.3 %     6,569,185       28.1 %     3,279,560       12.7 %
General and administrative expenses     3,116,656       47.3 %     3,455,996       40.7 %     10,104,489       43.2 %     10,472,224       40.6 %
Provision for credit losses     5,337,768       81.1 %     (4,089 )     (0.0 )%     6,074,587       25.8 %     1,901       0.0 %
Research and development expenses     938,564       14.2 %     235,819       2.8 %     2,734,770       11.7 %     1,356,149       5.3 %
Total operating expenses     11,454,683       173.9 %     4,650,293       54.8 %     25,483,031       108.8 %     15,109,834       58.6 %
                                                                 
Other income (expense):                                                                
Interest income     64,627       1.0 %     111,699       1.3 %     201,666       0.9 %     305,263       1.2 %
Interest expenses     (20,000 )     (0.3 )%     —       — %     (20,000 )     (0.1 )%     —       — %
Financing transaction costs     (799,630 )     (12.1 )%     —       — %     (799,630 )     (3.4 )%     —       — %
Change in fair value of SEPA derivative liability     (2,235 )     0.0 %     —       — %     (2,235 )     (0.0 )%     —       — %
Change in fair value of convertible notes – FVO     (69,502 )     (1.1 )%     —       — %     (69,502 )     (0.3 )%     —       — %
Other income     310       0.0 %     —       — %     122,644       0.5 %     118,399       0.5 %
Other expense     (35,375 )     (0.6 )%     (5,000 )     (0.1 )%     (87,716 )     (0.4 )%     (5,000 )     (0.0 )%
Total other (expense) income, net     (861,805 )     (13.1 )%     106,699       1.2 %     (654,773 )     (2.8 )%     418,662       1.7 %
                                                                 
(Loss) Income before income tax expense   $ (9,254,128 )     (140.5 )%   $ 600,222       7.0 %   $ (14,643,552 )     (62.5 )%   $ 2,117,913       8.2 %
                                                                 
Income tax benefit (expense)     2,147,653       32.6 %     (148,046 )     (1.7 )%     3,437,610       14.6 %     (536,514 )     (2.1 )%
                                                                 
Net (loss) income   $ (7,106,475 )     (107.9 )%   $ 452,176       5.3 %   $ (11,205,942 )     (47.9 )%   $ 1,581,399       6.1 %
                                                                 
Net loss attributable to noncontrolling interests     (40,062 )     (0.6 )%     —       — %     (40,224 )     (0.2 )%     —       — %
                                                                 
Net (loss) income attributable to common stockholders     (7,066,413 )     (107.3 )%     452,176       5.3 %     (11,165,718 )     (47.7 )%     1,581,399       6.1 %
                                                                 
Other Financial Data:                                                                
Adjusted EBITDA(1)   $ (3,932,017 )     (59.7 )%   $ 999,056       11.8 %   $ (6,553,609 )     (28.0 )%   $ 3,796,283       14.7 %

 

 

(1) We define adjusted EBITDA as net (loss) income attributable to common stockholders before net interest income, taxes and amortization expense, adjusted to eliminate stock-based compensation expense, including employer payroll taxes related to stock-based awards, provision for credit losses on other receivables and loans receivable, financing transaction costs, change in fair value of SEPA derivative liability, change in fair value of convertible notes and other non-recurring items. See “Adjusted EBITDA” below for more information and for a reconciliation of adjusted EBITDA to net income (loss) attributable to common stockholders, the most directly comparable financial measure calculated and presented in accordance with GAAP.

 

48

 

 

Adjusted EBITDA

 

   

Three Months Ended

September 30,

   

Nine Months Ended

September 30,

 
    2026     2025     2026     2025  
Reconciliation from Net (Loss) Income Attributable to Common Stockholders to Adjusted EBITDA:                        
Net (loss) income attributable to common stockholders   $ (7,066,413 )   $ 452,176     $ (11,165,718 )   $ 1,581,399  
Interest income     (44,627 )     (111,699 )     (181,666 )     (305,263 )
Amortization expense     278,747       217,981       1,002,534       489,947  
Income tax (benefit) expense     (2,147,653 )     148,046       (3,437,610 )     536,514  
Stock-based compensation expense, including employer payroll taxes related to stock-based awards     730,041       292,552       2,133,849       1,493,686  
Provision for credit losses on other receivables     2,582,529       —       3,322,302       —  
Provision for credit losses on loans receivable     863,992       —       863,992       —  
Financing transaction costs     799,630       —       799,630       —  
Change in fair value of SEPA derivative liability     2,235       —       2,235       —  
Change in fair value of convertible notes – FVO     69,502       —       69,502       —  
Other non-recurring items     —       —       37,341       —  
Total net adjustments     3,134,396       546,880       4,612,109       2,214,884  
Adjusted EBITDA   $ (3,932,017 )   $ 999,056     $ (6,553,609 )   $ 3,796,283  

 

Consolidated Balance Sheet Data

 

    September 30,
2026
    December 31,
2025
 
Cash and cash equivalents   $ 10,127,237     $ 7,669,754  
Accounts receivable, net of allowance for credit losses of $1,882,457 and $0 as of September 30, 2026 and December 31, 2025, respectively     3,177,652       756,288  
Other receivables, net of allowance for credit losses of $3,502,581 and $377,587 as of September 30, 2026 and December 31, 2025, respectively     1,669,747       3,467,814  
Software     8,148,785       6,530,894  
Total assets     28,032,954       23,089,961  
Total liabilities     15,153,831       5,977,896  
Total stockholders’ equity     12,879,123       17,112,065  

 

Cash and cash equivalents

 

As of September 30, 2026, cash and cash equivalents increased by $2,457,483 to $10,127,237, from $7,669,754 as of December 31, 2025. The increase was primarily attributable to net proceeds of $6,650,000 received on August 18, 2026 from the first Pre-Paid Advance under the Company’s SEPA with Yorkville and $6,381,000 in proceeds from the PIPE financing, net of placement agent fees and escrow agent fees, partially offset by net cash used in operating activities and investing activities during the nine months ended September 30, 2026. In connection with the first Pre-Paid Advance, the Company issued to Yorkville a promissory convertible note in the principal amount of $7 million, issued at a 5% original issue discount and initially convertible into shares of the Company’s Class A common stock at a fixed conversion price of $1.5735 per share, subject to adjustment (the “First Convertible Note”).

 

49

 

 

Accounts receivable, net

 

Accounts receivable, net, increased by $2,421,364 to $3,177,652 as of September 30, 2026, from $756,288 as of December 31, 2025. The transition to a new carrier required us, the TPAs, and the prior and new carriers to perform additional policy-level reconciliations of enrollment changes, premiums, claims activity, amounts attributable to each carrier and other adjustments. These procedures extended the time required to determine and settle amounts payable to us, delaying remittances from the prior carrier and the collection of certain receivables. The collection delays primarily reflected these operational and reconciliation requirements rather than a change in the underlying payment obligations.

 

During the three months ended September 30, 2026, the applicable TPAs began making payments on outstanding balances, and collection activity improved. We separately evaluated the recognized receivables for expected credit losses under ASC 326, distinguishing delays associated with determining or reconciling amounts payable from credit risk affecting collectability. This assessment considered receivable aging, contractual payment and reconciliation terms, the status of outstanding reconciliations, historical collection and credit-loss experience, counterparty creditworthiness, current payment trends and other reasonable and supportable information relevant to expected collectability.

 

Although collection activity improved, certain balances remained outstanding for an extended period and certain reconciliations remained unresolved. Based on our assessment of the remaining balances and their expected collectability, our allowance for credit losses was $1,882,457 as of September 30, 2026. We continue to pursue collection of the outstanding receivables and will reassess the allowance at each reporting date based on payments received, the aging of remaining balances, progress on outstanding reconciliations and other relevant facts and circumstances, adjusting the allowance as appropriate.

 

Other receivables, net

 

Other receivables, net, decreased by $1,798,067 to $1,669,747 as of September 30, 2026, from $3,467,814 as of December 31, 2025. The decrease primarily reflected a $3,203,626 reduction in deferred administrative surplus receivables, net, comprising a $3,124,995 increase in the related allowance for credit losses and a $78,631 decrease in the gross receivable balance. Deferred administrative surplus receivables had a net carrying amount of zero as of September 30, 2026.

 

This reduction was partially offset by a $1,213,184 increase in receivables from a TPA and a $192,375 increase in other miscellaneous receivables. The TPA receivable arose from fees payable to us that the TPA erroneously remitted to an unrelated third party.

 

Software

 

As of September 30, 2026, the balance of software increased by $1,617,891 to $8,148,785, from $6,530,894 as of December 31, 2025. This increase was mainly attributable to a $2,620,425 investment in software development, partially offset by a $1,002,534 increase in accumulated amortization for the nine months ended September 30, 2026.

 

Total liabilities

 

As of September 30, 2026, the balance of total liabilities increased by $9,175,935 to $15,153,831, from $5,977,896 as of December 31, 2025. This increase was mainly attributable to the promissory convertible note issued to Yorkville in connection with the first Pre-Paid Advance under the SEPA.

 

50

 

 

Total stockholders’ equity

 

As of September 30, 2026, the balance of total stockholders’ equity decreased by $4,232,942 to $12,879,123, from $17,112,065 as of December 31, 2025. This decrease was mainly attributable to a net loss of $11,205,942 for the nine months ended September 30, 2026, partially offset by $5,928,120 from the issuance of common stock in connection with PIPE financing, net of offering costs and placement agent fees, and $1,561,462 in stock-based compensation.

 

Comparison of Three months ended September 30, 2026 and 2025

 

Revenues

 

    Three months ended September 30,        
    2026     2025     Period-to-Period Change  
    Amount     Percentage of
Revenue
    Amount     Percentage of
Revenue
    Amount     Percentage  
Revenues from underwriting modeling (ICE)     632,613       9.6 %     1,389,604       16.4 %     (756,991 )     (54.5 )%
Revenues from fees (SMR)     5,954,439       90.4 %     7,100,489       83.6 %     (1,146,050 )     (16.1 )%
Program and platform management fees     1,007,672       15.3 %     7,100,489       83.6 %     (6,092,817 )     (85.8 )%
Self-funded plan administration fee     4,946,767       75.1 %     —       — %     4,946,767       NM  
Total revenues     6,587,052       100.0 %     8,490,093       100.0 %     (1,903,041 )     (22.4 )%

 

“NM” denotes that the percentage change is not meaningful.

 

Total revenues for the three months ended September 30, 2026 were $6.6 million, a decrease of 22.4% from $8.5 million in the same period of 2025. The decrease in revenue primarily reflected delays in the commencement of certain new policies associated with the transition to a new carrier. The new carrier’s different underwriting criteria and procedures required additional underwriting and approval before certain new policies could be bound and become effective. These requirements temporarily extended processing times for new business, resulting in fewer new clients being onboarded during the reporting period than in the comparative period. For these new policies, revenue recognition did not begin until the applicable contractual requirements were satisfied and the policies became effective, consistent with our revenue recognition policy. Accordingly, the principal revenue effect of the transition was a timing impact on the commencement of certain new policies.

 

The new carrier was onboarded during the second quarter of 2026, and transfers of existing in-force policies from the prior carrier to the new carrier were substantially completed as of September 30, 2026. The portfolio transfers did not interrupt employer coverage or change the policies’ existing contractual expiration dates. Upon each transfer, the new carrier assumed the applicable carrier responsibilities, while we continued to provide our contracted services and retained an enforceable right to consideration for those services over the remaining policy terms under the applicable contractual arrangements. Revenue from existing in-force policies continued to be recognized over the applicable policy terms, with no material reduction or delay attributable solely to the portfolio transfers.

 

The portfolio transfers required additional administrative coordination among us, the carriers and the applicable third-party administrators, including reconciliations of premiums, enrollment information, claims and other amounts. These procedures affected the timing of certain carrier settlements and receivable collections but did not cause us to suspend or defer revenue recognition, or reverse previously recognized revenue, for services provided under existing in-force policies.

 

51

 

 

Although the services provided by SMR and ICE are delivered as an interdependent and integrated solution and we evaluate their performance based on the total revenues generated, we provide the following breakdown for transparency. Revenues from underwriting modeling generated from ICE decreased by $0.8 million to $0.6 million, and revenues from fees generated from SMR decreased by $1.1 million to $6.0 million. 

 

The period-to-period percentage decline in revenues from underwriting modeling was larger than the decrease in revenues from fees, as SMR launched the pre-designed self-funded plan administration services effective on January 1, 2026. SMR enhances its services to offer pre-designed self-funded plans to employers, leveraging years of experience selecting and managing the vendors that are essential to the plan. This new service model provides employers with more streamlined, differentiated and flexible self-funded plan arrangements.

 

Cost of revenues

 

    Three months ended September 30,        
    2026     2025     Period-to-Period Change  
    Amount     Percentage of
Revenue
    Amount     Percentage of
Revenue
    Amount     Percentage of
Revenue
 
Cost of revenues     3,524,692       53.5 %     3,346,277       39.4 %     178,415       14.1 %

 

Cost of revenues increased by $0.2 million to $3.5 million for the three months ended September 30, 2026, from $3.3 million for the three months ended September 30, 2025. As a percentage of revenue, cost of revenues increased to 53.5% for the three months ended September 30, 2026, from 39.4% for the same period in 2025.

 

The increase was primarily attributable to costs of plan administrative services provided by the TPA and other vendors assigned to each TPA, as we continued to enhance our services and launched the pre-designed plan offerings in January 2026, which gave rise to the related plan administrative costs.

 

Sales and marketing expenses

 

    Three months ended September 30,        
    2026     2025     Period-to-Period Change  
    Amount     Percentage of
Revenue
    Amount     Percentage of
Revenue
    Amount     Percentage of
Revenue
 
Sales and marketing expenses     2,061,695       31.3 %     962,567       11.3 %     1,099,128       20.0 %

 

Sales and marketing expenses were $2.1 million for the three months ended September 30, 2026, compared to $1.0 million for the three months ended September 30, 2025. As a percentage of revenue, sales and marketing expenses increased to 31.3% for the three months ended September 30, 2026, compared to 11.3% for the same period in 2025, primarily due to the increase in sales distribution fees with agencies, which drives revenue growth without the need for a large in-house sales force.

 

52

 

 

General and administrative expenses

 

    Three months ended September 30,        
    2026     2025     Period-to-Period Change  
    Amount     Percentage of
Revenue
    Amount     Percentage of
Revenue
    Amount     Percentage of
Revenue
 
General and administrative expenses:                                    
Operations division     581,265       8.8 %     1,260,832       14.9 %     (679,567 )     (6.1 )%
Administrative division     2,535,391       38.5 %     2,195,164       25.8 %     340,227       12.7 %
Total General and administrative expenses     3,116,656       47.3 %     3,455,996       40.7 %     (339,340 )     6.6 %

 

We bifurcate general and administrative expenses as follows:

 

Operations division — The operations division mainly consists of payroll, stock-based compensation expense and benefits expenses incurred related to our underwriting, claims management, operations development, enrollment, nursing and strategic program development personnel.

 

Administrative division — The administrative division mainly represents payroll, stock-based compensation expense and benefits expenses incurred related to Executives, Human Resources, Accounting, Finance and Legal related personnel.

 

General and administrative expenses decreased by $0.3 million to $3.1 million for the three months ended September 30, 2026, from $3.4 million for the three months ended September 30, 2025. The decrease was primarily attributable to lower operations division personnel costs resulting from workforce optimization initiatives. As a percentage of revenue, general and administrative expenses increased to 47.3% for the three months ended September 30, 2026, from 40.7% for the same period in 2025, primarily reflecting decreased revenue due to delays in the commencement of certain new policies associated with the transition to a new carrier.

 

Provision for credit losses

 

    Three months ended September 30,        
    2026     2025     Period-to-Period Change  
    Amount     Percentage of
Revenue
    Amount     Percentage of
Revenue
    Amount     Percentage of
Revenue
 
Provision for credit losses     5,337,768       81.1 %     (4,089 )     (0.0 )%     5,341,857       81.1 %

 

Provision for credit losses increased to $5.3 million for the three months ended September 30, 2026, from negative $4,089 for the same period in 2025. The increase was primarily attributable to credit loss expenses of $2.4 million related to deferred administrative surplus receivables, $1.9 million related to accounts receivable, and $0.9 million related to a loan receivable, resulting from management’s updated assessment of their collectability. We also recognized $0.1 million of credit loss expense related to certain other receivables.

 

53

 

 

The provision related to deferred administrative surplus receivables reflected management’s updated assessment of expected collections based on collection activity and the status of the reconciliation process associated with the 2025 Purchase. The provision related to accounts receivable reflected management’s updated assessment of collectability based on the ongoing reconciliation and collection process following the transition to a new carrier, during which collection activity improved. The provision related to the loan receivable reflected management’s updated assessment of the borrower’s repayment capacity.

 

Research and development expenses

 

    Three months ended September 30,        
    2026     2025     Period-to-Period Change  
    Amount     Percentage of
Revenue
    Amount     Percentage of
Revenue
    Amount     Percentage of
Revenue
 
Research and development expenses     938,564       14.2 %     235,819       2.8 %     702,745       11.4 %

 

Research and development expenses increased by $0.7 million to $0.9 million for the three months ended September 30, 2026, from $0.2 million for the three months ended September 30, 2025. As a percentage of revenue, research and development expenses increased to 14.2% for the three months ended September 30, 2026, from 2.8% for the same period in 2025.

 

The increase was primarily attributable to our continued investment in technology development, driven by higher personnel costs as we expanded the development team. During the three months ended September 30, 2026, our IT remained focused on developing new functionalities and features for our next-generation platform and new AI-powered platform for the planned program offering.

 

(Loss) income before income taxes 

 

    Three months ended September 30,        
    2026     2025     Period-to-Period Change  
    Amount     Percentage of
Revenue
    Amount     Percentage of
Revenue
    Amount     Percentage of
Revenue
 
(Loss) income before income taxes     (9,254,128 )     (140.5 )%     600,222       7.0 %     (9,854,350 )     (147.5 )%

 

Income before income taxes decreased by $9.9 million to a loss of $9.3 million for the three months ended September 30, 2026, from income of $0.6 million for the three months ended September 30, 2025. This decrease was primarily attributable to increased provisions for credit losses resulting from management’s updated assessment of expected credit losses, decreased revenue reflected delays in the commencement of certain new policies associated with the transition to a new carrier, increased investment in sales, marketing and technology to support long-term growth and financing transaction costs associated with the issuance of the Convertible Notes and SEPA.

 

54

 

 

Income tax benefit (expense)

 

    Three months ended September 30,        
    2026     2025     Period-to-Period Change  
    Amount     Percentage of
Revenue
    Amount     Percentage of
Revenue
    Amount     Percentage of
Revenue
 
Income tax benefit (expense)     2,147,653       32.6 %     (148,046 )     (1.7 )%     2,295,699       34.3 %

 

Provision for income taxes decreased by $2.3 million to an income tax benefit of $2.2 million for the three months ended September 30, 2026, from an income tax expense of $0.1 million for the three months ended September 30, 2025. The decrease in provision for income taxes was primarily attributable to increased provisions for credit losses resulting from management’s updated assessment of expected credit losses, decreased revenue reflected delays in the commencement of certain new policies associated with the transition to a new carrier, increased investment in sales, marketing and technology to support long-term growth and financing transaction costs associated with the issuance of the Convertible Notes and SEPA. 

 

Adjusted EBITDA

 

    Three months ended September 30,        
    2026     2025     Period-to-Period Change  
    Amount     Percentage of
Revenue
    Amount     Percentage of
Revenue
    Amount     Percentage of
Revenue
 
Adjusted EBITDA     (3,932,017 )     (59.7 )%     999,056       11.8 %     (4,931,073 )     (71.5 )%

 

Adjusted EBITDA decreased by $4.9 million to negative $3.9 million for the three months ended September 30, 2026, from $1.0 million for the three months ended September 30, 2025. As a percentage of revenue, adjusted EBITDA decreased to negative 59.7% for the three months ended September 30, 2026, from 11.8% for the same period in 2025. The decrease in adjusted EBITDA was primarily attributable to increased provisions for credit losses resulting from management’s updated assessment of expected credit losses, decreased revenue reflected delays in the commencement of certain new policies associated with the transition to a new carrier, increased investment in sales, marketing and technology to support long-term growth and financing transaction costs associated with the issuance of the Convertible Notes and SEPA.

 

Comparison of Nine Months Ended September 30, 2026 and 2025

 

Revenues

 

    Nine Months Ended September 30,        
    2026     2025     Period-to-Period Change  
    Amount     Percentage of
Revenue
    Amount     Percentage of
Revenue
    Amount     Percentage  
Revenues from underwriting modeling (ICE)     3,374,074       14.4 %     5,832,164       22.6 %     (2,458,090 )     (42.1 )%
Revenues from fees (SMR)     20,041,244       85.6 %     19,986,762       77.4 %     54,482       0.3 %
Program and platform management fees     5,683,574       24.3 %     19,986,762       77.4 %     (14,303,188 )     (71.6 )%
Self-funded plan administration fee     14,357,670       61.3 %     —       — %     14,357,670       NM  
Total revenues     23,415,318       100.0 %     25,818,926       100.0 %     (2,403,608 )     (9.3 )%

 

“NM” denotes that the percentage change is not meaningful.

 

55

 

 

Total revenues for the nine months ended September 30, 2026 reached $23.4 million, down 9.3% from $25.8 million in the same period of 2025. The decrease in revenue primarily reflected delays in the commencement of certain new policies associated with the transition to a new carrier. The new carrier’s different underwriting criteria and procedures required additional underwriting and approval before certain new policies could be bound and become effective. These requirements temporarily extended processing times for new business, resulting in fewer new clients being onboarded during the reporting period than in the comparative period. For these new policies, revenue recognition did not begin until the applicable contractual requirements were satisfied and the policies became effective, consistent with our revenue recognition policy. Accordingly, the principal revenue effect of the transition was a timing impact on the commencement of certain new policies.

 

The new carrier was onboarded during the second quarter of 2026, and transfers of existing in-force policies from the prior carrier to the new carrier were substantially completed as of September 30, 2026. The portfolio transfers did not interrupt employer coverage or change the policies’ existing contractual expiration dates. Upon each transfer, the new carrier assumed the applicable carrier responsibilities, while we continued to provide our contracted services and retained an enforceable right to consideration for those services over the remaining policy terms under the applicable contractual arrangements. Revenue from existing in-force policies continued to be recognized over the applicable policy terms, with no material reduction or delay attributable solely to the portfolio transfers.

The portfolio transfers required additional administrative coordination among us, the carriers and the applicable third-party administrators, including reconciliations of premiums, enrollment information, claims and other amounts. These procedures affected the timing of certain carrier settlements and receivable collections but did not cause us to suspend or defer revenue recognition, or reverse previously recognized revenue, for services provided under existing in-force policies.

 

Although the services provided by SMR and ICE are delivered as an interdependent and integrated solution and we evaluate their performance based on the total revenues generated, we provide the following breakdown for transparency. While revenues from underwriting modeling generated from ICE decreased by $2.5 million to $3.4 million, this decline was partially offset by a $0.1 million increase in revenues from fees generated from SMR, resulting in a net decrease of $2.4 million in total revenues from the integrated solution. 

 

Revenues from fees continue to outpace revenues from underwriting modeling as SMR launched the pre-designed self-funded plan administration services effective on January 1, 2026. SMR enhances its services to offer pre-designed self-funded plans to employers, leveraging years of experience selecting and managing the vendors that are essential to the plan. This new service model provides employers with more streamlined, differentiated and flexible self-funded plan arrangements.

 

Cost of revenues

 

    Nine Months Ended September 30,        
    2026     2025     Period-to-Period Change  
    Amount     Percentage of
Revenue
    Amount     Percentage of
Revenue
    Amount     Percentage of
Revenue
 
Cost of revenues     11,921,066       50.9 %     9,009,841       34.9 %     2,911,225       16.0 %

 

Cost of revenues increased by $2.9 million to $11.9 million for the nine months ended September 30, 2026, from $9.0 million for the nine months ended September 30, 2025. As a percentage of revenue, cost of revenues increased to 50.9% for the nine months ended September 30, 2026, from 34.9% for the same period in 2025.

 

56

 

 

The increase was primarily attributable to costs of plan administrative services provided by the TPA and other vendors assigned to each TPA, as we continued to enhance our services and launched the pre-designed plan offerings in January 2026, which gave rise to the related plan administrative costs.

 

Sales and marketing expenses

 

    Nine Months Ended September 30,        
    2026     2025      Period-to-Period Change  
    Amount     Percentage of
Revenue
    Amount     Percentage of
Revenue
    Amount     Percentage of
Revenue
 
Sales and marketing expenses     6,569,185       28.1 %     3,279,560       12.7 %     3,289,625       15.4 %
                                                 

 

Sales and marketing expenses were $6.6 million for the nine months ended September 30, 2026, doubled compared to $3.3 million for the nine months ended September 30, 2025. As a percentage of revenue, sales and marketing expenses increased to 28.1% for the nine months ended September 30, 2026, compared to 12.7% for the same period in 2025, primarily due to the increase in sales distribution fees with agencies, which drives revenue growth without the need for a large in-house sales force.

 

General and administrative expenses

 

    Nine Months Ended September 30,        
    2026     2025     Period-to-Period Change  
    Amount     Percentage of
Revenue
    Amount     Percentage of
Revenue
    Amount     Percentage of
Revenue
 
General and administrative expenses:                                                
Operations division     2,571,518       11.0 %     4,047,296       15.7 %     (1,475,778 )     (4.7 )%
Administrative division     7,532,971       32.2 %     6,424,928       24.9 %     1,108,043       7.3 %
Total General and administrative expenses     10,104,489       43.2 %     10,472,224       40.6 %     (367,735 )     2.6 %

 

We bifurcate general and administrative expenses as follows:

 

Operations division — The operations division mainly consists of payroll, stock-based compensation expense and benefits expenses incurred related to our underwriting, claims management, operations development, enrollment, nursing and strategic program development personnel.

 

Administrative division — The administrative division mainly represents payroll, stock-based compensation expense and benefits expenses incurred related to Executives, Human Resources, Accounting, Finance and Legal related personnel.

 

General and administrative expenses decreased by $0.4 million to $10.1 million for the nine months ended September 30, 2026, from $10.5 million for the nine months ended September 30, 2025. The decrease reflected a $1.5 million reduction in operations division expenses primarily due to lower personnel costs resulting from workforce optimization initiatives, partially offset by a $1.1 million increase in administrative division expenses primarily due to higher stock-based compensation expense. As a percentage of revenue, general and administrative expenses increased to 43.2% for the nine months ended September 30, 2026, from 40.6% for the same period in 2025, primarily reflecting decreased revenue due to delays in the commencement of certain new policies associated with the transition to a new carrier.

 

57

 

 

Provision for credit losses

 

    Nine months ended September 30,        
    2026     2025     Period-to-Period Change  
    Amount     Percentage of
Revenue
    Amount     Percentage of
Revenue
    Amount     Percentage of
Revenue
 
Provision for credit losses     6,074,587       25.8 %     1,901       0.0 %     6,072,686       25.8 %

 

Provision for credit losses increased to $6.1 million for the nine months ended September 30, 2026, from $1,901 for the same period in 2025. The increase was primarily attributable to credit loss expenses of $3.1 million related to deferred administrative surplus receivables, $1.9 million related to accounts receivable, and $0.9 million related to a loan receivable, resulting from management’s updated assessment of their collectability. We also recognized $0.2 million of credit loss expense related to certain other receivables.

 

The provision related to deferred administrative surplus receivables reflected management’s updated assessment of expected collections based on collection activity and the status of the reconciliation process associated with the 2025 Purchase. The provision related to accounts receivable reflected management’s updated assessment of collectability based on the ongoing reconciliation and collection process following the transition to a new carrier, during which collection activity improved. The provision related to the loan receivable reflected management’s updated assessment of the borrower’s repayment capacity.

 

Research and development expenses

 

    Nine Months Ended September 30,        
    2026     2025     Period-to-Period Change  
    Amount     Percentage of
Revenue
    Amount     Percentage of
Revenue
    Amount     Percentage of
Revenue
 
Research and development expenses     2,734,770       11.7 %     1,356,149       5.3 %     1,378,621       6.4 %

 

Research and development expenses increased by $1.3 million to $2.7 million for the nine months ended September 30, 2026, from $1.4 million for the nine months ended September 30, 2025. As a percentage of revenue, research and development expenses increased to 11.7% for the nine months ended September 30, 2026, from 5.3% for the same period in 2025.

 

The increase was primarily attributable to our continued investment in technology development, driven by higher personnel costs as we expanded the development team. 

 

As development activities progressed during the nine months ended September 30, 2026, our efforts were directed toward gathering business requirements, identifying necessary features, and evaluating alternatives, activities that did not meet the criteria for capitalization. Accordingly, the personnel-related costs capitalized for software development decreased by $0.5 million to $1.0 million for the nine months ended September 30, 2026, from $1.5 million for the same period in 2025. During the nine months ended September 30, 2026, our IT team remained focused on developing new functionalities and features for our next-generation platform and new AI-powered platform for the planned program offering.

 

58

 

 

(Loss) income before income taxes 

 

    Nine Months Ended September 30,        
    2026     2025     Period-to-Period Change  
    Amount     Percentage of
Revenue
    Amount     Percentage of
Revenue
    Amount     Percentage of
Revenue
 
(Loss) income before income taxes     (14,643,552 )     (62.5 )%     2,117,913       8.2 %     (16,761,465 )     (70.7 )%

 

Income before income taxes decreased by $16.7 million to a loss of $14.6 million for the nine months ended September 30, 2026, from income of $2.1 million for the nine months ended September 30, 2025. This decrease was primarily attributable to increased provisions for credit losses resulting from management’s updated assessment of expected credit losses, decreased revenue reflected delays in the commencement of certain new policies associated with the transition to a new carrier, the plan administrative service costs associated with the pre-designed self-funded plan administration services launched in January 2026, increased investment in sales, marketing and technology to support long-term growth and financing transaction costs associated with the issuance of the Convertible Notes and SEPA.

 

Income tax benefit (expense)

 

    Nine Months Ended September 30,              
    2026     2025     Period-to-Period Change  
    Amount     Percentage of
Revenue
    Amount     Percentage of
Revenue
    Amount     Percentage of
Revenue
 
Income tax benefit (expense)     3,437,610       14.6 %     (536,514 )     (2.1 )%     3,974,124       16.7 %

 

Provision for income taxes decreased by $3.9 million to an income tax benefit of $3.4 million for the nine months ended September 30, 2026, from an income tax expense of $0.5 million for the nine months ended September 30, 2025. The decrease in provision for income taxes was primarily attributable to increased provisions for credit losses resulting from management’s updated assessment of expected credit losses, decreased revenue reflected delays in the commencement of certain new policies associated with the transition to a new carrier, the plan administrative service costs associated with the pre-designed self-funded plan administration services launched in January 2026, increased investment in sales, marketing and technology to support long-term growth and financing transaction costs associated with the issuance of the Convertible Notes and SEPA. 

 

Adjusted EBITDA

 

    Nine Months Ended September 30,        
    2026     2025     Period-to-Period Change  
    Amount     Percentage of
Revenue
    Amount     Percentage of
Revenue
    Amount     Percentage of
Revenue
 
Adjusted EBITDA     (6,553,609 )     (28.0 )%     3,796,283       14.7 %     (10,349,892 )     (42.7 )%

 

Adjusted EBITDA decreased by $10.3 million to negative $6.5 million for the nine months ended September 30, 2026, from $3.8 million for the nine months ended September 30, 2025. As a percentage of revenue, adjusted EBITDA decreased to negative 28.0% for the nine months ended September 30, 2026, from 14.7% for the same period in 2025. The decrease in adjusted EBITDA was primarily attributable to increased provisions for credit losses resulting from management’s updated assessment of expected credit losses, decreased revenue reflected delays in the commencement of certain new policies associated with the transition to a new carrier, the plan administrative service costs associated with the pre-designed self-funded plan administration services launched in January 2026, increased investment in sales, marketing and technology to support long-term growth and financing transaction costs associated with the issuance of the Convertible Notes and SEPA.

 

59

 

 

Liquidity and Capital Resources

 

Sources of Liquidity

 

To date, we have funded our operations primarily through cash generated from operating activities, our IPO completed in December 2024, our PIPE financing completed in March 2026 and our issuance of the promissory convertible note in 2026.

 

Our cash and cash equivalents as of September 30, 2026 were held in order to fund our working capital needs. We do not enter into investments for trading or speculative purposes. Our policy is to invest any cash in excess of our immediate requirements in investments designed to preserve the principal balance and provide liquidity.

 

Accordingly, our cash and cash equivalents are invested primarily in demand deposit and money market accounts that are currently providing minimal returns.

 

Our anticipated cash requirements include working capital needs, software development costs and scheduled payments on the Convertible Notes, including principal, accrued interest and applicable payment premiums. While the Convertible Notes remain outstanding, net proceeds from sales of Class A common stock under the SEPA are required to be applied toward repayment of the Convertible Notes, subject to the applicable terms and conditions of the SEPA and the Convertible Notes, unless otherwise agreed by Yorkville. In November 2026, we received $2.85 million in net proceeds from the issuance of the Second Convertible Note, with scheduled repayments beginning in October 2027. Our other contractual cash requirements include the remaining $100,000 SEPA commitment fee, payable by February 2027. See Notes 7, 8 and 11 to the consolidated financial statements.

 

In assessing our liquidity, management considered our existing cash reserves, anticipated operating cash flows and expenditures, scheduled repayments of the Convertible Notes and expected financing sources, including planned sales under the SEPA and the required application of those proceeds to debt repayment. This assessment also incorporates our current sales plans and assumptions regarding the conversion of sales pipeline opportunities and prospective clients into revenue and cash receipts. These projections involve estimates and assumptions regarding future operating performance and the availability and timing of financing, and actual results may differ from our expectations.

 

Based on this assessment, we currently expect to have sufficient liquidity to fund our operations and meet our obligations as they become due for at least twelve months from the date of this Quarterly Report on Form 10-Q.

 

Summary of Cash Flows

 

    Nine Months Ended
September 30,
 
    2026     2025  
Cash (used in) provided by:            
Operating activities   $ (7,277,043 )   $ 2,682,602  
Investing activities     (1,801,287 )     (2,358,213 )
Financing activities     11,535,813       (150,024 )
Increase in cash and cash equivalents   $ 2,457,483     $ 174,365  

 

Operating Activities

 

Net cash used in operating activities was $7.3 million for the nine months ended September 30, 2026, compared to $2.7 million of net cash provided by operating activities for the same period in 2025. This shift was primarily due to the net loss in the nine months ended September 30, 2026, compared to net income in the same period in 2025.

 

60

 

 

Cash used in operating activities for the nine months ended September 30, 2026, principally resulted from a net loss of $11.2 million, offset by $7.0 million in adjustments for non-cash items primarily related to amortization, deferred tax benefit, stock-based compensation expense, provision for credit losses on other receivables and loans receivable, bad debt expense, provision for refund liability and financing transaction costs. This also included $3.1 million of cash used to fund changes in working capital, including an increase in accounts receivable of $4.3 million, an increase in other receivables of $1.2 million, a decrease in prepaid expenses and other assets of $1.0 million, an increase in accounts payable and accrued expenses of $2.7 million and a decrease in other current liabilities of $1.4 million.

 

Cash provided by operating activities for the nine months ended September 30, 2025, principally resulted from our net income of $1.6 million, $4.3 million in adjustments for non-cash items primarily related to amortization, provision for refund liability and stock-based compensation expense, and offset by $3.2 million of cash used to fund changes in working capital, including a decrease in accounts receivable of $0.8 million, an increase in other receivables of $3.4 million, an increase in prepaid expenses and other current assets of $0.9 million, an increase in accounts payable and accrued expenses of $2.0 million, a decrease in income taxes payable of $0.2 million and a decrease in other current liabilities of $1.5 million.

 

Investing Activities

 

Cash used in investing activities decreased by $0.6 million to $1.8 million for the nine months ended September 30, 2026, compared to $2.4 million for the same period in 2025. The decrease was partially attributable to the timing of payments for capitalized software development costs. The primary use of cash in investing activities for the nine months ended September 30, 2026 and 2025 were both related to the development of our proprietary AI-enabled platform, reflecting our continued investment in enhancing our technology platforms.

 

Financing Activities

 

Net cash provided by financing activities was $11.5 million for the nine months ended September 30, 2026, compared to $0.2 million of net cash used in financing activities for the same period in 2025. The increase was primarily attributable to proceeds from the issuance of Class A Common Stock in connection with our PIPE financing of $6.4 million and proceeds from the issuance of convertible notes, net of discount, of $6.7 million, partially offset by payments of deferred offering costs of $0.5 million, payments of financing costs related to the SEPA and convertible notes of $0.6 million and taxes paid related to net share settlement of equity awards of $0.5 million. For the nine months ended September 30, 2025, the primary use of cash in financing activity was related to the payments of deferred offering cost for our public offering.

 

Contractual Obligations and Commitments

 

Our principal commitments consist of obligations under our non-cancellable lease for our office and the First Convertible Note. The following table summarizes the contractual obligations as of September 30, 2026. Future events could cause actual payments to differ from these estimates.

 

    Payment due by period  
    Total     Less than
1 year
    1 – 3 
years
    3 – 5 
years
    More than
5 years
 
Operating lease obligations     88,240       88,240       —       —       —  
The First Convertible Note principal     7,000,000       6,949,000       51,000       —       —  
The First Convertible Note interest     398,156       397,789       367       —       —  
The First Convertible Note payment premium     280,000       277,960       2,040       —       —  
SEPA commitment fee     100,000       100,000       —       —       —  

 

61

 

 

The amounts presented for the First Convertible Note are based on the scheduled repayments, assuming no conversions. Yorkville may elect to convert all or a portion of the outstanding amounts into shares of Class A common stock, in which case the amounts converted would be settled in equity rather than cash. The payment premiums presented assume cash repayments and do not apply to repayments funded through SEPA Advances. Actual payments may differ from the amounts presented.

 

Critical Accounting Policies and Estimate

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of revenue and expenses during the reported periods. The critical accounting estimate discussed below is one we believe involves a significant level of estimation uncertainty and has had a material impact on our results of operations during the current period. Although management believes its assumptions and estimates are reasonable, actual results could differ from those estimates.

 

Fair Value Measurements of Convertible Notes and SEPA Derivative Liability

 

In connection with the SEPA entered into during the third quarter of 2026, we issued a Convertible Note containing embedded features that could require bifurcation and separate accounting. The Company elected the FVO under ASC 825 to measure the entire Convertible Note, including accrued and unpaid interest, at fair value. The SEPA is separately accounted for as a derivative liability under ASC 815. Both instruments are initially recognized at fair value and subsequently remeasured at each reporting date. Changes in the fair value of the Convertible Note are recognized in earnings, except for changes attributable to instrument-specific credit risk, which are recognized in other comprehensive income. Changes in the fair value of the SEPA derivative liability are recognized in earnings.

 

We determine the fair values of these instruments with the assistance of an independent valuation specialist using a Monte Carlo simulation model that considers various potential settlement outcomes, including repayment, conversion, redemption and other contractual features. The valuation incorporates our stock price, equity volatility, risk-adjusted discount rates and management’s assessment of the probability of future equity issuances that could trigger a down-round adjustment. The down-round probability represents a significant unobservable input.

 

These fair value measurements require significant judgment, particularly in assessing potential future financing events and settlement scenarios. Changes in market conditions and valuation assumptions could result in changes in the estimated fair values of these instruments and affect our financial position and results of operations.

 

As of September 30, 2026, the fair values of the Convertible Note and SEPA derivative liability were $6,639,108 and $82,629, respectively. See Notes 7, 8 and 10 to the unaudited consolidated financial statements for additional information.

 

Recent Accounting Pronouncements

 

In November 2024, the FASB issued ASU 2024-03 Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. This standard calls for enhanced disclosures about components of expense captions on the face of the income statement. This standard will be effective for fiscal years beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with the option to apply it retrospectively. Early adoption is allowed. Currently, we are assessing the potential impact of this guidance on our consolidated financial statement disclosures.

 

In September 2025, the FASB issued ASU 2025-06 Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software, which amends certain aspects of the accounting for and disclosure of software costs under ASC 350-40. The new standard is effective for annual periods beginning after December 15, 2027, and interim reporting periods within those annual reporting periods. Early adoption is allowed. The new standard may be applied prospectively, retrospectively, or via a modified prospective transition method. Currently, we are assessing the potential impact of this guidance on our consolidated financial statement disclosures.

 

62

 

 

In December 2025, the FASB issued ASU 2025-12 Codification Improvements (“ASU 2025-12”). This update addresses suggestions received from stakeholders regarding the Accounting Standards Codification (“Codification”) and makes other incremental improvements to GAAP. The update represents changes to the Codification that clarify, correct errors in or make other improvements to a variety of topics that are intended to make it easier to understand and apply. ASU 2025-12 is effective for fiscal years beginning after December 15, 2026 and interim periods within those fiscal years. Entities are required to apply the amendments to ASC 260, Earnings Per Share, retrospectively. All other amendments may be applied prospectively or retrospectively. Early adoption is permitted. Currently, we are assessing the potential impact of this guidance on our consolidated financial statement disclosures.

 

We do not believe that any other recently issued but not yet effective accounting pronouncements are expected to have a material effect on our consolidated financial statements.

 

JOBS Act

 

We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. We have elected to early adopt certain new accounting standards, as disclosed herein. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.

 

We will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the completion of our initial public offering, (b) in which we have total annual gross revenue of at least $1.235 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our Class A Common Stock that is held by non-affiliates exceeds $700 million as of the prior September 30, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period. References herein to emerging growth company will have the meaning associated with it in the JOBS Act.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

 

We are a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required by this Item.

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

Disclosure controls and procedures are controls and other procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is accumulated and communicated to Management, including our Chief Executive Officer and Chief Financial Officer (together, the “Certifying Officers”), or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.  

 

Under the supervision and with the participation of our Management, including our Certifying Officers, we carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on the foregoing, our Certifying Officers concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Quarterly Report on Form 10-Q. Accordingly, Management believes that the financial statement contained elsewhere in this Report present fairly in all material respects our financial position, results of operations and cash flows for the period presented.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting, as defined in Rules 13a-15(f) and 15(d)-15(f) promulgated under the Securities Exchange Act of 1934, during the period ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

63

 

 

Part II. OTHER INFORMATION

 

Item 1. Legal Proceedings

 

We are not party to any material legal proceedings. We have in the past, and from time to time may be in the future, involved in legal proceedings or subject to claims incident to the ordinary course of business. Regardless of the outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.

 

Item 1A. Risk Factors

 

Risk factors that may affect our business and financial results are discussed within Item 1A “Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the SEC on March 25, 2026, and our subsequent filings with the SEC. In addition to those in our prior filings, the following is an additional risk factor to consider:

 

Risks Related to Exchange Listing

 

Nasdaq may delist our securities from its exchange which could limit investors’ ability to make transactions in its securities and subject us to additional trading restrictions.

 

On October 12, 2026, the Company received a letter from the Listing Qualifications Department of Nasdaq (the “Nasdaq Staff”) indicating that, for the last thirty (30) consecutive business days, the closing bid price for the Class A Common Stock was below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “bid price requirement”). The letter has no immediate effect on the listing or trading of the Class A Common Stock. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until April 12, 2027, to regain compliance. The letter states that the Nasdaq Staff will provide written notification that the Company has achieved compliance with the bid price requirement if at any time before April 12, 2027, the bid price of the Class A Common Stock closes at $1.00 per share or more for a minimum of ten (10) consecutive business days. If the Company chooses to effect a reverse stock split to regain compliance, it must complete the split no later than ten (10) business days prior to April 12, 2027.

 

The Company intends to monitor the closing bid price of its Class A Common Stock and consider available options if its Class A Common Stock does not trade at a level likely to result in the Company regaining compliance with Nasdaq’s minimum bid price rule by April 12, 2027, which could include effecting a reverse stock split. If the Company does not regain compliance with Rule 5550(a)(2) by April 12, 2027, the Company may be eligible for an additional 180 calendar day compliance period. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and would need to provide the Nasdaq Staff with written notice of its intention to cure the deficiency during the second compliance period, which may include, if necessary, effectuation of a reverse stock split. However, if it appears to the Nasdaq Staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq would notify the Company that its securities would be subject to delisting. In the event of such a notification, the Company may appeal the Nasdaq Staff’s determination to delist its securities. There can be no assurance that the Company will regain compliance with the bid price requirement, that the Company will be eligible for the additional 180 calendar day compliance period, if applicable, or that the Nasdaq Staff would grant the Company’s request for continued listing subsequent to any delisting notification. Should we fail to regain compliance with this continued listing requirement, our Class A Common Stock may be delisted and that could limit investors’ ability to make transactions in the Class A Common Stock and subject us to additional trading restrictions.

 

64

 

 

Risks Related to the Standby Equity Purchase Agreement

 

Substantial blocks of our Class A Common Stock may be sold into the market as a result of the convertible notes we sold or will sell to Yorkville or shares of Class A Common Stock we may sell to Yorkville, in each case, under the SEPA (as defined below), if not terminated and if and when available, which may cause the price of our Class A Common Stock to decline.

 

On August 12, 2026, the Company entered into a Standby Equity Purchase Agreement (the “SEPA”) and on August 18, 2026 signed the related Registration Rights Agreement with YA II PN, Ltd. (“Yorkville”). Subject to the terms and conditions set forth therein, Yorkville agreed to advance to us up to $15.0 million in Pre-Paid Advances, less certain amounts, paid in up to three tranches, in exchange for our issuance to Yorkville of convertible promissory notes (each, a “Convertible Note” and, collectively, the “Convertible Notes”) as described below. On August 18, 2026, Yorkville disbursed the first tranche of the Pre-Paid Advances, in the amount of $6,650,000 after accounting for a 5% purchase discount, to us. In exchange, we issued Yorkville a First Convertible Note for the principal amount of $7 million. On November 2, 2026, Yorkville disbursed the second tranche of the Pre-Paid Advances, in the amount of $2,850,000 after accounting for a 5% purchase discount, to us. In exchange, we issued Yorkville a Second Convertible Note for the principal amount of $3 million. A third tranche of the Pre-Paid Advances in the net amount of up to $4,750,000, if requested by the Company and agreed upon in writing by Yorkville in its sole and absolute discretion, shall take place on such date as is mutually agreed to by the Company and Yorkville and be in a principal amount of up to $5,000,000. Yorkville may convert all or any portion of the outstanding principal amount, accrued and unpaid interest and other amounts outstanding under the Convertible Notes we issue it into shares of Class A Common Stock, at any time and from time to time during the term of the Convertible Notes, at a fixed conversion price of $1.5735 per share, subject to a 4.99% beneficial ownership limitation as between Yorkville and its affiliates, an Exchange Cap (as defined and described below), certain anti-dilution and price-adjustment provisions and a floor price of $0.204 per share.

 

Under the SEPA, we also have the right to sell to Yorkville an additional up to $20.0 million of shares of our Class A Common Stock in the form of one or more Advances, subject to certain limitations and conditions. Sales of our shares of Class A Common Stock to Yorkville as Advances under the SEPA, and the timing of any such sales, are at our complete discretion and we are under no obligation to sell any shares of Class A Common Stock to Yorkville under the SEPA.

 

The price of our Class A Common Stock could decline if there are substantial sales of shares of our Class A Common Stock, if there is a large number of shares of our Class A Common Stock available for sale, or if there is the perception that these sales could occur.

 

Any issuance of shares of Class A Common Stock pursuant to the SEPA, if not terminated and if and when available, whether upon conversion by Yorkville of a Convertible Note or upon issuance of Class A Common Stock in the form of an Advance, will dilute the percentage ownership of our stockholders and may dilute the per share projected earnings (if any) or book value of our Class A Common Stock. Sales of a substantial number of shares of our Class A Common Stock in the public market or other issuances of shares of our Class A Common Stock, or the perception that these sales or issuances could occur, could cause the market price of our Class A Common Stock to decline and may make it more difficult for you to sell your shares at a time and price that you deem appropriate.

 

The actual number of shares of Class A Common Stock we will issue pursuant to the SEPA, if not terminated and if and when available, at any one time or in total, is uncertain.

 

Subject to certain conditions in the SEPA, if not terminated and if and when available, and subject to compliance with applicable law, we have issued Convertible Notes to Yorkville, which may be converted into shares of our Class A Common Stock at any time and from time to time during the term of the Convertible Notes, subject to certain exceptions, and we may also issue additional shares of our Class A Common Stock to Yorkville in connection with Advances under the SEPA. The number of shares of Class A Common Stock that are issued to Yorkville will fluctuate based on a number of factors, including, among other things, the market price of our Class A Common Stock, which has historically fluctuated significantly and may continue to do so in the future. It is not possible at this stage to predict the number of shares of Class A Common Stock that will be ultimately issued pursuant to the SEPA, if not terminated and if and when available.

 

65

 

 

Outstanding amounts under the SEPA, if not terminated and if and when available, will make us more vulnerable to downturns in our financial condition, and any shares of Class A Common Stock we issue under the SEPA, if not terminated and if and when available, will further dilute our stockholders.

 

As of the date of this Quarterly Report on Form 10-Q, the principal amount of $9,750,000 is outstanding under the convertible notes issued pursuant to the SEPA, and there may be additional amounts outstanding under the SEPA in the future. If our cash flow from operations is insufficient to meet our payments under the SEPA, which pursuant to the terms of the SEPA are to be paid in monthly installments with a 4% premium, or if we are unable to offset amounts outstanding under the SEPA with the issuance of shares of Class A Common Stock, we would incur an event of default under the SEPA, in which case, all outstanding amounts would be immediately due and payable. Any debt we incur from Yorkville or other parties could make us more vulnerable to a downturn in our operating results or a downturn in economic conditions. If our cash flow from operations is insufficient to meet any debt service requirements or we incur an event of default, we could be required to refinance our obligations, or dispose of assets in order to meet debt service requirements.

 

In addition, any shares of Class A Common Stock that we issue to Yorkville under the SEPA, if not terminated and if and when available, will further dilute our current stockholders.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

(a) Recent Sales of Unregistered Equity Securities

 

None.

 

(b) Use of Proceeds

 

None.

 

(c) Issuer Purchases of Equity Securities

 

The table below summarizes information about the Company’s purchases of its equity securities during the three months ended September 30, 2026.

 

Period   (a)
Total number of shares purchased and received (1)
    (b)
Average price paid per share (1)
    (c)
Total number of shares purchased as part of public announced plans or programs
    (d)
Maximum dollar value of shares that may yet be purchased under the  plans or programs
(in thousands)
 
July 2026     80,026     $ 1.04       -     $      -  
August 2026     78,517       1.06       -       -  
September 2026     101,859       0.89       -       -  

 

(1)

During the three months ended September 30, 2026, all of the shares received were surrendered by employees to satisfy tax withholding obligations in connection with the net settlement of equity awards.

 

Item 3. Defaults Upon Senior Securities

 

None.

 

66

 

 

Item 4. Mine Safety Disclosures

 

Not applicable. 

 

Item 5. Other Information

 

(a)

 

Election of New Director

 

On November 10, 2026, at the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”), the Company’s stockholders elected Tim Cortes as a member of the Board of Directors. Mr. Cortes previously served as Chief Technology Officer at Plug Power, Inc. (Nasdaq: PLUG) from March 2021 to June 2025 and as Vice President of Hydrogen Energy Systems at Plug Power from January 2015 to March 2021. The Board believes that Mr. Cortes’s technical expertise and business acumen as a leader in technology and product strategy qualify him to serve as a director of the Company. The Board has also appointed Mr. Cortes to the Audit Committee of the Board (the “Audit Committee”).

 

As a result of Mr. Cortes’ election to the Board and appointment to the Audit Committee, the Company has regained compliance with Nasdaq’s independent director and audit committee requirements as set forth in Nasdaq Listing Rules 5605(b)(1) and 5605(c)(2)(A), which among other things require, respectively, that a majority of the Board be comprised of “independent directors” under Nasdaq criteria and that the Audit Committee consist of at least three members meeting such independence criteria. As previously reported in a Current Report on Form 8-K filed with the SEC on October 16, 2026, on October 14, 2026, the Company received a letter from the Nasdaq Staff relating to the Company’s non-compliance with Nasdaq Listing Rules 5605(b)(1) and 5605(c)(2)(A) as of such date as a result of the resignation of Sanjay Shrestha from the Board and the Audit Committee on August 10, 2026, as was previously disclosed in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 filed with the SEC on August 13, 2026.

 

Amendment to Second Amended and Restated Articles of Incorporation

 

As was disclosed in a Current Report on Form 8-K filed with the SEC on November 12, 2026 (the “2026 Annual Meeting Results Form 8-K”), at the 2026 Annual Meeting, the Company’s stockholders approved, to be effective as of the same date, an amendment to the Company’s Second Amended and Restated Articles of Incorporation to increase the total authorized shares of capital stock of the Company from 220,000,000 to 720,000,000, consisting of 650,000,000 shares of Class A Common Stock, 50,000,000 shares of Class B Common Stock and 20,000,000 shares of Series A Preferred Stock, $0.001 par value per share. The full results of the 2026 Annual Meeting are disclosed in the Current Report on Form 8-K filed by the Company with the SEC on November 12, 2026.

 

Approval of Issuances Under the Standby Equity Purchase Agreement

 

As discussed above and as disclosed in a Current Report on Form 8-K filed by the Company with the SEC on November 6, 2026, on August 12, 2026, the Company entered into the SEPA and a related Registration Rights Agreement with Yorkville. On October 15, 2026, the Company satisfied the condition set forth in the SEPA which required that the Company have a registration statement under the Securities Act of 1933, as amended, declared effective by the SEC, registering for resale the shares of Class A Common Stock issued or issuable by the Company to Yorkville under the SEPA (the “SEPA Registration Statement”). The SEPA Registration Statement was filed on Form S-3 (File No. 333- 298758) and declared effective by the SEC on October 15, 2026.

 

67

 

 

Pursuant to the SEPA, in no event may we issue to Yorkville under the SEPA or otherwise, including under conversion of the Convertible Notes, collectively more than an Exchange Cap of 13,100,378 shares of Class A Common Stock (representing 19.99% of the aggregate number of Class A Common Stock and Class B Common Stock outstanding as of the date of entry into the SEPA) unless and until we received the requisite stockholder approval to issue shares of Class A Common Stock in excess thereof in accordance with applicable Nasdaq rules. On November 10, 2026, at the 2026 Annual Meeting, our stockholders approved, for purposes of complying with Nasdaq Listing Rules 5635(b) and 5635(d), the issuance of more than 20% of the Company’s issued and outstanding Class A Common Stock pursuant to the SEPA, including upon conversion of the Convertible Notes issued or issuable thereunder. The full results of the 2026 Annual Meeting are disclosed in the Current Report on Form 8-K filed by the Company with the SEC on November 12, 2026.

 

Amendment to the Health In Tech, Inc. Equity Incentive Plan (2024)

 

As was disclosed in the 2026 Annual Meeting Results Form 8-K, at the 2026 Annual Meeting, the Company’s stockholders approved, to be effective as of the same date, an amendment to the Health In Tech, Inc. Equity Incentive Plan (2024), to increase the total number of shares of Class A Common Stock authorized for issuance pursuant to awards granted thereunder, including upon the exercise of incentive stock options, from 10,677,849 shares to 30,677,849 shares, and to increase the aggregate incentive stock option limit to 13,000,000 shares. The full results of the 2026 Annual Meeting are disclosed in the Current Report on Form 8-K filed by the Company with the SEC on November 12, 2026. The Health In Tech, Inc. Equity Incentive Plan (2024), as amended, is filed herewith as Exhibit 10.8.

 

Appointment of Directors

 

On November 12, 2026, our Board of Directors appointed Sanjay Shrestha, our Chief Executive Officer, and Christina Rizopoulos Valauri as directors of the Company, effective immediately, with Ms. Valauri serving as an independent director.

 

Additional information regarding these appointments will be included in a Current Report on Form 8-K to be filed with the SEC. 

 

(b) Not applicable. 

 

(c)

 

Rule 10b5-1 Trading Arrangements

 

During the quarter ended September 30, 2026, none of our directors or executive officers informed us of the adoption or termination of a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Regulation S-K, Item 408, except as follows:

 

On September 15, 2026, Tim Johnson, the Executive Chairman of our Board of Directors, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act, effective as of December 15, 2026. Mr. Johnson’s plan is for the sale of up to 200,000 shares of the Company’s Class A Common Stock, net of shares subject to withholding to satisfy applicable taxes. The foregoing sales will be made in accordance with the prices and formulas set forth in the plan and such plan terminates on the earlier of the date all the shares under the plan are sold December 15, 2027.

 

68

 

 

Item 6. Exhibits

 

Exhibit
Number
 
  Description of Document
3.1(1)     Second Amended and Restated Articles of Incorporation of Health In Tech, Inc.
3.2*   Certificate of Amendment to Second Amended and Restated Articles of Incorporation of Health In Tech, Inc.
3.2(2)     Third Amended and Restated Bylaws of Health In Tech, Inc.
10.8*   Health In Tech, Inc. Equity Incentive Plan (2024), as amended.
10.14*   Employment Agreement Between Health In Tech, Inc. and Sanjay Shrestha dated October 20, 2026.
10.15*   Health In Tech, Inc. Equity Incentive Plan Restricted Stock Award Agreement with Sanjay Shrestha dated October 20, 2026.
31.1*   Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*   Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**   Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**   Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS   Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.
101.SCH   Inline XBRL Taxonomy Extension Schema Document.
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

* Filed herewith.
   
** Exhibits 32.1 and 32.2 are being furnished to the SEC pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise specifically stated in such filing.
   
(1) Filed as an exhibit to the registrant’s Annual Report on Form 10-K filed with the SEC on March 17, 2025.
   
(2) Filed as an exhibit to the registrant’s Current Report on Form 8-K filed with the SEC on February 27, 2025.

 

69

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

  Health In Tech, Inc.
     
Date: November 13, 2026 By: /s/ Sanjay Shrestha
    Sanjay Shrestha
    Chief Executive Officer
(Principal Executive Officer)
     
Date: November 13, 2026 By: /s/ LinLin Qian
    LinLin Qian
    Chief Financial Officer
(Principal Financial and Accounting Officer)

 

70

 

Keep reading